Body and Mind (BMMJ) S-1 13 Mar 20 IPO registration Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Oct. 31, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	BODY & MIND INC.
Entity Central Index Key	0001715611
Entity Filer Category	Non-accelerated Filer
Document Type	S-1
Amendment Flag	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Consolidated Interim Balance Sh

Consolidated Interim Balance Sheets - USD ($)	Oct. 31, 2019	Jul. 31, 2019	Jul. 31, 2018
Current
Cash and cash equivalents	$ 6,898,235	$ 9,004,716	$ 324,837
Amounts receivable	747,551	966,909	632,477
Prepaids	721,302	227,843	99,014
Inventory (Note 5)	1,247,220	1,390,419	953,417
Total Current Assets	9,614,308	11,589,887	2,009,745
Convertible Loan Receivable (Note 6)	67,166	52,225
Investment in NMG Ohio LLC (Note 17)	3,568,645	3,465,902	77,600
Investment in and advances to GLDH (Note 18)	10,898,324	7,373,036
Other investments (Note 19)	400,593	255,980
Property and Equipment (Note 7)	4,189,710	2,694,500	2,615,898
Brand and Licenses (Note 14)	8,172,000	8,172,000	8,172,000
Goodwill (Note 14)	2,635,721	2,635,721	2,635,721
TOTAL ASSETS	39,546,467	36,239,251	15,510,964
Current
Accounts payables	758,250	979,384	447,703
Accrued liabilities	95,210	95,234	95,481
Income taxes	239,358	239,358	239,358
Due to related parties (Note 8)	41,703	12,952	51,081
Notes payable (Note 9)			2,175,000
Lease liabilities (Note 20)	191,020
Total Current Liabilities	1,325,541	1,326,928	3,008,623
Lease Liabilities (Note 20)	953,007
Deferred Tax Liability	1,716,120	1,716,120	1,716,120
TOTAL LIABILITIES	3,994,668	3,043,048	4,724,743
STOCKHOLDERS' EQUITY
Capital Stock - Statement 3 (Note 11) Authorized:900,000,000 Common Shares - Par Value $0.0001 Issued and Outstanding:101,760,232 (31July2019 - 97,279,891 and 31 July 2018 - 47,774,817) Common Shares	10,176	9,728	4,778
Additional Paid-in Capital	44,794,072	41,676,611	16,918,082
Shares to be Issued (Notes 10, 11 and 14)	1,134,106	1,118,815	103,267
Equity Component of Convertible Debenture	88,797	88,797
Other Comprehensive Income	946,507	827,314	532,405
Deficit	(11,421,859)	(10,525,062)	(6,772,311)
TOTAL STOCKHOLDERS' EQUITY	35,551,799	33,196,203	10,786,221
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 39,546,467	$ 36,239,251	$ 15,510,964

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Oct. 31, 2019	Jul. 31, 2019	Jul. 31, 2018
Statement of Financial Position [Abstract]
Capital stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Capital stock, shares authorized	900,000,000	900,000,000	900,000,000
Common stock shares issued	101,760,232	97,279,891	47,774,817
Common stock, shares outstanding	101,760,232	97,279,891	47,774,817

Consolidated Interim Statements

Consolidated Interim Statements of Operations - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Income Statement [Abstract]
Sales	$ 1,441,626	$ 1,325,978	$ 5,336,557	$ 2,692,979
Sales tax	(198,524)	(131,419)	(724,339)	(279,931)
Net sales			4,612,218	2,413,048
Cost of sales	(922,973)	(737,621)	(2,831,642)	(1,216,851)
Gross Profit	320,129	456,938	1,780,576	1,196,197
General and Administrative Expenses
Accounting and legal (Note 8)	44,193	78,381	895,263	350,502
Consulting fees (Notes 8 and 16)	220,227	2,600	167,942	206,913
Depreciation	4,875	3,140	12,870	8,811
Insurance	28,725	22,238	76,659	29,793
Lease expense	56,704
Interest and accretion expense (Notes 9 and 10)			1,242,808	277,219
Licenses, utilities and office administration	304,724	85,092	931,045	281,671
Listing fees				465,481
Management fees (Note 8)	129,578	52,844	420,202	219,120
Regulatory, filing and transfer agent fees	16,736	7,196	137,117	23,641
Rent	12,365	18,362	119,074	51,000
Salaries and wages	484,051	194,175	926,198	380,371
Stock-based compensation (Notes 8 and 11)	289,578		880,595	789,679
Transaction costs (Note 14)				330,324
Travel	50,901	2,023	56,214	28,237
Total	(1,642,657)	(466,051)	(5,865,987)	(3,442,762)
Loss Before Other Items	(1,322,528)	(9,113)	(4,085,411)	(2,246,565)
Other Items
Foreign exchange, net	(82,920)	(71,554)	(241,862)	(193,959)
Interest income	278,000	48	719,865	5,615
Management fee income	18,000		37,000
Other income	125,000
Equity pickup of investee (Note 17)	87,651	(7,620)	56,466
Early loan repayment penalty (Note 9)			(200,000)
Write off of amounts receivable			(38,809)	(873)
Write off of deposit				(250,000)
Net Loss for the Period Before Income Tax	(896,797)	(88,239)	(3,752,751)	(2,685,782)
Income taxes
Deferred income tax recovery				1,144,080
Income tax expense		(123,555)		(239,358)
Net Loss for the Period	(896,797)	(211,794)	(3,752,751)	(1,781,060)
Other Comprehensive Income (Loss)
Foreign currency translation adjustment	119,193	73,315	294,909	175,577
Comprehensive Loss for the Period	$ (777,604)	$ (138,479)	$ (3,457,842)	$ (1,605,483)
Loss per Share - Basic and Diluted	$ 0.01	$ 0	$ (0.05)	$ (0.05)
Weighted Average Number of Shares Outstanding	101,149,232	47,774,817	69,548,041	38,934,166

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Share Capital Common Shares	Additional paid-in capital	Shares to be issued	Equity component of convertible debenture	Other comprehensive income	Deficit	Total
Beginning Balance at Jul. 31, 2017	$ 1,914	$ 4,954,932			$ 356,828	$ (4,991,251)	$ 322,423
Beginning Balance (in shares) at Jul. 31, 2017	19,137,783
Private placements	$ 974	5,025,520					5,026,494
Private placements (in shares)	9,739,534
Acquisition of Nevada Medical Group LLC	$ 1,883	6,335,482	$ 135,202				6,472,567
Acquisition of Nevada Medical Group LLC (in shares)	18,827,000
Issuance of escrowed shares	$ 7	31,928	(31,935)
Issuance of escrowed shares (in shares)	70,500
Share issue costs		(219,459)					(219,459)
Stock-based compensation		789,679					789,679
Foreign currency translation adjustment					175,577		175,577
Loss for the period						(1,781,060)	(1,781,060)
Ending Balance at Jul. 31, 2018	$ 4,778	16,918,082	103,267		532,405	(6,772,311)	10,786,221
Ending Balance (in shares) at Jul. 31, 2018	47,774,817
Foreign currency translation adjustment					73,315		73,315
Loss for the period						(211,794)	(211,794)
Ending Balance at Oct. 31, 2018	$ 4,778	16,918,082	103,267		605,720	(6,984,105)	10,647,742
Ending Balance (in shares) at Oct. 31, 2018	47,774,817
Beginning Balance at Jul. 31, 2018	$ 4,778	16,918,082	103,267		532,405	(6,772,311)	10,786,221
Beginning Balance (in shares) at Jul. 31, 2018	47,774,817
Private placements	$ 2,778	15,085,636					15,088,414
Private placements (in shares)	27,780,134
Exercise of warrants	$ 1,601	5,955,166					5,956,767
Exercise of warrants (in shares)	16,007,333
Issuance of escrowed shares	$ 14	50,003	(50,017)
Issuance of escrowed shares (in shares)	141,000
Share issue costs	$ 31	(270,767)					(270,736)
Share issue costs (in shares)	322,581
Finance fee for promissory note	$ 111	822,383					822,494
Finance fee for promissory note (in shares)	1,105,083
Investment agreement with Australis	$ 177	$ 786,946					$ 787,123
Investment agreement with Australis (in shares)	1,768,545
Acquisition of NMG Ohio LLC	238	1,448,567					1,448,805
Acquisition of NMG Ohio LLC (in shares)	$ 2,380,398
Shares to be issued on conversion of debt			1,065,565				$ 1,065,565
Equity component of convertible debenture				$ 88,797			88,797
Stock-based compensation		$ 880,595					880,595
Foreign currency translation adjustment					294,909		294,909
Loss for the period						(3,752,751)	(3,752,751)
Ending Balance at Jul. 31, 2019	$ 9,728	41,676,611	1,118,815	88,797	827,314	(10,525,062)	33,196,203
Ending Balance (in shares) at Jul. 31, 2019	97,279,891
Acquisition of GLDH	$ 434	2,752,348					2,752,782
Acquisition of GLDH (in shares)	4,337,111
Exercise of warrants	$ 14	75,535					75,549
Exercise of warrants (in shares)	143,230
Stock-based compensation		289,578					289,578
Share subscriptions received in advance			15,291				15,291
Foreign currency translation adjustment					119,193		119,193
Loss for the period						(896,797)	(896,797)
Ending Balance at Oct. 31, 2019	$ 10,176	$ 44,794,072	$ 1,134,106	$ 88,797	$ 946,507	$ (11,421,859)	$ 35,551,799
Ending Balance (in shares) at Oct. 31, 2019	101,760,232

Consolidated Statements of Cash

Consolidated Statements of Cash Flows	3 Months Ended		12 Months Ended
	Oct. 31, 2019USD ($)	Oct. 31, 2018USD ($)	Jul. 31, 2019USD ($)	Jul. 31, 2018USD ($)
Operating Activities
Loss for the year	$ (896,797)	$ (211,794)	$ (3,752,751)	$ (1,781,060)
Items not affecting cash:
Accrued interest and accretion			1,242,808	277,219
Accrued interest income	(260,000)		(693,333)
Depreciation	78,597	69,557	289,560	167,737
Deferred Tax Recovery				(1,144,080)
Foreign exchange	1,377	738	(59,265)	204,390
Income tax		123,555		239,358
(Gain) or loss of equity investee	(87,651)	7,620	(56,466)
Stock-based compensation	289,578		880,595	789,679
Transaction cost				330,324
Write off of amounts receivable			38,809	873
Amounts receivable	(274,101)	(115,717)	(373,241)	(361,854)
Advance				103,495
Prepaids			(128,829)	(26,434)
Inventory	143,199	(159,095)	(437,002)	(454,737)
Trade payables and accrued liabilities	(221,158)	102,343	531,434	(371,586)
Due to related parties	28,751	(41,006)	(38,129)	46,276
Net Cash Used In Operating Activities	(1,198,205)	(223,799)	(2,555,810)	(2,139,327)
Investing Activities
Business combination, net of cash acquired				(2,048,158)
Investment in NMG Ohio, LLC	(16,469)	(30,000)	(1,854,883)	(77,600)
Investment in GLDH	(512,506)		(6,650,641)
Other investments	(144,613)		(255,980)
Purchase of property and equipment	(429,780)	(43,872)	(368,162)	(564,305)
Convertible loan receivable	(14,941)		(52,225)
Net Cash Used In Investing Activities	(1,118,309)	(73,872)	(9,181,891)	(2,690,063)
Financing Activities
Issuance of shares, net of share issue costs	75,549		21,561,568	4,806,025
Share subscriptions received	15,291
Loans obtained			5,217,547
Loans repaid			(6,656,444)
Financing Activities	90,840		20,122,671	4,806,025
Effect of exchange rate changes on cash	119,193	73,315	294,909	(18,382)
Net Increase in Cash	(2,106,481)	(224,356)	8,679,879	(41,747)
Cash-Beginning of Period	9,004,716	324,837	324,837	366,584
Cash - End of Period	$ 6,898,235	$ 100,481	$ 9,004,716	$ 324,837

Nature and Continuance of Opera

Nature and Continuance of Operations	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature and Continuance of Operations	1. Nature and Continuance of Operations Body and Mind Inc. (the “Company”) was incorporated on 5 November 1998 in the State of Delaware, USA, under the name Concept Development Group, Inc. In May 2004, the Company acquired 100% of Kaleidoscope Venture Capital, Inc. (formerly Vocalscape Networks, Inc.) (“Kaleidoscope”) and changed its name to Vocalscape, Inc. In November 2005, the Company changed its name to Nevstar Precious Metals Inc. and in September 2008, the Company changed its name to Deploy Technologies Inc. On 14 November 2017, the Company acquired Nevada Medical Group, LLC (“NMG”) and changed its name to Body and Mind Inc. The Company is now a supplier and grower of medical and recreational cannabis in the state of Nevada, and has retail operations in California, Ohio and Arkansas. These unaudited consolidated interim financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These unaudited consolidated interim financial statements do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the financial statements for the year ended 31 July 2019. The unaudited consolidated interim financial statements should be read in conjunction with the Company’s audited financial statements for the year ended 31 July 2019. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended 31 October 2019 are not necessarily indicative of the results that may be expected for the year ending 31 July 2020. Principles of Consolidation These consolidated financial statements include the financial statements of the Company and its subsidiaries as follows: Name Jurisdiction Ownership Date of acquisition or formation DEP Nevada Inc. (“DEP Nevada”) Nevada, USA 100% 10 August 2017 Nevada Medical Group LLC (“NMG”) Nevada, USA 100% 14 November 2017 NMG Retail LLC Nevada, USA 75% 14 September 2018 NMG Long Beach LLC California, USA 100% 18 December 2018 NMG Cathedral City LLC California, USA 100% 4 January 2019 NMG Chula Vista LLC California, USA 51% 10 January 2019 NMG San Diego LLC California, USA 60% 30 January 2019 All inter-company transactions and balances are eliminated upon consolidation. These consolidated financial statements include the following investments accounted for using the equity method of accounting: Name Jurisdiction Ownership Date of acquisition or formation NMG Ohio LLC Ohio, USA 30% 27 April 2017	1. Nature of Operations Body and Mind Inc. (the “Company”) was incorporated on 5 November 1998 in the State of Delaware, USA, under the name Concept Development Group, Inc. In May 2004, the Company acquired 100% of Kaleidoscope Venture Capital, Inc. (formerly Vocalscape Networks, Inc.) (“Kaleidoscope”) and changed its name to Vocalscape, Inc. In November 2005, the Company changed its name to Nevstar Precious Metals Inc. and in September 2008, the Company changed its name to Deploy Technologies Inc. On 14 November 2017, the Company acquired Nevada Medical Group, LLC (“NMG”) and changed its name to Body and Mind Inc. The Company is now a supplier and grower of medical and recreational cannabis in the state of Nevada, and has retail operations in California, Ohio and Arkansas.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Accounting Policies [Abstract]
Recent Accounting Pronouncements	2. Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years beginning after 15 December 2019. The Company does not anticipate this amendment to have a significant impact on the financial statements. In August 2018, the FASB issued ASU 2018-13, Disclosure Framework –Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). ASU 2018-13 adds, modifies, and removes certain fair value measurement disclosure requirements. ASU 2018-13 is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the effect of adopting this ASU on the Company’s financial statements. The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial position, statements of operations and cash flows.	2. Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02 (Topic 842) "Leases." Topic 842 supersedes the lease recognition requirements in Accounting Standards Codification (“ASC”) Topic 840 "Leases." Under Topic 842, lessees are required to recognize assets and liabilities on the balance sheet for most leases and provide enhanced disclosures. Leases will continue to be classified as either finance or operating. Topic 842 is effective for annual reporting periods and interim periods within those years beginning after 15 December 2018. Early adoption by public entities is permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements, and there are certain optional practical expedients that an entity may elect to apply. Full retrospective application is prohibited. The Company is currently evaluating the impact that this new standard will have on its financial statements. In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years beginning after 15 December 2019. The Company does not anticipate this amendment to have a significant impact on the financial statements. In February 2018, the FASB issued ASU No. 2018-02, “Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. The amendments in this ASU address a narrow-scope financial reporting issue related to the tax effects that may become “stranded” in accumulated other comprehensive income (AOCI) as a result of the Tax Cuts and Jobs Act (TCJA). The amendments in ASU 2018-02 are effective for all entities for fiscal years beginning after 15 December 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in ASU 2018-02 should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company does not anticipate this amendment to have a significant impact on the financial statements. In August 2018, the FASB issued ASU 2018-13, Disclosure Framework –Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). ASU 2018-13 adds, modifies, and removes certain fair value measurement disclosure requirements. ASU 2018-13 is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the effect of adopting this ASU on the Company’s financial statements. The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial position, statements of operations and cash flows.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies The following is a summary of significant accounting policies used in the preparation of these consolidated financial statements. Basis of presentation These consolidated interim financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is 31 July. Cash and cash equivalents Cash and cash equivalents include highly liquid investments with original maturities of three months or less. Amounts receivable Amounts receivable represents amounts owed from customers for sale of medical and recreational cannabis and sales tax recoverable. Amounts are presented net of the allowance for doubtful accounts, which represents the Company’s best estimate of the amount of probable credit losses in the existing accounts receivable balance. The Company determines the allowance for doubtful accounts based on historical experience and current economic conditions. The Company reviews the adequacy of its allowance for doubtful accounts on a quarterly basis. As at 31 October 2019 and 31 July 2019, the Company has no allowance for doubtful accounts. Revenue recognition The Company derives revenue primarily from the sale of medical and recreational cannabis. In accordance with ASC 606, revenue is recognized when persuasive evidence of an arrangement exists, the services have been rendered and the goods have been delivered, the amount is fixed and determinable, and collection is reasonably assured. The Company does not have standard terms that permit return of product; however, in certain markets where returns occur management estimates the amount of returns as variable consideration based on historical return experience and adjust revenue accordingly. Products that do not meet the Company’s high-quality standards are returned by the customer or recalled and destroyed and are recorded as a reduction of revenue. The reversal of revenue is recorded upon determination that the product will be recalled and destroyed. Management estimates the costs required to facilitate product returns and records them in cost of goods sold as required. Inventory Inventory consists of raw material, work in progress (live plants and plants in the drying process), finished goods, and consumables. The Company values its raw material, finished goods and consumables at the lower of the actual costs or its current estimated market value less costs to sell. The Company values its work in progress at cost. The Company periodically reviews its inventory for obsolete and potentially impaired items. Property and equipment Property and equipment are stated at cost and are amortized over their estimated useful lives on a straight-line basis as follows: Office equipment 7 years Cultivation equipment 7 years Production equipment 7 years Kitchen equipment 7 years Vehicles 7 years Vault equipment 7 years Leasehold improvements shorter of 15 years or the term of the lease Right-of-use asset Term of the lease Brands and licenses Intangible assets acquired from third parties are measured initially at fair value and either classified as indefinite life or finite life depending on their characteristics. Intangible assets with indefinite lives are tested for impairment at least annually and intangible assets with finite lives are reviewed for indicators of impairment at least annually. The Company’s brands and licenses have indefinite lives; therefore no amortization is recognized. Income taxes Deferred income taxes are reported for timing differences between items of income or expense reported in the consolidated financial statements and those reported for income tax purposes in accordance with ASC 740, “Income Taxes”, which requires the use of the asset/liability method of accounting for income taxes. Deferred income taxes and tax benefits are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases, and for tax losses and credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company provides for deferred taxes for the estimated future tax effects attributable to temporary differences and carry-forwards when realization is more likely than not. Basic and diluted net loss per share The Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excluded all dilutive potential shares if their effect is anti-dilutive. Segments of an enterprise and related information ASC 280, “Segment Reporting” establishes guidance for the way that public companies report information about operating segments in annual consolidated financial statements and requires reporting of selected information about operating segments in interim consolidated financial statements issued to the public. It also establishes standards for disclosures regarding products and services, geographic areas and major customers. ASC 280 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company has evaluated this Codification and does not believe it is applicable at this time. Comprehensive loss ASC 220, “Comprehensive Income”, establishes standards for the reporting and display of comprehensive income/loss and its components in the consolidated financial statements. As at 31 July 2019, the Company reported foreign currency translation adjustments as other comprehensive income or loss and included a schedule of comprehensive income/loss in the consolidated financial statements. Foreign currency translation The Company’s functional currency is the Canadian dollar and its reporting currency is the U.S. dollars. The Company’s subsidiaries have a functional currency of U.S. dollars. The consolidated financial statements of the Company are translated to U.S. dollars in accordance with ASC 830, “Foreign Currency Matters”. Exchange gains and losses on inter-company balances that form part of the net investment in foreign operations are included in other comprehensive income. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. Stock-based compensation The Company accounts for stock-based compensation issued to those other than employees in accordance with ASC 505-50. Equity instruments issued to those other than employees are valued at the earlier of a commitment date or upon completion of the services, based on the fair value of the equity instruments and is recognized as expense over the service period. The Company estimates the fair value of share-based payments using the Black-Scholes Option Pricing Model for common stock options and the closing price of the Company’s common stock for common share issuances. Fair value measurements The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: · Level 1 – inputs are based upon unadjusted quoted prices for identical instruments in active markets. · Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques (e.g. the Black-Scholes model) for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, credit spreads, foreign exchange rates, and forward and spot prices for currencies. · Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models. Our Level 3 assets and liabilities include investments in other private entities, and goodwill and intangible assets, when they are recorded at fair value due to an impairment charge. Unobservable inputs used in the models are significant to the fair values of the assets and liabilities. The Company measures equity investments without readily determinable fair values on a nonrecurring basis. The fair values of these investments are determined based on valuation techniques using the best information available, and may include quoted market prices, market comparables, and discounted cash flow projections. Other current financial assets and current financial liabilities have fair values that approximate their carrying values. Use of estimates and assumptions The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenditures during the reporting period. Actual results could differ from these estimates. Lease accounting Under ASC 842, leases are separated into two classifications: operating leases and financial leases. Lease classification under ASC 842 is relatively similar to ASC 840. For a lease to be classified as a finance lease, it must meet one of the five finance lease criteria: (1) transference of title/ownership to the lessee, (2) purchase option, (3) lease term for major part of the remaining economic life of the asset, (4) present value represents substantially all of the fair value of the asset, and (5) asset specialization. Any lease that does not meet these criteria is classified as an operating lease. ASC 842 requires all leases to be recognized on the Company’s balance sheet. Specifically, for operating leases, the Company must recognize a right-of-use asset and a corresponding lease liability upon lease commitment. Comparative figures Certain comparative figures have been adjusted to conform to the current year’s presentation.	3. Significant Accounting Policies The following is a summary of significant accounting policies used in the preparation of these consolidated financial statements. Basis of presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is 31 July. Principles of consolidation These consolidated financial statements include the financial statements of the Company and its subsidiaries as follows: Name Jurisdiction Ownership Date of acquisition or formation DEP Nevada, Inc. (“Dep Nevada”) Nevada, USA 100 % 10 August 2017 Nevada Medical Group, LLC (“NMG”) Nevada, USA 100 % 14 November 2017 NMG Retail, LLC Nevada, USA 75 % 14 September 2018 NMG Long Beach, LLC California, USA 100 % 18 December 2018 NMG Cathedral City, LLC California, USA 100 % 4 January 2019 NMG Chula Vista, LLC California, USA 51 % 10 January 2019 NMG San Diego, LLC California, USA 60 % 30 January 2019 All inter-company transactions and balances are eliminated upon consolidation. These consolidated financial statements include the following investments accounted for using the equity method of accounting: Name Jurisdiction Ownership Date of acquisition or formation NMG Ohio, LLC Ohio, USA 30 % 27 April 2017 Cash and cash equivalents include highly liquid investments with original maturities of three months or less. Cash and cash equivalents Amounts receivable Amounts receivable represents amounts owed from customers for sale of medical and recreational cannabis and sales tax recoverable. Amounts are presented net of the allowance for doubtful accounts, which represents the Company’s best estimate of the amount of probable credit losses in the existing accounts receivable balance. The Company determines the allowance for doubtful accounts based on historical experience and current economic conditions. The Company reviews the adequacy of its allowance for doubtful accounts on a quarterly basis. As at 31 July 2019 and 2018, the Company has no allowance for doubtful accounts. Revenue recognition In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Since its initial release, the FASB has issued several amendments to the standard, which include clarification of accounting guidance related to identification of performance obligations and principal versus agent considerations. Topic 606 became effective for the Company in the first quarter of the 2019 fiscal year. The adoption of this guidance had no impact on the Company’s financial statements. The Company derives revenue primarily from the sale of medical and recreational cannabis. In accordance with ASC 606, revenue is recognized when persuasive evidence of an arrangement exists, the services have been rendered and the goods have been delivered, the amount is fixed and determinable, and collection is reasonably assured. The Company does not have standard terms that permit return of product; however, in certain markets where returns occur management estimates the amount of returns as variable consideration based on historical return experience and adjust revenue accordingly. Products that do not meet the Company’s high-quality standards are returned by the customer or recalled and destroyed and are recorded as a reduction of revenue. The reversal of revenue is recorded upon determination that the product will be recalled and destroyed. Management estimates the costs required to facilitate product returns and records them in cost of goods sold as required. Inventory Inventory consists of raw material, work in progress (live plants and plants in the drying process), finished goods, and consumables. The Company values its raw material, finished goods and consumables at the lower of the actual costs or its current estimated market value less costs to sell. The Company values its work in progress at cost. The Company periodically reviews its inventory for obsolete and potentially impaired items. Property and equipment Property and equipment are stated at cost and are amortized over their estimated useful lives on a straight-line basis as follows: Office equipment 7 years Cultivation equipment 7 years Production equipment 7 years Kitchen equipment 7 years Vehicles 7 years Vault equipment 7 years Leasehold improvements shorter of 15 years or the term of the lease Brands and licenses Intangible assets acquired from third parties are measured initially at fair value and either classified as indefinite life or finite life depending on their characteristics. Intangible assets with indefinite lives are tested for impairment at least annually and intangible assets with finite lives are reviewed for indicators of impairment at least annually. The Company’s brands and licenses have indefinite lives; therefore no amortization is recognized. Income taxes Deferred income taxes are reported for timing differences between items of income or expense reported in the consolidated financial statements and those reported for income tax purposes in accordance with ASC 740, “Income Taxes”, which requires the use of the asset/liability method of accounting for income taxes. Deferred income taxes and tax benefits are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases, and for tax losses and credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company provides for deferred taxes for the estimated future tax effects attributable to temporary differences and carry-forwards when realization is more likely than not. Basic and diluted net loss per share The Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excluded all dilutive potential shares if their effect is anti-dilutive. Segments of an enterprise and related information ASC 280, “Segment Reporting” establishes guidance for the way that public companies report information about operating segments in annual consolidated financial statements and requires reporting of selected information about operating segments in interim consolidated financial statements issued to the public. It also establishes standards for disclosures regarding products and services, geographic areas and major customers. ASC 280 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company has evaluated this Codification and does not believe it is applicable at this time. Comprehensive loss ASC 220, “Comprehensive Income”, establishes standards for the reporting and display of comprehensive income/loss and its components in the consolidated financial statements. As at 31 July 2019, the Company reported foreign currency translation adjustments as other comprehensive income or loss and included a schedule of comprehensive income/loss in the consolidated financial statements. Foreign currency translation The Company’s functional currency is the Canadian dollar and its reporting currency is the U.S. dollars. The Company’s subsidiaries have a functional currency of U.S. dollars. The consolidated financial statements of the Company are translated to U.S. dollars in accordance with ASC 830, “Foreign Currency Matters”. Exchange gains and losses on inter-company balances that form part of the net investment in foreign operations are included in other comprehensive income. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. Stock-based compensation The Company accounts for stock-based compensation issued to those other than employees in accordance with ASC 505-50. Equity instruments issued to those other than employees are valued at the earlier of a commitment date or upon completion of the services, based on the fair value of the equity instruments and is recognized as expense over the service period. The Company estimates the fair value of share-based payments using the Black-Scholes Option Pricing Model for common stock options and the closing price of the Company’s common stock for common share issuances. Fair Value Measurements The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: · Level 1 – inputs are based upon unadjusted quoted prices for identical instruments in active markets. · Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques (e.g. the Black-Scholes model) for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, credit spreads, foreign exchange rates, and forward and spot prices for currencies. · Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models. Our Level 3 assets and liabilities include investments in other private entities, and goodwill and intangible assets, when they are recorded at fair value due to an impairment charge. Unobservable inputs used in the models are significant to the fair values of the assets and liabilities. The Company measures equity investments without readily determinable fair values on a nonrecurring basis. The fair values of these investments are determined based on valuation techniques using the best information available, and may include quoted market prices, market comparables, and discounted cash flow projections. Other current financial assets and current financial liabilities have fair values that approximate their carrying values. The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenditures during the reporting period. Actual results could differ from these estimates. Use of estimates and assumptions Comparative figures Certain comparative figures have been adjusted to conform to the current year’s presentation.

Financial Instruments

Financial Instruments	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Investments, All Other Investments [Abstract]
Financial Instruments	4. Financial Instruments The following table represents the Company’s assets that are measured at fair value as of 31 October 2019 and 31 July 2019: As at 31 October 2019 As at 31 July 2019 Financial assets at fair value Cash $ 6,898,235 $ 9,004,716 Convertible loan receivable 67,166 52,225 Total financial assets at fair value $ 6,965,401 $ 9,056,941 Management of financial risks The financial risk arising from the Company’s operations include credit risk, liquidity risk, interest rate risk and currency risk. These risks arise from the normal course of operations and all transactions undertaken are to support the Company’s ability to continue as a going concern. The risks associated with these financial instruments and the policies on how to mitigate these risks are set out below. Management manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner. Credit risk Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company is not exposed to credit risk related to cash and cash equivalents as it does not hold cash in excess of federally insured limits, with major financial institutions. Credit risk associated with the convertible loans receivable (including the investment in and advances to GLDH) arises from the possibility that the principal and/or interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationship. The Company is not currently exposed to any significant credit risk associated with its trade receivable. Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company had a working capital of $8,288,767 as at 31 October 2019 and accordingly is not currently exposed to any liquidity risk. Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk as it does not hold financial instruments that will fluctuate in value due to changes in interest rates. Currency risk Currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is exposed to currency risk by incurring expenditures and holding assets denominated in currencies other than its functional currency. Assuming all other variables remain constant, a 1% change in the Canadian dollar against the US dollar would not result in a significant change to the Company’s consolidated interim statement of operations. Other risks The Company is not exposed to other risks unless otherwise noted.	4. Financial Instruments The following table represents the Company’s assets that are measured at fair value as of 31 July 2019 and 2018: As at 31 July 2019 As at 31 July 2018 Financial assets at fair value Cash $ 9,004,716 $ 324,837 Convertible loan receivable 52,225 - Total financial assets at fair value $ 9,056,941 $ 324,837 Management of financial risks The financial risk arising from the Company’s operations include credit risk, liquidity risk, interest rate risk and currency risk. These risks arise from the normal course of operations and all transactions undertaken are to support the Company’s ability to continue as a going concern. The risks associated with these financial instruments and the policies on how to mitigate these risks are set out below. Management manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner. Credit risk Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company is not exposed to credit risk related to cash and cash equivalents as it does not hold cash in excess of federally insured limits, with major financial institutions. Credit risk associated with the convertible loans receivable (including the investment in and advances to GLDH) arises from the possibility that the principal and/or interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationship. The Company is not currently exposed to any significant credit risk associated with its trade receivable. Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company had a working capital of $10,262,959 as at July 31, 2019 and accordingly is not currently exposed to any liquidity risk. Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk as it does not hold financial instruments that will fluctuate in value due to changes in interest rates. Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company had a working capital of $8,288,767 as at 31 October 2019 and accordingly is not currently exposed to any liquidity risk. Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk as it does not hold financial instruments that will fluctuate in value due to changes in interest rates. Currency risk Currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is exposed to currency risk by incurring expenditures and holding assets denominated in currencies other than its functional currency. Assuming all other variables remain constant, a 1% change in the Canadian dollar against the US dollar would not result in a significant change to the Company’s consolidated interim statement of operations. Other risks The Company is not exposed to other risks unless otherwise noted.

Inventory

Inventory	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Inventory Disclosure [Abstract]
Inventory	5. Inventory 31 October 2019 31 July 2019 Work in progress $ 245,750 $ 208,417 Finished goods 468,162 615,108 Consumables 533,308 566,894 Total $ 1,247,220 $ 1,390,419	5. Inventory 31 July 2019 31 July 2018 Raw materials $ - $ 9,705 Work in progress 208,417 151,039 Finished goods 615,108 567,563 Consumables 566,894 225,110 Total $ 1,390,419 $ 953,417

Convertible loan receivable

Convertible loan receivable	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Convertible loan receivable [Abstract]
Convertible loan receivable	6. Convertible loan receivable Effective March 15, 2018, the Company, through its wholly owned subsidiaries, DEP Nevada and NMG, entered into a convertible loan agreement and a management agreement with Comprehensive Care Group LLC (“CCG”), an Arkansas limited liability company, with respect to the development of a medical cannabis dispensary facility in West Memphis, Arkansas. Pursuant to the management agreement, NMG will provide operations and management services, including management, staffing, operations, administration, oversight, and other related services. Under the management agreement, NMG will be required to obtain approval from CCG for any key decisions as defined in the agreement and accordingly the Company does not control CCG. NMG will be paid a monthly management fee equal to 66.67% of the monthly net profits of CCG, subject to conversion of the convertible loan as discussed below upon which the monthly management fee shall be $6,000 per month, unless otherwise agreed by the parties in writing. The convertible loan agreement is for an amount up to $1,250,000 from DEP to CCG with proceeds to be used to fund construction of a facility, working capital and initial operating expenses. The loan bears interest at a fixed rate of $6,000 per month until the parties mutually agree to increase the interest. Upon the latter of one year of granting of a medical cannabis dispensary license by the appropriate authorities or one year after entering into the convertible loan agreement, DEP may elect to convert the loan into preferred units of CCG equal to 40% of all outstanding units of CCG, subject to approval of the Arkansas Medical Marijuana Commission. The Company evaluated the convertible loan receivable’s settlement provisions and elected the fair value option in accordance with ASC 825 “Financial Instruments”, to value this instrument. Under such election, the loan receivable is measured initially and subsequently at fair value, with any changes in the fair value of the instrument being recorded in the consolidated financial statements as a change in fair value of the financial instruments. The Company estimates the fair value of this instrument by first estimating the fair value of the straight debt portion, excluding the embedded conversion option, using a discounted cash flow model. The Company then estimates the fair value of the embedded conversion option using the Black-Scholes Option Pricing Model. The sum of these two valuations is the fair value of the loan receivable. Management believes that the accretion of the straight debt portion and embedded derivative related to the conversion option are not material. As at 31 October 2019, the Company had advanced $67,166 (31 July 2019 - $52,225) and accrued interest income of $45,000 (2018 - $Nil) which is included in accounts receivable.	6. Convertible loan receivable Effective March 15, 2019, the Company, through its wholly owned subsidiaries, DEP Nevada and NMG, entered into a convertible loan agreement and a management agreement with Comprehensive Care Group LLC (“CCG”), an Arkansas limited liability company, with respect to the development of a medical cannabis dispensary facility in West Memphis, Arkansas. Pursuant to the management agreement, NMG will provide operations and management services, including management, staffing, operations, administration, oversight, and other related services. Under the management agreement, NMG will be required to obtain approval from CCG for any key decisions as defined in the agreement and accordingly the Company does not control CCG. NMG will be paid a monthly management fee equal to 66.67% of the monthly net profits of CCG, subject to conversion of the convertible loan as discussed below upon which the monthly management fee shall be $6,000 per month, unless otherwise agreed by the parties in writing. The convertible loan agreement is for an amount up to $1,250,000 from DEP to CCG with proceeds to be used to fund construction of a facility, working capital and initial operating expenses. The loan bears interest at a fixed rate of $6,000 per month until the parties mutually agree to increase the interest. Upon the latter of one year of granting of a medical cannabis dispensary license by the appropriate authorities or one year after entering into the convertible loan agreement, DEP may elect to convert the loan into preferred units of CCG equal to 40% of all outstanding units of CCG, subject to approval of the Arkansas Medical Marijuana Commission. The Company evaluated the convertible loan receivable’s settlement provisions and elected the fair value option in accordance with ASC 825 “Financial Instruments”, to value this instrument. Under such election, the loan receivable is measured initially and subsequently at fair value, with any changes in the fair value of the instrument being recorded in the consolidated financial statements as a change in fair value of the financial instruments. The Company estimates the fair value of this instrument by first estimating the fair value of the straight debt portion, excluding the embedded conversion option, using a discounted cash flow model. The Company then estimates the fair value of the embedded conversion option using the Black-Scholes Option Pricing Model. The sum of these two valuations is the fair value of the loan receivable. Management believes that the accretion of the straight debt portion and embedded derivative related to the conversion option are not material. As at July 31, 2019, the Company had advanced $52,225 (2018 - $Nil) and accrued interest income of $27,000 (2018 - $Nil).

Property and Equipment

Property and Equipment	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	7 . Property and Equipment Office Equipment Cultivation Equipment Production Equipment Kitchen Equipment Vehicles Vault Equipment Leasehold Improvements Right-of-use Assets Total Cost: Balance, 31 July 2018 $ 24,586 $ 435,109 $ 261,957 $ 27,694 $ 38,717 $ 1,644 $ 1,993,928 $ - $ 2,783,635 Additions 7,491 28,647 36,004 23,414 - 528 272,078 - 368,162 Balance, 31 July 2019 32,077 463,756 297,961 51,108 38,717 2,172 2,266,006 - 3,151,797 Additions 26,980 - 154,982 9,022 - - 238,796 - 429,780 ASC 842 adoption (Note 20) - - - - - - - 1,187,116 1,187,116 Balance, 31 October 2019 59,057 463,756 452,943 60,130 38,717 2,172 2,504,802 1,187,116 4,768,693 Accumulated Depreciation: Balance, 31 July 2018 3,177 41,169 25,446 2,554 5,500 228 89,663 - 167,737 Depreciation 5,119 73,597 44,547 4,546 7,751 358 153,642 - 289,560 Balance, 31 July 2019 8,296 114,766 69,993 7,100 13,251 586 243,305 - 457,297 Depreciation 1,911 19,066 12,093 2,127 1,954 100 41,346 - 78,597 Asset lease expense (Note 20) - - - - - - - 43,089 43,089 Balance, 31 October 2019 10,207 133,832 82,086 9.227 15,205 686 284,651 43,089 578,983 Net Book Value: As at 31 July 2018 21,409 393,940 236,511 25,140 33,217 1,416 1,904,265 - 2,615,898 As at 31 July 2019 23,781 348,990 227,968 44,008 25,466 1,586 2,022,701 - 2,694,500 As at 31 October 2019 $ 48,850 $ 329,924 $ 370,857 $ 50,903 $ 23,512 $ 1,486 $ 2,220,151 $ 1,144,027 $ 4,189,710	7. Property and Equipment Office Equipment Cultivation Equipment Production Equipment Kitchen Equipment Vehicles Vault Equipment Leasehold Improvements Total Cost: Balance, 31 July 2017 $ - $ - $ - $ - $ - $ - $ - $ - Acquired assets (Note 14) 23,105 245,659 176,354 15,809 38,717 1,644 1,455,649 1,956,937 Additions 1,481 189,450 85,603 11,885 - - 538,279 826,698 Balance, 31 July 2018 24,586 435,109 261,957 27,694 38,717 1,644 1,993,928 2,783,635 Additions 7,491 28,647 36,004 23,414 - 528 272,078 368,162 Balance, 31 July 2019 32,077 463,756 297,961 51,108 38,717 2,172 2,266,006 3,151,797 Accumulated Depreciation: Balance, 31 July 2017 - - - - - - - - Depreciation 3,177 41,169 25,446 2,554 5,500 228 89,663 167,737 Balance, 31 July 2018 3,177 41,169 25,446 2,554 5,500 228 89,663 167,737 Depreciation 5,119 73,597 44,547 4,546 7,751 358 153,642 289,560 Balance, 31 July 2019 8,296 114,766 69,993 7,100 13,251 586 243,305 457,297 Net Book Value: As at 31 July 2018 21,409 393,940 236,511 25,140 33,217 1,416 1,904,265 2,615,898 As at 31 July 2019 $ 23,781 $ 348,990 $ 227,968 $ 44,008 $ 25,466 $ 1,586 $ 2,022,701 $ 2,694,500

Related Party Balances and Tran

Related Party Balances and Transactions	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Related Party Transactions [Abstract]
Related Party Balances and Transactions	8. Related Party Balances and Transactions In addition to those disclosed elsewhere in these consolidated interim financial statements, related party transactions for the three month period ended 31 October 2019 and 2018 are as follows: a) During the three months ended 31 October 2019, management fees of $34,311 (2018 - $Nil) and consulting fees of $7,556 (2018 – $Nil) were paid/accrued to a company controlled by the President and Interim Chief Executive Officer of the Company. b) During the three months ended 31 October 2019, management fees of $22,668 (2018 - $Nil) and accounting fees of $Nil (2018 - $6,908) were paid/accrued to a company controlled by the Chief Financial Officer and a director of the Company. c) During the three months ended 31 October 2019, salaries and wages of $45,000 (2018 - $Nil) were paid/accrued to the Chief Operating Officer of the Company. d) During the three months ended 31 October 2019, management fees of $50,000 (2018 - $33,654) were paid/accrued to a company controlled by a director of the Company. e) During the three months ended 31 October 2019, management fees of $5,667 (2018 - $11,514) and consulting fees of $11,334 (2018 - $Nil) were paid/accrued to a company controlled by the Corporate Secretary of the Company. f) As at 31 October 2019, the Company owed $482 (31 July 2019 - $7,825) to the Interim Chief Executive Officer of the Company and a company controlled by him. g) As at 31 October 2019, the Company owed $7,888 (31 July 2019 - $5,172) to the Chief Financial Officer of the Company h) As at 31 October 2019, the Company owed $33,333 (31 July 2019 - $Nil) to a director of the Company and a company controlled by him. The above amounts owing to related parties are unsecured, non-interest bearing and are due on demand. Included in stock-based compensation for the three months ended 31 October 2019 is $187,705 (2018 - $Nil) related to stock options issued to directors and offices of the Company.	8. Related Party Balances and Transactions In addition to those disclosed elsewhere in these consolidated financial statements, related party transactions for the years ended 31 July 2019 and 2018 are as follows: a) During the year ended 31 July 2019, management fees of $50,072 (2018 - $Nil) were paid/accrued to a company controlled by the Interim Chief Executive Officer of the Company. b) During the year ended 31 July 2019, accounting fees of $37,791 (2018 - $29,531) and management fees of $Nil (2018 - $9,425) were paid/accrued to a company controlled by the Chief Financial Officer and a director of the Company. c) During the year ended 31 July 2019, management fees of $90,696 (2018 - $66,759) were paid/accrued to companies related to the former Chief Executive Officer and a former director of the Company. d) During the year ended 31 July 2019, management fees of $225,992 (2018 - $144,528) were paid/accrued to a company controlled by a director of the Company. e) During the year ended 31 July 2019, management fees of $62,353 (2018 - $47,124) were paid/accrued to a company controlled by the former Chief Financial Officer of the Company. f) During the year ended 31 July 2019, consulting fees of $90,000 (2018 - $Nil) were paid/accrued to the Chief Operating Officer of the Company. g) During the year ended 31 July 2019, management fees of $Nil (2018 - $2,712) were paid/accrued to a former Chief Executive Officer of the Company. h) As at 31 July 2019, the Company owed $7,825 (31 July 2018 - $Nil) to the Interim Chief Executive Officer of the Company and a company controlled by him. i) As at 31 July 2019, the Company owed $5,127 (31 July 2018 - $1,210) to the Chief Financial Officer and a director of the Company and a company controlled by him. j) As at 31 July 2019, the Company owed $Nil (31 July 2018 - $17,028) to a former Chief Executive Officer and a former director of the Company and a company controlled by him. k) As at 31 July 2019, the Company owed $Nil (31 July 2018 - $28,810) to a director of the Company and a company controlled by him. l) As at 31 July 2019, the Company owed $Nil (31 July 2018 - $4,033) to the former Chief Financial Officer of the Company. The above amounts owing to related parties are unsecured, non-interest bearing and are due on demand. Included in stock-based compensation for the year ended 31 July 2019 is $579,904 (2018 - $377,443) related to stock options issued to directors and officers of the Company. During the year ended 31 July 2019, the Company entered into an agreement to purchase the remaining 70% of NMG Ohio for total cash payments of $1,575,000 and issuance of 3,173,864 common shares of the Company (Note 17), of which cash of $461,251 and 929,488 common shares are payable to directors of the Company.

Notes Payable

Notes Payable	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Notes Payable [Abstract]
Notes Payable	9. Notes Payable In connection with the Acquisition of NMG, on 14 November 2017, the Company issued promissory notes totaling $2,175,000 to NMG Members (Note 14). As these promissory notes are non-interest bearing, they were discounted to a present value of $1,887,863 at a rate of 12%. These promissory notes are non-interest bearing, secured by the assets of the Company, and due the earlier of 14 February 2019 or within 30 days from the date of the Company completes a financing of at least $500,000. Any unpaid amounts at maturity will bear interest at a rate of 10% per annum. At 31 July 2018, the promissory notes were accreted to their face value as it was estimated that repayment would occur imminently due to the Company’s fund raising initiatives. On 12 November 2018 the notes were amended such that $1,175,000 was repaid and the balance of $1,000,000 would be due on 14 February 2019. As the balance was not repaid on 14 February 2019, interest commenced accruing at 8% per annum and the principal plus interest is to be repaid on the earlier of i) 12 months from due date or ii) within 10 business days of closing a financing greater than $5,000,000. During the year ended 31 July 2019, because the Company completed a financing of more than $500,000, the Company accrued interest expense of $24,443 (2018 - $277,219) and repaid the note in full. In connection with the investment of Green Light District Holdings, Inc. (“GLDH”) on 29 November 2018, the Company issued a promissory note in the amount of $4,000,000 to Australis Capital Inc. (“Australis”) (Notes 15 and 18). The promissory note bears interest at a rate of 15% per annum, is secured by the assets of the Company, matures in two years and requires semi-annual interest payments unless the Company elects to accrue the interest by adding it to the principal amount. The Company issued 1,105,083 common shares of the Company as a finance fee to Australis valued at $822,494 (Note 11). During the year ended 31 July 2019, the Company accrued interest and accretion expense of $1,118,051 (2018 - $Nil) and repaid the note in full. The Company also paid a prepayment penalty of $200,000 for repaying the note prior to the maturity date. 31 October 2019 31 July 2019 Balance, beginning $ - $ 2,175,000 Issuance of promissory notes - 4,000,000 Deferred finance costs - (822,494 ) Repayment of promissory notes - (6,695,000 ) Early repayment penalty - 200,000 Interest and accretion expense - 1,142,494 Balance, ending $ - $ -	9. Notes Payable In connection with the Acquisition of NMG, on 14 November 2017, the Company issued promissory notes totaling $2,175,000 to NMG Members (Note 14). As these promissory notes are non-interest bearing, they were discounted to a present value of $1,887,863 at a rate of 12%. These promissory notes are non-interest bearing, secured by the assets of the Company, and due the earlier of 14 February 2019 or within 30 days from the date of the Company completes a financing of at least $500,000. Any unpaid amounts at maturity will bear interest at a rate of 10% per annum. At 31 July 2018, the promissory notes were accreted to their face value as it was estimated that repayment would occur imminently due to the Company’s fund raising initiatives. On 12 November 2018 the notes were amended such that $1,175,000 was repaid and the balance of $1,000,000 would be due on 14 February 2019. As the balance was not repaid on 14 February 2019, interest commenced accruing at 8% per annum and the principal plus interest is to be repaid on the earlier of i) 12 months from due date or ii) within 10 business days of closing a financing greater than $5,000,000. During the year ended 31 July 2019, because the Company completed a financing of more than $500,000, the Company accrued interest expense of $24,443 (2018 - $277,219) and repaid the note in full. In connection with the investment of Green Light District Holdings, Inc. (“GLDH”) on 29 November 2018, the Company issued a promissory note in the amount of $4,000,000 to Australis Capital Inc. (“Australis”) (Notes 15 and 18). The promissory note bears interest at a rate of 15% per annum, is secured by the assets of the Company, matures in two years and requires semi-annual interest payments unless the Company elects to accrue the interest by adding it to the principal amount. The Company issued 1,105,083 common shares of the Company as a finance fee to Australis valued at $822,494 (Note 11). During the year ended 31 July 2019, the Company accrued interest and accretion expense of $1,118,051 (2018 - $Nil) and repaid the note in full. The Company also paid a prepayment penalty of $200,000 for repaying the note prior to the maturity date. 31 July 2019 31 July 2018 Balance, beginning $ 2,175,000 $ - Issuance of promissory notes 4,000,000 1,887,863 Deferred finance costs (822,494 ) - Repayment of promissory notes (6,695,000 ) - Early repayment penalty 200,000 - Interest and accretion expense 1,142,494 277,219 Foreign exchange adjustment - 9,918 Balance, ending $ - $ 2,175,000

Convertible debenture

Convertible debenture	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Convertible Debt [Abstract]
Convertible Debenture [Text Block]	10. Convertible Debenture In connection with an investment agreement with Australis on 30 October 2018 (Notes 11, 15 and 16), the Company issued an unsecured convertible debenture in the amount of CAD$1,600,000 to Australis. The convertible debenture bears interest at a rate of 8% per annum. Repayment of the outstanding principal amount of the convertible debenture, together with any accrued and unpaid interest, is to be made on or prior to 30 October 2020. The convertible debenture is convertible at the option of Australis into common shares of the Company at a conversion price of CAD$0.55 per common share, subject to adjustment and acceleration in certain circumstances. At the date of issue, a beneficial conversion feature of $88,797 (CAD$116,714) was recognized and the debt portion of the convertible debentures was recorded at a value of $1,128,750 (CAD$1,483,636). The value of the beneficial conversion feature was recorded in equity as additional paid-in capital. Subsequent to initial recognition, the debt has been amortized over the term of the debt using the effective interest rate method at a rate of 11.3% per annum. During the year ended 31 July 2019, the Company accrued interest and accretion expense of $98,392 (2018 - $Nil). The Company paid interest of $72,623 (2018 - $Nil) calculated up to July 31, 2019 and further paid interest of $88,821 in advance up to 30 June 2020. As consideration for receiving the interest in advance, Australis agreed to convert the debt into equity on July 1, 2020 and has given up the right to receive cash. The number of shares to be issued on conversion is fixed at 2,909,091 common shares and, accordingly, the debt is presented within equity as shares to be issued. 31 October 2019 31 July 2019 Balance, beginning $ 1,065,565 $ - Issuance of convertible debenture - 1,128,750 Interest and accretion expense - 98,392 Interest paid - (72,623 ) Interest advanced - (88,821 ) Foreign exchange adjustment - (133 ) Balance, ending $ 1,065,565 $ 1,065,565	10. Convertible Debt In connection with an investment agreement with Australis on 30 October 2018 (Notes 11, 15 and 16), the Company issued an unsecured convertible debenture in the amount of CAD$1,600,000 to Australis. The convertible debenture bears interest at a rate of 8% per annum. Repayment of the outstanding principal amount of the convertible debenture, together with any accrued and unpaid interest, is to be made on or prior to 30 October 2020. The convertible debenture is convertible at the option of Australis into common shares of the Company at a conversion price of CAD$0.55 per common share, subject to adjustment and acceleration in certain circumstances. At the date of issue, a beneficial conversion feature of $88,797 (CAD$116,714) was recognized and the debt portion of the convertible debentures was recorded at a value of $1,128,750 (CAD$1,483,636). The value of the beneficial conversion feature was recorded in equity as additional paid-in capital. Subsequent to initial recognition, the debt has been amortized over the term of the debt using the effective interest rate method at a rate of 11.3% per annum. During the year ended 31 July 2019, the Company accrued interest and accretion expense of $98,392 (2018 - $Nil). The Company paid interest of $72,623 (2018 - $Nil) calculated up to 31 July, 2019 and further paid interest of $88,821 in advance up to 30 June 2020. As consideration for receiving the interest in advance, Australis agreed to convert the debt into equity on 1 July, 2020 and has given up the right to receive cash. The number of shares to be issue on conversion is fixed at 2,909,091 common shares and, accordingly, the debt is presented within equity as shares to be issued. 31 July 2019 31 July 2018 Balance, beginning $ - $ - Issuance of convertible debenture 1,128,750 - Interest and accretion expense 98,392 - Interest paid (72,623 ) Interest advanced (88,821 ) Foreign exchange adjustment (133 ) - Balance, ending $ 1,065,565 $ -

Capital Stock

Capital Stock	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Capital [Abstract]
Capital Stock	11. Capital Stock The Company’s authorized share capital comprises 900,000,000 Common Shares, with a $0.0001 par value per share. On 2 November 2018, the Company closed a non-brokered private placement of 16,000,000 units at a price of $0.30 (CAD$0.40) per unit for aggregate gross proceeds of $4,883,840 (CAD$6,400,000) (Note 10, 15 and 16). Each unit consists of one common share and one share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CAD$0.50 per warrant for a period of two years. The Company paid cash of $152,720 and issued 322,581 common shares valued at $221,691 as finders’ fees in relation to this private placement. On 29 November 2018, the Company issued 1,105,083 common shares as a finance fee to Australis valued at $822,494 (Note 9). On 30 November 2018, the Company issued 3,206,160 common shares upon exercise of 3,206,160 warrants by Australis at a price of CAD$0.50 per common share for aggregate proceeds of $1,205,196 (CAD$1,603,080). On 31 January 2019, the Company issued 1,768,545 common shares to Australis for proceeds of $787,123 pursuant to the Investment Agreement (Note 16). On 31 January 2019, the Company issued 2,380,398 common shares valued at $1,448,805 in relation to acquiring the remaining 70% of NMG Ohio LLC (Note 17). On 14 May 2019, the Company issued 70,500 previously escrowed shares with a fair value of $22,689 to Toro Pacific Management Inc. in connection with the acquisition of NMG (Note 14). On 17 May 2019, the Company closed a private placement of 11,780,904 units at a price of $0.93 (CAD$1.25) per unit for aggregate gross proceeds of $10,956,241 (CAD$14,726,130). Each unit is comprised of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one common share of the Company at an exercise price of CAD$1.50 for a period of 48 months following the closing date, subject to adjustment in certain events. The agents received a cash commission of $589,499 (CAD$793,938). The agents also received as additional consideration 635,150 non-transferable broker warrants. Each broker warrant entitles the holder to acquire one unit at an exercise price of CAD$1.25 per unit for a period of 48 months following the closing date. A corporate finance fee of $63,774 (CAD $84,750) was also paid. On 28 May 2019, the Company issued 12,793,840 common shares upon exercise of 12,793,840 warrants by Australis at a price of CAD$0.50 per common share for aggregate proceeds of $4,746,515 (CAD$6,396,920). The proceeds were used, in part, to fully repay the outstanding senior secured note in the amount of $4,495,890 owing to Australis by the Company (Note 9). On 16 July 2019, the Company issued 7,333 common shares upon exercise of 7,333 warrants at a price of CAD$0.90 per common share for aggregate proceeds of $5,057 (CAD$6,600). On 12 August 2019, the Company issued a total of 4,337,111 common shares of the Company in connection with the Purchase Agreement, NMG SD Settlement Agreement and the Lease Assignment Agreement (Note 18). On 12 August 2019, the Company issued 81,591 common shares upon exercise of 81,591 warrants at a price of CAD$0.66 per common share for aggregate proceeds of $40,765 (CAD$53,850). On 12 September 2019, the Company issued 38,912 common shares upon exercise of 38,912 warrants at a price of CAD$0.66 per common share for aggregate proceeds of $19,450 (CAD$25,682). On 4 October 2019, the Company issued 22,727 common shares upon exercise of 22,727 warrants at a price of CAD$0.90 per common share for aggregate proceeds of $15,360 (CAD$20,454). Stock options The Company previously approved an incentive stock option plan, pursuant to which the Company may grant stock options up to an aggregate of 10% of the issued and outstanding common shares in the capital of the Company from time to time. On 11 December 2018, the Company issued 2,050,000 stock options in accordance with the Company’s stock option plan at an exercise price of CAD$0.57 per share for a five year term expiring 10 December 2023. The options were granted to current directors, officers, employees and consultants of the Company. The fair value of the stock options was calculated to be $880,595 (CAD$1,165,117) using the Black-Scholes Option Pricing Model with the following assumptions: Expected life of the options 5 years Expected volatility 265 % Expected dividend yield 0 % Risk-free interest rate 2.03 % On 21 August 2019, the Company issued 2,850,000 stock options with an exercise price of CAD$0.88 per share for a term of five years expiring on 21 August 2024. The options are subject to vesting provisions such that 25% of the options vest six months from the date of grant, 25% of the options vest twelve months from the date of grant, 25% of the options vest eighteen months from the date of grant and 25% of the options vest twenty-four months from the date of grant. On 16 October 2019, the Company cancelled 400,000 stock options previously granted to a director due to forfeiture, which had not vested. The total fair value of the stock options granted was calculated to be $1,373,856 (CAD$1,818,232) using the Black-Scholes Option Pricing Model with the following assumptions: Expected life of the options 5 years Expected volatility 140 % Expected dividend yield 0 % Risk-free interest rate 1.28 % During the three months ended 31 October 2019, the Company recorded a stock-based compensation of $276,987 (CAD$366,779) related to these options. On 1 October 2019, the Company issued 250,000 stock options with an exercise price of CAD$0.93 per share for a term of five years expiring on 1 October 2024. The options are subject to vesting provisions such that 25% of the options vest six months from the date of grant, 25% of the options vest twelve months from the date of grant, 25% of the options vest eighteen months from the date of grant and 25% of the options vest twenty-four months from the date of grant. The total fair value of the stock options granted was calculated to be $145,045 (CAD$191,960) using the Black-Scholes Option Pricing Model with the following assumptions: Expected life of the options 5 years Expected volatility 140 % Expected dividend yield 0 % Risk-free interest rate 1.37 % During the three months ended 31 October 2019, the Company recorded a stock-based compensation of $12,591 (CAD$16,663) related to these options. 31 October 2019 31 July 2019 Number of options Exercise Price Number of options Exercise Price Opening balance 6,075,000 CAD$0.62 4,025,000 CAD$0.65 Granted 3,100,000 CAD$0.88 2,050,000 CAD$0.57 Forfeited (400,000 ) CAD$0.88 - - Closing balance 8,775,000 CAD$0.70 6,075,000 CAD$0.62 Share purchase warrants and brokers’ warrants 31 October 2019 31 July 2019 Number of warrants Exercise Price Number of warrants Exercise Price Opening balance 22,514,771 CAD$1.22 10,106,820 CAD$0.89 Issued - - 28,415,284 CAD$0.93 Exercised (143,230 ) CAD$0.70 (16,007,333 ) CAD$0.50 Expired (225,083 ) CAD$0.66 - - Closing balance 22,146,458 CAD$1.23 22,514,771 CAD$1.22 As at 31 October 2019, the following warrants are outstanding: Number of warrants outstanding and exercisable Exercise price Expiry dates 21,700 CAD$0.66 3 November 2019 9,072,081 CAD$0.90 14 November 2019 637,393 CAD$0.90 1 December 2019 11,780,134 CAD$1.50 17 May 2023 635,150 CAD$1.25 16 May 2023 22,146,458	11. Capital Stock The Company’s authorized share capital comprises 900,000,000 Common Shares, with a $0.0001 par value per share. On 15 August 2017 and 16 August 2017, the Company closed the first two of four tranches of a non-brokered private placement and issued 8,276,294 Subscription Receipts (defined below) at a price of $0.52 (CAD$0.66) per Subscription Receipt for aggregate gross proceeds of $4,270,017 (CAD$5,462,354). On 31 October 2017, the Company closed a third tranche of a non-brokered private placement and issued 757,666 Subscription Receipts at a price of $0.52 (CAD$0.66) per Subscription Receipt for aggregate gross proceeds of $390,822 (CAD$500,060) (Note 14). On 1 November 2017, the Company closed a fourth and final tranche of a non-brokered private placement and issued 68,181 Subscription Receipts at a price of $0.52 (CAD$0.66) per Subscription Receipt for aggregate gross proceeds of $35,169 (CAD$45,000) (Note 14). On 14 November 2017, the Company issued a total of 18,827,000 common shares valued at $6,337,365 in connection with the Acquisition of NMG (Note 14). The Company is obligated to issue 423,000 common shares, which have a fair value of $135,202 (Note 14). On 14 November 2017, a total of 9,102,141 Subscription Receipts converted to 9,102,141 common shares and 9,102,141 share purchase warrants exercisable at CAD $0.66 or CAD$0.90 for a period of 24 months pursuant to the closing of the Acquisition of NMG (Note 14). The Company issued a total of 367,286 brokers’ warrants with a fair value of $62,357 (CAD$78,122) in connection with these financings. The brokers’ warrants are exercisable at CAD$0.90 for a period of 24 months. The Company incurred other share issuance costs of $219,459 (CAD$279,352) in relation to this private placement. On 1 December 2017, the Company closed a non-brokered private placement of 637,393 units at a price of $0.52 (CAD$0.66) per unit for aggregate gross proceeds of $330,486 (CAD$420,680). Each unit consists of one common share and one share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CAD$0.90 per warrant for a period of 24 months from the closing. On 16 May 2018, the Company issued 70,500 previously escrowed shares with a fair value of $27,328 to Toro Pacific Management Inc. in connection with the acquisition of NMG (Note 14). On 2 November 2018, the Company closed a non-brokered private placement of 16,000,000 units at a price of $0.30 (CAD$0.40) per unit for aggregate gross proceeds of $4,883,840 (CAD$6,400,000) (Note 10, 15 and 16). Each unit consists of one common share and one share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CAD$0.50 per warrant for a period of two years. The Company paid cash of $152,720 and issued 322,581 common shares valued at $221,691 as finders’ fees in relation to this private placement. On 29 November 2018, the Company issued 1,105,083 common shares as a finance fee to Australis valued at $822,494 (Note 9). On 30 November 2018, the Company issued 3,206,160 common shares upon exercise of 3,206,160 warrants by Australis at a price of CAD$0.50 per common share for aggregate proceeds of $1,205,196 (CAD$1,603,080). On 31 January 2019, the Company issued 1,768,545 common shares to Australis for proceeds of $787,123 pursuant to the Investment Agreement (Note 16). On 31 January 2019, the Company issued 2,380,398 common shares valued at $1,448,805 in relation to acquiring the remaining 70% of NMG Ohio LLC (Note 17). On 14 May 2019, the Company issued 70,500 previously escrowed shares with a fair value of $22,689 to Toro Pacific Management Inc. in connection with the acquisition of NMG (Note 14). On 17 May 2019, the Company closed a private placement of 11,780,134 units at a price of $0.93 (CAD$1.25) per unit for aggregate gross proceeds of $10,204,574 (CAD$14,726,130). Each unit is comprised of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one common share of the Company at an exercise price of CAD$1.50 for a period of 48 months following the closing date, subject to adjustment in certain events. The agents received a cash commission of $589,499 (CAD$793,938). The agents also received as additional consideration 635,150 non-transferable broker warrants. Each broker warrant entitles the holder to acquire one unit at an exercise price of CAD$1.25 per unit for a period of 48 months following the closing date. A corporate finance fee of $63,774 (CAD $84,750) was also paid. On 28 May 2019, the Company issued 12,793,840 common shares upon exercise of 12,793,840 warrants by Australis at a price of CAD$0.50 per common share for aggregate proceeds of $4,746,515 (CAD$6,396,920). The proceeds were used, in part, to fully repay the outstanding senior secured note in the amount of $4,495,890 owing to Australis by the Company (Note 9). On 16 July 2019, the Company issued 7,333 common shares upon exercise of 7,333 warrants at a price of CAD$0.90 per common share for aggregate proceeds of $5,057 (CAD$6,600). Stock options The Company previously approved an incentive stock option plan, pursuant to which the Company may grant stock options up to an aggregate of 10% of the issued and outstanding common shares in the capital of the Company from time to time. On 24 November 2017, the Company issued an aggregate of 3,850,000 stock options in accordance with the Company’s stock option plan at an exercise price of CAD$0.66 per share for a five year term expiring 24 November 2022. The options were granted to officers, directors and consultants of the Company. The fair value of the stock options was calculated to be $726,578 (CAD$922,403) using the Black-Scholes Option Pricing Model with the following assumptions: Expected life of the options 5 years Expected volatility 198 % Expected dividend yield 0 % Risk-free interest rate 1.63 % On 6 June 2018, the Company issued 175,000 stock options in accordance with the Company’s stock option plan at an exercise price of CAD$0.47 per share for a five year term expiring 6 June 2023. The options were granted to a consultant of the Company. The fair value of the stock options was calculated to be $63,101 (CAD$81,129) using the Black-Scholes Option Pricing Model with the following assumptions: Expected life of the options 5 years Expected volatility 262 % Expected dividend yield 0 % Risk-free interest rate 2.16 % On 11 December 2018, the Company issued 2,050,000 stock options in accordance with the Company’s stock option plan at an exercise price of CAD$0.57 per share for a five year term expiring 10 December 2023. The options were granted to current directors, officers, employees and consultants of the Company. The fair value of the stock options was calculated to be $880,595 (CAD$1,165,117) using the Black-Scholes Option Pricing Model with the following assumptions: Expected life of the options 5 years Expected volatility 265 % Expected dividend yield 0 % Risk-free interest rate 2.03 % 31 July 2019 31 July 2018 Number of options Exercise Price Number of options Exercise Price Opening balance 4,025,000 CAD$0.65 - - Options granted 2,050,000 CAD$0.57 4,025,000 CAD$0.65 Closing balance 6,075,000 CAD$0.62 4,025,000 CAD$0.65 Share purchase warrants and brokers’ warrants 31 July 2019 31 July 2018 Number of warrants Exercise Price Number of warrants Exercise Price Opening balance 10,106,820 CAD$0.89 - - Warrants issued 28,415,284 CAD$0.93 10,106,820 CAD$0.89 Warrants exercised (16,007,333 ) CAD$0.50 - - Closing balance 22,514,771 CAD$1.22 10,106,820 CAD$0.89 As at 31 July 2019, the following warrants are outstanding: Number of warrants outstanding and exercisable Exercise price Expiry dates 248,350 CAD$0.66 15 August 2019 58,324 CAD$0.66 16 August 2019 60,612 CAD$0.66 3 November 2019 9,094,808 CAD$0.90 14 November 2019 637,393 CAD$0.90 1 December 2019 11,780,134 CAD$1.50 17 May 2023 635,150 CAD$1.25 17 May 2023 22,514,771

Segmented Information and Major

Segmented Information and Major Customers	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Segment Reporting [Abstract]
Segmented Information and Major Customers	12. Segmented Information and Major Customers The Company’s activities are all in the one industry segment of medical and recreational cannabis. All of the Company’s revenue generating activities and capital assets relate to this segment and are located in the USA. During the three months ended 31 October 2019, no individual customer accounts for 10% or more of revenue (31 July 2019 – one major customers for 12% of revenues).	12. Segmented Information and Major Customers The Company’s activities are all in the one industry segment of medical and recreational cannabis. All of the Company’s revenue generating activities and capital assets relate to this segment and are located in the USA. During the year ended 31 July 2019, the Company relied on one major customer for 12% of its revenues (31 July 2018 – three major customers for 37% of revenues).

Supplemental Disclosures with R

Supplemental Disclosures with Respect to Cash Flows	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosures with Respect to Cash Flows	13. Supplemental Disclosures with Respect to Cash Flows Three Month Period Ended 31 October 2019 2018 Cash paid during the period for interest $ - $ - Cash paid during the period for income taxes $ - $ -	13. Supplemental Disclosures with Respect to Cash Flows Year Ended 31 July 2019 2018 Cash paid during the period for interest $ 392,623 $ - Cash paid during the period for income taxes $ - $ -

Business Acquisition

Business Acquisition	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Business Combinations [Abstract]
Business Acquisition	14. Business Acquisition On 15 May 2017, the Company entered into an assignment and novation agreement (the “Assignment Agreement”) with Toro Pacific Management Inc. (the “Transferor”) pursuant to which the Transferor assigned a letter of intent (the “LOI”) effective 12 May 2017 to the Company in accordance with its terms. The Assignment Agreement and the LOI contemplated a business combination transaction (the “Acquisition”) to acquire all of the issued and outstanding securities of NMG, an arm’s length Nevada-based licensed producer of medical cannabis. As consideration for the Assignment Agreement, the Company will issue to the Transferor 1,000,000 common shares of the Company. On 13 November 2017, the Assignment Agreement was amended, whereby the Company would issue the 1,000,000 common shares as follows: a. 470,000 common shares to Benjamin Rutledge upon closing of the Acquisition (issued); b. 60,000 common shares to Chris Hunt upon closing of the Acquisition (issued); c. 470,000 common shares to the Transferor according to the following schedule: · 1/10 of the Transferor’s shares upon closing of the Acquisition (issued); · 1/6 of the remaining Transferor’s shares 6 months after closing the Acquisition (issued); · 1/5 of the remaining Transferor’s shares 12 months after closing the Acquisition (issued); · 1/4 of the remaining Transferor’s shares 18 months after closing the Acquisition (issued); · 1/3 of the remaining Transferor’s shares 24 months after closing the Acquisition; · 1/2 of the remaining Transferor’s shares 30 months after closing the Acquisition; and · the remaining Transferor’s shares 36 months after closing the Acquisition. The remaining 423,000 shares to be issued to the Transferor over the 36 month period are included in equity as shares to be issued with a total fair value of $135,202 as at 13 November 2017 (Note 11). On 14 September 2017, the Company and DEP Nevada entered into a definitive agreement (the “Share Exchange Agreement”) with NMG. Pursuant to the Share Exchange Agreement, DEP Nevada acquired all of the issued and outstanding securities of NMG in exchange for the issuance of the Company’s common shares and certain cash and other non-cash consideration (the “Acquisition”). The Company completed a concurrent financing consisting of 9,102,141 subscription receipts of the Company (the “Subscription Receipts”), at an issue price of CAD$0.66 per Subscription Receipt, with each Subscription Receipt being automatically converted, at no additional cost to the subscriber, upon the completion of the Acquisition for one common share and one share purchase warrant exercisable at a price of CAD$0.90 for a period of 24 months from the date of issuance. Each warrant is subject to acceleration provisions following the six-month anniversary of the date of closing, if the closing trading price of the common shares is equal to or greater than CAD$1.20 for seven consecutive trading days, at which time the Company may accelerate the expiry date of the warrants by issuing a press release announcing the reduced warrant term whereupon the warrant will expire 21 calendar days after the date of such press release. These Subscription Receipts were recognized as liability on initial receipt. During the year ended 31 July 2018, the Acquisition closed and the shares were issued; therefore the Subscription Receipts were reclassified from liability to equity on conversion to common shares. On 14 November 2017, the Company closed the Acquisition, and acquired all of the issued and outstanding membership units of NMG (the “Units”). In consideration for the Units, the Company issued to the NMG Members an aggregate of 16,000,000 common shares with a fair value of $5,386,155 as well as a cash payment of $2,309,000 pro rata amongst the NMG members and promissory notes to the NMG members in the aggregate amount of $2,175,000. The Company also issued 2,037,879 common shares to TI Nevada with a fair value of $685,788, 212,121 common shares to Charles Fox with a fair value of $71,383, 47,000 common shares to Toro Pacific Management Inc. with a fair value of $15,816, 60,000 common shares to Chris Hunt with a fair value of $20,192, and 470,000 common shares to Benjamin Rutledge with a fair value of $159,114 in connection with the Acquisition. The Company has an obligation to issue a further 423,000 common shares to Toro Pacific Management Inc., which had a fair value of $135,202 on the date of acquisition. The Company recognized $330,324 in transaction costs in connection with the shares issued to non-NMG members. The promissory notes totalling $2,175,000 were discounted to a present value of $1,887,277 (Note 9). In connection with the closing of the Acquisition, the net proceeds of the Company’s private placements of Subscription Receipts in support of the Acquisition was released to the Company from escrow. Immediately prior to closing of the Acquisition, the Company completed a consolidation of its common shares on the basis of three (3) pre-consolidation common shares to one (1) post-consolidation common share, as well a name change, changing the name of the Company from Deploy Technologies, Inc. to Body and Mind Inc. The Company eliminated its authorized Class A Preferred shares (Note 11). As a result of the acquisition of NMG, the Company changed its business focus to growing and supplying medical and recreational cannabis in the state of Nevada. The acquisition of NMG was accounted for as a business combination, in which the assets acquired and the liabilities assumed are recorded at their estimated fair values. The allocation of the purchase consideration is as follows: Purchase consideration Share considerations $ 6,143,326 Cash considerations 2,309,000 Promissory notes issued 1,887,277 TOTAL $ 10,339,603 Assets acquired: Cash $ 260,842 Amounts receivable 253,697 Prepaid expenses 44,552 Inventory 498,680 Property and equipment 1,951,696 Brand 247,000 Licenses 7,925,000 Liabilities assumed: Trade payable and accrued liabilities (367,385 ) Loans payable (250,000 ) Deferred tax liability (2,860,200 ) Net assets acquired 7,703,882 Goodwill 2,635,721 TOTAL $ 10,339,603 Goodwill recognized comprises the assembled workforce and their knowledge with respect to NMG, regulatory affairs and the cannabis industry; and expected revenue growth and future market development with legalization of recreational cannabis in Nevada.	14. Business Acquisition On 15 May 2017, the Company entered into an assignment and novation agreement (the “Assignment Agreement”) with Toro Pacific Management Inc. (the “Transferor”) pursuant to which the Transferor assigned a letter of intent (the “LOI”) effective 12 May 2017 to the Company in accordance with its terms. The Assignment Agreement and the LOI contemplated a business combination transaction (the “Acquisition”) to acquire all of the issued and outstanding securities of NMG, an arm’s length Nevada-based licensed producer of medical cannabis. As consideration for the Assignment Agreement, the Company will issue to the Transferor 1,000,000 common shares of the Company. On 13 November 2017, the Assignment Agreement was amended, whereby the Company would issue the 1,000,000 common shares as follows: a. 470,000 common shares to Benjamin Rutledge upon closing of the Acquisition (issued); b. 60,000 common shares to Chris Hunt upon closing of the Acquisition (issued); c. 470,000 common shares to the Transferor according to the following schedule: · 1/10 of the Transferor’s shares upon closing of the Acquisition (issued); · 1/6 of the remaining Transferor’s shares 6 months after closing the Acquisition (issued); · 1/5 of the remaining Transferor’s shares 12 months after closing the Acquisition (issued); · 1/4 of the remaining Transferor’s shares 18 months after closing the Acquisition (issued); · 1/3 of the remaining Transferor’s shares 24 months after closing the Acquisition; · 1/2 of the remaining Transferor’s shares 30 months after closing the Acquisition; and · the remaining Transferor’s shares 36 months after closing the Acquisition. The remaining 423,000 shares to be issued to the Transferor over the 36 month period are included in equity as shares to be issued with a total fair value of $135,202 as at 13 November 2017 (Note 11). On 14 September 2017, the Company and Dep Nevada entered into a definitive agreement (the “Share Exchange Agreement”) with NMG. Pursuant to the Share Exchange Agreement, Dep Nevada acquired all of the issued and outstanding securities of NMG in exchange for the issuance of the Company’s common shares and certain cash and other non-cash consideration (the “Acquisition”). The Company completed a concurrent financing consisting of 9,102,141 subscription receipts of the Company (the “Subscription Receipts”), at an issue price of CAD$0.66 per Subscription Receipt, with each Subscription Receipt being automatically converted, at no additional cost to the subscriber, upon the completion of the Acquisition for one common share and one share purchase warrant exercisable at a price of CAD$0.90 for a period of 24 months from the date of issuance. Each warrant is subject to acceleration provisions following the six-month anniversary of the date of closing, if the closing trading price of the common shares is equal to or greater than CAD$1.20 for seven consecutive trading days, at which time the Company may accelerate the expiry date of the warrants by issuing a press release announcing the reduced warrant term whereupon the warrant will expire 21 calendar days after the date of such press release. These Subscription Receipts were recognized as liability on initial receipt. During the year ended 31 July 2018, the Acquisition closed and the shares were issued; therefore the Subscription Receipts were reclassified from liability to equity on conversion to common shares. On 14 November 2017, the Company closed the Acquisition, and acquired all of the issued and outstanding membership units of NMG (the “Units”). In consideration for the Units, the Company issued to the NMG Members an aggregate of 16,000,000 common shares with a fair value of $5,386,155 as well as a cash payment of $2,309,000 pro rata amongst the NMG members and promissory notes to the NMG members in the aggregate amount of $2,175,000. The Company also issued 2,037,879 common shares to TI Nevada with a fair value of $685,788, 212,121 common shares to Charles Fox with a fair value of $71,383, 47,000 common shares to Toro Pacific Management Inc. with a fair value of $15,816, 60,000 common shares to Chris Hunt with a fair value of $20,192, and 470,000 common shares to Benjamin Rutledge with a fair value of $159,114 in connection with the Acquisition. The Company has an obligation to issue a further 423,000 common shares to Toro Pacific Management Inc., which had a fair value of $135,202 on the date of acquisition. The Company recognized $330,324 in transaction costs in connection with the shares issued to non-NMG members. The promissory notes totalling $2,175,000 were discounted to a present value of $1,887,863 (Note 9). In connection with the closing of the Acquisition, the net proceeds of the Company’s private placements of Subscription Receipts in support of the Acquisition was released to the Company from escrow. Immediately prior to closing of the Acquisition, the Company completed a consolidation of its common shares on the basis of three (3) pre-consolidation common shares to one (1) post-consolidation common share, as well a name change, changing the name of the Company from Deploy Technologies, Inc. to Body and Mind Inc. The Company eliminated its authorized Class A Preferred shares (Note 11). As a result of the acquisition of NMG, the Company changed its business focus to growing and supplying medical and recreational cannabis in the state of Nevada. The acquisition of NMG was accounted for as a business combination, in which the assets acquired and the liabilities assumed are recorded at their estimated fair values. The allocation of the purchase consideration is as follows: Purchase consideration Share considerations, net of transaction costs $ 6,143,326 Cash considerations 2,309,000 Promissory notes issued 1,887,277 TOTAL $ 10,339,603 Assets acquired: Cash $ 260,842 Amounts receivable 253,697 Prepaid expenses 44,552 Inventory 498,680 Property and equipment 1,951,696 Brand 247,000 Licenses 7,925,000 Liabilities assumed: Trade payable and accrued liabilities (367,385 ) Loans payable (250,000 ) Deferred tax liability (2,860,200 ) Net identifiable assets acquired 7,703,882 Goodwill 2,635,721 TOTAL $ 10,339,603 Goodwill recognized comprises the assembled workforce and their knowledge with respect to NMG, regulatory affairs and the cannabis industry; and expected revenue growth and future market development with legalization of recreational cannabis in Nevada.

Commitments

Commitments	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments	15. Commitments a) In connection with the strategic investment agreement with Australis dated 30 October 2018 (the “Investment Agreement”) (Notes 10, 11 and 16), the Company agreed to pay a monthly service fee of $10,000 to Australis. In connection with the Company’s investment in GLDH and the promissory note provided by Australis (Note 9), the Company agreed to increase the monthly services fee to Australis to $16,500 per month for 5 years unless ownership held by Australis drops below 10% in which the fee will cease. Following the repayment of the promissory note, the monthly service fee to Australis was reduced to $12,000 commencing June 2019. b) On 25 October 2017, NMG Ohio entered into a five-year lease agreement for the property located at 709 Sugar Lane, Elyria, Ohio, containing approximately 4,100 square feet. The monthly rent is $4,200 c) On 13 June 2019, the five-year lease agreement dated 1 December 2018 for the property located at 7625 Carroll Road, San Diego, California, containing approximately 4,600 square feet was assigned to NMG San Diego. Under the terms of the assignment and first amendment to the original lease agreement dated 13 June 2019, the Company has three options to extend the lease and each option is for five years. The monthly base rent is currently $15,000. The guaranteed monthly rent is subject to a 1-6% increase on each anniversary date of the lease, based on increases in the Consumer Price Index for San Diego County d) On 8 March 2019, the five-year lease agreement dated 10 January 2017, as amended on 7 September 2018, for the property located at 3411 E. Anaheim St., Long Beach, California, containing approximately 1,856 square feet was assigned to NMG Long Beach. Under the terms of the amended lease agreement, the Company has one option to extend the lease for five years. The monthly base rent is $6,636.40 plus common area expenses, totaling $8,000 every month. The guaranteed minimum monthly rent is subject to a 5% increase on each anniversary date of the lease. e) On 21 August 2019, the Company entered into new and updated management and consulting agreements with the following individuals: · President and the Interim Chief Executive Officer – $12,500 per month; · Chief Financial Officer – CAD$10,000 per month; · Chief Operating Officer – $15,000 per month; · Corporate Secretary – CAD$7,500 per month; · President of NMG and a director – $16,666 per month; and · Former Chief Executive Officer and an advisor - $12,500 per month.	15. Commitments a) On 10 November 2017, NMG entered into a revised five-year lease agreement for the property located at 3375 Pepper Lane, Las Vegas, NV, containing approximately 18,000 square feet. The Company has four options to extend the lease and each option is for five years. The monthly rent was $12,500 plus common area expenses, which increased to $12,875 plus common area expenses on 1 January 2019. The guaranteed minimum monthly rent is subject to a 2% increase on each anniversary date of the lease. b) On 14 November 2017, the Company entered into the following consulting agreements: i. $16,667 per month to TI Nevada, which is controlled by an officer of the Company, for a term of three years; and ii. CAD$10,000 per month to Toro Pacific Management Inc., which is controlled by an officer of the Company. c) In connection with the strategic investment agreement with Australis dated 30 October 2018 (the “Investment Agreement”) (Notes 10, 11 and 16), the Company agreed to pay a monthly service fee of $10,000 to Australis. In connection with the Company’s investment in GLDH and the promissory note provided by Australis (Note 9), the Company agreed to increase the monthly services fee to Australis to $16,500 per month for 5 years unless ownership held by Australis drops below 10% in which the fee will cease. Following the repayment of the promissory note, the monthly service fee to Australis was reduced to $12,000 commencing June 2019. d) On 9 April 92019, NMG entered into a three-year lease agreement for the property located at 6420 Sunset Corporate Drive, Las Vegas, NV, containing approximately 7,700 square feet. The Company has one option to extend the lease for an additional three-year term and an option to purchase the property at any point during the initial term. The monthly rent is $6,026 plus $1,129 in common area expenses, totaling $7,156 every month. e) On 25 October 2017, NMG Ohio entered into a five-year lease agreement for the property located at 709 Sugar Lane, Elyria, Ohio, containing approximately 4,100 square feet. The monthly rent is $4,200. f) On 13 June 2019, the five-year lease agreement dated 1 December 2018 for the property located at 7625 Carroll Road, San Diego, California, containing approximately 4,600 square feet was assigned to NMG San Diego. Under the terms of the assignment and first amendment to the original lease agreement dated 13 June 2019, the Company has three options to extend the lease and each option is for five years. The monthly base rent is currently $15,000. The guaranteed monthly rent is subject to a 1-6% increase on each anniversary date of the lease, based on increases in the Consumer Price Index for San Diego County. g) On 8 March 2019, the five-year lease agreement dated 10 January 2017, as amended on 7 September 2018, for the property located at 3411 E. Anaheim St., Long Beach, California, containing approximately 1,856 square feet was assigned to NMG Long Beach. Under the terms of the amended lease agreement, the Company has one option to extend the lease for five years. The monthly base rent is $6,636.40 plus common area expenses, totaling $8,000 every month. The guaranteed minimum monthly rent is subject to a 5% increase on each anniversary date of the lease.

Investment Agreement

Investment Agreement	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Investment Agreement [Abstract]
Investment Agreement	16. Investment Agreement On 30 October 2018, the Company entered into the Investment Agreement with Australis. Pursuant to the terms of the Investment Agreement, Australis will acquire (i) 16,000,000 units of the Company (Note 11), and (ii) CAD$1,600,000 principal amount 8% unsecured convertible debentures (Note 10). Under the terms of the Investment Agreement, the parties agreed to negotiate in good faith a license agreement pursuant to which the Company will grant Australis an exclusive and assignable license to use the Body and Mind brand outside of the United States of America on commercially reasonable terms. In addition, the Company will enter into a commercial advisory agreement with Australis Capital (Nevada) Inc. (“Australis Nevada”), a wholly-owned subsidiary of Australis, pursuant to which Australis Nevada will provide advisory and consulting services to the Company at $10,000 per month for a term ending on the date that is the earlier of: (i) five years following the closing of the transactions contemplated by the Investment Agreement, and (ii) the date Australis no longer holds 10% or more of the issued and outstanding Common Shares (Note 15). Subject to certain exceptions, Australis will be entitled to maintain its’ pro rata interest in the Company until such time as it no longer holds 10% or more of the issued and outstanding Common Shares. Subject to applicable laws and the rules of the Canadian Securities Exchange (the “CSE”), for as long as Australis owns at least 10% of the issued and outstanding common shares, Australis will be entitled to nominate one director for election to the Board of Directors of the Company (the “Board”). If Australis exercises all of the warrants and converts all of the debentures purchased, Australis will be entitled to nominate a second director for election to the Board. On 2 November 2018, the Company executed the Investment Agreement and completed the sale of securities pursuant to the Investment Agreement. On 31 January 2019, the Company issued 1,768,545 common shares to Australis for proceeds of $787,123 pursuant to the Investment Agreement whereby the Company granted Australis anti-dilution participation rights to allow Australis to maintain a 35.783% ownership interest in the Company (Note 11).	16. Investment Agreement On 30 October 2018, the Company entered into the Investment Agreement with Australis. Pursuant to the terms of the Investment Agreement, Australis will acquire (i) 16,000,000 units of the Company (Note 11), and (ii) CAD$1,600,000 principal amount 8% unsecured convertible debentures (Note 10). Under the terms of the Investment Agreement, the parties agreed to negotiate in good faith a license agreement pursuant to which the Company will grant Australis an exclusive and assignable license to use the Body and Mind brand outside of the United States of America on commercially reasonable terms. In addition, the Company will enter into a commercial advisory agreement with Australis Capital (Nevada) Inc. (“Australis Nevada”), a wholly-owned subsidiary of Australis, pursuant to which Australis Nevada will provide advisory and consulting services to the Company at $10,000 per month for a term ending on the date that is the earlier of: (i) five years following the closing of the transactions contemplated by the Investment Agreement, and (ii) the date Australis no longer holds 10% or more of the issued and outstanding Common Shares (Note 15). Subject to certain exceptions, Australis will be entitled to maintain its’ pro rata interest in the Company until such time as it no longer holds 10% or more of the issued and outstanding Common Shares. Subject to applicable laws and the rules of the Canadian Securities Exchange (the “CSE”), for as long as Australis owns at least 10% of the issued and outstanding common shares, Australis will be entitled to nominate one director for election to the Board of Directors of the Company (the “Board”). If Australis exercises all of the warrants and converts all of the debentures purchased, Australis will be entitled to nominate a second director for election to the Board. On 2 November 2018, the Company executed the Investment Agreement and completed the sale of securities pursuant to the Investment Agreement. On 31 January 2019, the Company issued 1,768,545 common shares to Australis for proceeds of $787,123 pursuant to the Investment Agreement whereby the Company granted Australis anti-dilution participation rights to allow Australis to maintain a 35.783% ownership interest in the Company (Note 11).

Investment in NMG Ohio LLC

Investment in NMG Ohio LLC	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Investment in NMG Ohio LLC	17. Investment in NMG Ohio LLC On 31 January 2019, the Company entered into a definitive agreement (“Definitive Agreement”) to acquire 100% ownership of NMG Ohio. The Company will purchase the remaining 70% interest for total cash payments of $1,575,000 and issuance of 3,173,864 common shares of the Company (Note 8). As at 31 July 2019 the Company had issued 2,380,398 of the 3,173,864 common shares with a fair value of $1,448,805. During the year ended 31 July 2019, the Company made cash payments of $1,181,250. At 31 October 2019, the Definitive Agreement had not closed. The remaining cash payments totaling $393,750 and the remaining issuance of 793,466 common shares are expected to be paid and issued upon completion of the remaining Definitive Agreement closing items. Until such time as the Definitive Agreement closes, the Company will continue to account for its 30% ownership interest in NMG Ohio as an investment using the equity method of accounting. During the three months ended 31 October 2019, NMG Ohio recorded net revenues of $961,444, expenses of $669,273 and a net income of $292,171. The Company recorded an equity pickup of $87,651 relating to its 30% pro rata share of net income which was included in other items on the statement of operations. 31 October 2019 31 July 2019 Opening balance $ 3,465,902 $ 77,600 Acquisition costs: Common shares issued to vendors at fair value - 1,448,805 Acquisition costs: Cash payments to vendors - 1,181,250 Dispensary build-out related costs 16,469 573,633 License fees - 100,000 Equity pickup 87,651 56,466 Foreign exchange (1,377 ) 28,148 Total $ 3,568,645 $ 3,465,902 Summarized financial information for NMG Ohio is as follows: 31 October 2019 Current assets $ 768,603 Non-current assets 853,383 Total assets 1,621,986 Current liabilities 465,933 Non-current liabilities - Total liabilities 465,933 Revenues 961,444 Gross profit 420,904 Net income 292,171 Net income attributable to the Company $ 87,651	17. Investment in NMG Ohio LLC On 31 January 2019, the Company entered into a definitive agreement (“Definitive Agreement”) to acquire 100% ownership of NMG Ohio. The Company will purchase the remaining 70% interest for total cash payments of $1,575,000 and issuance of 3,173,864 common shares of the Company (Note 8). As at 31 July 2019 the Company had issued 2,380,398 of the 3,173,864 common shares with a fair value of $1,448,805. During the year ended 31 July 2019, the Company made cash payments of $1,181,250. At 31 July 2019 the Definitive Agreement had not closed. The remaining cash payments totaling $393,750 and the remaining issuance of 793,466 common shares are expected to be paid and issued upon completion of the remaining Definitive Agreement closing items. Until such time as the Definitive Agreement closes, the Company will continue to account for its 30% ownership interest in NMG Ohio as an investment using the equity method of accounting. During the year ended 31 July 2019, NMG Ohio recorded net revenues of $1,148,465, expenses of $960,244 and a net income of $188,244. The Company recorded an equity pickup of $56,514 relating to its 30% pro rata share of net income which was included in other items on the statement of operations. 31 July 2019 Balance, 31 July 2018 $ 77,600 Acquisition costs: Common shares issued to vendors at fair value 1,448,805 Acquisition costs: Cash payments to vendors 1,181,250 Dispensary build-out related costs 573,633 License fees 100,000 Equity pickup 56,466 Foreign exchange 28,148 Total $ 3,465,902 Summarized financial information for NMG Ohio is as follows: 31 July 2019 Current assets $ 271,121 Non-current assets 923,387 Total assets 1,194,508 Current liabilities 338,427 Non-current liabilities - Total liabilities 338,427 Revenues 1,225,238 Gross profit 513,643 Net income 188,244 Net income attributable to the Company $ 56,466

Investment in and advances to G

Investment in and advances to GLDH	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Investments [Abstract]
Investment in and advances to GLDH	18. Investment in and advances to GLDH Interim Agreement – 28 November 2018 On 28 November 2018, the Company entered into a binding interim agreement (the “Interim Agreement”) with GLDH, a private company incorporated under the laws of Delaware, and David Barakett (“Barakett”) whereby the Company agreed to acquire 100% of the issued and outstanding common shares of GLDH in connection with the issuance of convertible notes (the “Transaction”). GLDH holds a number of assets relating to the production and sale of cannabis products in the United States of America. The Transaction will be contingent upon the Company completing its due diligence. The terms of the Interim Agreement include the following: The Company shall issue to Barakett common shares of the Company (the “Earn Out Shares”) based on the CSE listed 5-day VWAP of the common shares of the Company and at the USD/CAD exchange rate at the close of market on 27 November 2018. The common shares of the Company had a 5-day VWAP of CAD$0.7439 at a USD/CAD exchange rate of 1.3296 and as a result the Company agreed to issue up to a maximum of 11,255,899 common shares with a maximum consideration of US$6,297,580 or CAD$8,373,263. Barakett will be eligible to receive Earn Out Shares for a period of 12 months on the following basis: 1. upon GLDH obtaining all of (i) the Long Beach Recreational License; (ii) the San Diego Medical License; (iii) the San Diego Recreational License; and (iv) the San Diego State License (“Milestone I”), the issuance of Earn Out Shares to Barakett totalling 5,627,950 shares (50% of the total Earn Out Shares); 2. upon GLDH achieving total attributable revenues of at least US$3,300,000 over a period of three consecutive months from each of the Long Beach dispensary, the San Diego dispensary and Las Vegas ShowGrow (“Milestone II”), the issuance of Earn Out Shares to Barakeet totalling 4,502,360 (40% of the total Earn Out Shares); and 3. prior to the completion of Milestone I and Milestone II, and upon completion of a certain audit of GLDH showing no taxes outstanding or any unknown material liabilities for GLDH, the issuance of Earn Out Shares to Barakett totalling 1,125,589 shares (10% of the total Earn Out Shares). Additionally, the Company made an investment into GLDH by way of a US$5,200,000 senior secured convertible note (the “Note”) bearing interest at a rate of 20% per annum to be repaid to the Company on 28 November 2020 unless converted by the Company in accordance with the agreement. The Note is secured by a general security agreement and a UCC-1 financing statement in all U.S. states where GLDH has assets. Barakett provided a personal guarantee to the Company for the Note. In order for the Company to fund the Note: 1. the Company entered into a loan agreement with Australis, whereby Australis provided the Company a two-year US$4,000,000 loan (Note 9); and 2. Australis exercised 3,206,160 common shares upon exercise of 3,206,160 warrants at a price of CAD$0.50 per common share for aggregate proceeds of approximately US$1,200,000 (Note 11). Definitive Agreement (Superseding Interim Agreement) On 3 July 2019, the Company entered into the following agreements with GLDH and other third parties: 1. a definitive asset purchase agreement (the “Purchase Agreement”) between the Company’s wholly owned subsidiary, NMG Long Beach, LLC (“NMG LB”), GLDH and Airport Collective, Inc. to acquire 100% ownership interest in GLDH’s Long Beach, California dispensary; 2. a settlement agreement (“NMG SD Settlement Agreement”) between the Company and its subsidiaries, and GLDH and its subsidiaries, to acquire a 60% ownership interest in GLDH’s San Diego, California dispensary; and 3. a lease assignment (the “Lease Assignment Agreement”) on the San Diego operation between the Company’s 60%-owned subsidiary, NMG San Diego, LLC (“NMG SD”), Green Road, LLC, Show Grow San Diego, LLC (“SGSD”), and SJJR LLC. The Purchase Agreement, NMG SD Settlement Agreement and Lease Assignment agreement supersede the Interim Agreement and are subject to certain closing conditions including receipt of applicable licences. 1. The Purchase Agreement was executed under the following terms: The purchase price is USD$6,700,000 (the “Purchase Price”). The consideration under the Purchase Agreement includes the following on closing: i. The USD$5,200,000 Note is to be applied towards the Purchase Price; and ii. USD$1,500,000 to be paid in common shares of the Company at a price of CAD$0.7439 per common share to a maximum of 2,681,006 common shares (the “Share Payment”) (issued) (Note 11) upon NMG LB receiving the transfer of all licenses, permits and BCC authorizations for NMG LB to conduct medical and adult-use commercial cannabis retail operations. The Share Payment is subject to reduction in the event there are undisclosed liabilities by GLDH and Airport Collective. 2. The NMG SD Settlement Agreement’s consideration includes the following on closing: i. USD$500,000 to be paid in common shares (issued) (Note 11) to SGSD at a share price equal to the maximum allowable discount pursuant to Canadian Securities Exchange policies, upon execution of the settlement agreement; ii. USD$750,000 to be paid in common shares to Barakett at a price of CAD$0.7439 per common share to a maximum of 1,340,502 Common Shares (the “DB Share Payment”) upon NMG SD receiving all licenses, permits and authorizations for NMG SD to conduct medical commercial cannabis retail operations. The DB Share Payment is subject to reduction whereby the reduction is tied to Barakett agreeing to pay the Company 40% of the NMG SD start-up costs; and iii. USD$750,000 to be paid in common shares to Barakett at a price of CAD$0.7439 per common share to a maximum of 1,340,502 common shares (the “DB Additional Shares Payment”) upon NMG SD receiving all licenses, permits and authorizations for NMG SD to conduct adult-use commercial cannabis retail operations. The DB Additional Shares Payment is subject reduction whereby the reduction is tied to Barakett agreeing to pay the Company 40% of the NMG SD start-up costs. 3. The Lease Assignment Agreement was executed under the following terms: The Company is required to issue cash and share payments totaling USD$2,283,765 to the landlord as follows: i. USD$750,000, payable in common shares (issued) (Note 11) at a share price equal to the maximum allowable discount pursuant to Canadian Securities Exchange policies, upon execution of the assignment agreement; ii. USD$783,765, payable in cash, within 5 business days following execution of the assignment agreement (paid); and iii. USD$750,000, payable in cash, including interest at 5% per annum, upon receipt of the San Diego Conditional Use Permit allowing adult-use commercial cannabis retail operations. Additionally: 1. The Company is to provide a loan to GLDH in the amount of USD$200,000 at an interest rate of 12% per annum, accrued and compounded quarterly and due within 3 years (provided); 2. The Company is to enter into a consulting agreement with Barakett through NMG LB to provide certain consulting and advisory services to NMG LB, agreeing to pay Barakett a total of USD$200,000 ($50,000 paid in fiscal 2019 and additional $90,000 paid during the period); 3. The Company will forgive approximately USD$800,000 for prior operating loans advanced by the Company to GLDH; and; 4. The Company licenses certain intellectual property from Green Light District Management, LLC and GLDH (collectively referred to as “Licensor”). The Licensor grants the Company a perpetual license to utilize its operational intellectual property consisting of customer data, sales data, customer outreach strategies standard operating procedures, and other proprietary operational intellectual property. Licensor grants the Company a license for 2 years to utilize intellectual property such as trademarks and branding (the “Branding IP”). As consideration for the licenses, the Company has agreed to utilize the Branding IP until 19 June 2021 at the Company’s premises and at the San Diego retail locations for a period of 2 years from operations commencing at that location. Additionally, the Company agreed to pay the Licensor 3% of gross receipts from sales at the Company’s premises. The total investment in GLDH at 31 October 2019 and 31 July 2019 is as follows: 31 October 2019 31 July 2019 Note receivable $ 7,373,036 $ 5,200,000 Share issuances 2,752,782 - Interest income accrued on the Note 260,000 693,333 Advances for working capital 512,506 666,876 Lease Assignment Agreement payment - 783,765 Foreign exchange - 29,062 Total $ 10,898,324 $ 7,373,036	18. Investment in and advances to GLDH Interim Agreement – 28 November 2018 On 28 November 2018, the Company entered into a binding interim agreement (the “Interim Agreement”) with GLDH, a private company incorporated under the laws of Delaware, and David Barakett (“Barakett”) whereby the Company agreed to acquire 100% of the issued and outstanding common shares of GLDH in connection with the issuance of convertible notes (the “Transaction”). GLDH holds a number of assets relating to the production and sale of cannabis products in the United States of America. The Transaction will be contingent upon the Company completing its due diligence. The terms of the Interim Agreement include the following: The Company shall issue to Barakett common shares of the Company (the “Earn Out Shares”) based on the CSE listed 5-day VWAP of the common shares of the Company and at the USD/CAD exchange rate at the close of market on 27 November 2018. The common shares of the Company had a 5-day VWAP of CAD$0.7439 at a USD/CAD exchange rate of 1.3296 and as a result the Company agreed to issue up to a maximum of 11,255,899 common shares with a maximum consideration of US$6,297,580 or CAD$8,373,263. Barakett will be eligible to receive Earn Out Shares for a period of 12 months on the following basis: 1. upon GLDH obtaining all of (i) the Long Beach Recreational License; (ii) the San Diego Medical License; (iii) the San Diego Recreational License; and (iv) the San Diego State License (“Milestone I”), the issuance of Earn Out Shares to Barakett totalling 5,627,950 shares (50% of the total Earn Out Shares); 2. upon GLDH achieving total attributable revenues of at least US$3,300,000 over a period of three consecutive months from each of the Long Beach dispensary, the San Diego dispensary and Las Vegas ShowGrow (“Milestone II”), the issuance of Earn Out Shares to Barakeet totalling 4,502,360 (40% of the total Earn Out Shares); and 3. prior to the completion of Milestone I and Milestone II, and upon completion of a certain audit of GLDH showing no taxes outstanding or any unknown material liabilities for GLDH, the issuance of Earn Out Shares to Barakett totalling 1,125,589 shares (10% of the total Earn Out Shares). Additionally, the Company made an investment into GLDH by way of a US$5,200,000 senior secured convertible note (the “Note”) bearing interest at a rate of 20% per annum to be repaid to the Company on 28 November 2020 unless converted by the Company in accordance with the agreement. The Note is secured by a general security agreement and a UCC-1 financing statement in all U.S. states where GLDH has assets. Barakett provided a personal guarantee to the Company for the Note. In order for the Company to fund the Note: 1. the Company entered into a loan agreement with Australis, whereby Australis provided the Company a two-year US$4,000,000 loan (Note 9); and 2. Australis exercised 3,206,160 common shares upon exercise of 3,206,160 warrants at a price of CAD$0.50 per common share for aggregate proceeds of approximately US$1,200,000 (Note 11). Definitive Agreement (Superseding Interim Agreement) On 3 July 2019, the Company entered into the following agreements with GLDH and other third parties: 1. a definitive asset purchase agreement (the “Purchase Agreement”) between the Company’s wholly owned subsidiary, NMG Long Beach, LLC (“NMG LB”), GLDH and Airport Collective, Inc. to acquire 100% ownership interest in GLDH’s Long Beach, California dispensary; 2. a settlement agreement (“NMG SD Settlement Agreement”) between the Company and its subsidiaries, and GLDH and its subsidiaries, to acquire a 60% ownership interest in GLDH’s San Diego, California dispensary; and 3. a lease assignment (the “Lease Assignment Agreement”) on the San Diego operation between the Company’s 60%-owned subsidiary, NMG San Diego, LLC (“NMG SD”), Green Road, LLC, Show Grow San Diego, LLC (“SGSD”), and SJJR LLC. The Purchase Agreement, NMG SD Settlement Agreement and Lease Assignment agreement supersede the Interim Agreement and are subject to certain closing conditions including receipt of applicable licences. 1. The Purchase Agreement was executed under the following terms: The purchase price is USD$6,700,000 (the “Purchase Price”). The consideration under the Purchase Agreement includes the following on closing: i. The USD$5,200,000 Note is to be applied towards the Purchase Price; and ii. USD$1,500,000 to be paid in common shares of the Company at a price of CAD$0.7439 per common share to a maximum of 2,681,006 common shares (the “Share Payment”) (issued subsequent to year end) (Note 21) upon NMG LB receiving the transfer of all licenses, permits and BCC authorizations for NMG LB to conduct medical and adult-use commercial cannabis retail operations. The Share Payment is subject to reduction in the event there are undisclosed liabilities by GLDH and Airport Collective. 2. The NMG SD Settlement Agreement’s consideration includes the following on closing: i. USD$500,000 to be paid in common shares (issued subsequent to year end) (Note 21) to SGSD at a share price equal to the maximum allowable discount pursuant to Canadian Securities Exchange policies, upon execution of the settlement agreement; ii. USD$750,000 to be paid in common shares to Barakett at a price of CAD$0.7439 per common share to a maximum of 1,340,502 Common Shares (the “DB Share Payment”) upon NMG SD receiving all licenses, permits and authorizations for NMG SD to conduct medical commercial cannabis retail operations. The DB Share Payment is subject to reduction whereby the reduction is tied to Barakett agreeing to pay the Company 40% of the NMG SD start-up costs; and iii. USD$750,000 to be paid in common shares to Barakett at a price of CAD$0.7439 per common share to a maximum of 1,340,502 common shares (the “DB Additional Shares Payment”) upon NMG SD receiving all licenses, permits and authorizations for NMG SD to conduct adult-use commercial cannabis retail operations. The DB Additional Shares Payment is subject reduction whereby the reduction is tied to Barakett agreeing to pay the Company 40% of the NMG SD start-up costs. 3. The Lease Assignment Agreement was executed under the following terms: The Company is required to issue cash and share payments totaling USD$2,283,765 to the landlord as follows: i. USD$750,000, payable in common shares (issued subsequent to year end) (Note 21) at a share price equal to the maximum allowable discount pursuant to Canadian Securities Exchange policies, upon execution of the assignment agreement; ii. USD$783,765, payable in cash, within 5 business days following execution of the assignment agreement (paid); and iii. USD$750,000, payable in cash, including interest at 5% per annum, upon receipt of the San Diego Conditional Use Permit allowing adult-use commercial cannabis retail operations. Additionally: 1. The Company is to provide a loan to GLDH in the amount of USD$200,000 at an interest rate of 12% per annum, accrued and compounded quarterly and due within 3 years (provided subsequent to year end); 2. The Company is to enter into a consulting agreement with Barakett through NMG LB to provide certain consulting and advisory services to NMG LB, agreeing to pay Barakett a total of USD$200,000 ($50,000 paid in fiscal 2019 and additional $90,000 paid subsequent to year end); 3. The Company will forgive approximately USD$800,000 for prior operating loans advanced by the Company to GLDH; and; 4. The Company licenses certain intellectual property from Green Light District Management, LLC and GLDH (collectively referred to as “Licensor”). The Licensor grants the Company a perpetual license to utilize its operational intellectual property consisting of customer data, sales data, customer outreach strategies standard operating procedures, and other proprietary operational intellectual property. Licensor grants the Company a license for 2 years to utilize intellectual property such as trademarks and branding (the “Branding IP”). As consideration for the licenses, the Company has agreed to utilize the Branding IP until 19 June 2021 at the Company’s premises and at the San Diego retail locations for a period of 2 years from operations commencing at that location. Additionally, the Company agreed to pay the Licensor 3% of gross receipts from sales at the Company’s Long Beach location premises on a monthly basis for only the first twelve months of the term of the license agreement. The total investment in GLDH at 31 July 2019 is as follows: 31 July 2019 Note receivable $ 5,200,000 Interest income accrued on the Note 693,333 Advances for working capital 666,876 Lease Assignment Agreement payment 783,765 Foreign exchange 29,062 Total $ 7,373,036

Other Investments

Other Investments	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Other Investments [Abstract]
Other Investments	19. Other Investments The Company and NMG Cathedral City (“NMG CC”) entered into a management and administrative services agreement (the "Management Agreement") with Satellites Dip, LLC, ("SD"), a licensed cannabis business conducting commercial cannabis activity within the state of California. The one year Management Agreement commenced on 6 June 2019 (Note 21) and encompasses the following: a. Management Fee: NMG CC will be paid a management fee of 30% of Net Profits or $10,000 per month, whichever is greater; b. Brand Licensing: NMG CC shall work to broker commercial arrangements between SD and third-party cannabis brand owners whereby SD licenses commercial cannabis brands from third parties in connection with SD's commercial cannabis activity in exchange for a license fee; c. Equipment and Capital: NMG CC shall furnish all equipment and machinery necessary for SD's manufacturing of the Branded Products. Any equipment provided by NMG CC to SD shall be owned by NMG CC in its entirety and, subject to SD's approval of the terms, leased to SD pursuant to an Equipment Lease Agreement entered into between NMG CC and SD, dated 6 June 2019; and d. Loan: The Parties have entered into a certain secured loan agreement dated 6 June 2019 whereby NMG CC has loaned SD $250,000 (the "Loan") to be used solely in connection with SD's commercial cannabis activity. The Loan shall be due and payable on 6 June 2020 (the "Maturity Date") and shall bear interest at a rate of 12% per annum which shall be accrued, compounded quarterly and payable on the Maturity Date. The Loan will be secured by a security interest in and to all of SD's assets.	19. Other Investments The Company and NMG Cathedral City (“NMG CC”) entered into a management and administrative services agreement (the "Management Agreement") with Satellites Dip, LLC, ("SD"), a licensed cannabis business conducting commercial cannabis activity within the state of California. The one year Management Agreement commenced on June 6, 2019 and encompasses the following: a. Management Fee: NMG CC will be paid a management fee of 30% of Net Profits or $10,000 per month, whichever is greater; b. Brand Licensing: NMG CC shall work to broker commercial arrangements between SD and third-party cannabis brand owners whereby SD licenses commercial cannabis brands from third parties in connection with SD's commercial cannabis activity in exchange for a license fee; c. Equipment and Capital: NMG CC shall furnish all equipment and machinery necessary for SD's manufacturing of the Branded Products. Any equipment provided by NMG CC to SD shall be owned by NMG CC in its entirety and, subject to SD's approval of the terms, leased to SD pursuant to an Equipment Lease Agreement entered into between NMG CC and SD, dated June 6, 2019; and d. Loan: The Parties have entered into a certain secured loan agreement dated June 6, 2019 whereby NMG CC has loaned SD $250,000 (the "Loan") to be used solely in connection with SD's commercial cannabis activity. The Loan shall be due and payable on June 6, 2020 (the "Maturity Date") and shall bear interest at a rate of 12% per annum which shall be accrued, compounded quarterly and payable on the Maturity Date. The Loan will be secured by a security interest in and to all of SD's assets.

Lease Liabilities

Lease Liabilities	3 Months Ended
	Oct. 31, 2019
Leases [Abstract]
Lease Liabilities	20. Lease Liabilities a) On 10 November 2017, NMG entered into a revised five-year lease agreement for the property located at 3375 Pepper Lane, Las Vegas, NV, containing approximately 18,000 square feet. The Company has four options to extend the lease and each option is for five years. The monthly rent was $12,500 plus common area expenses, which increased to $12,875 plus common area expenses on 1 January 2019. The guaranteed minimum monthly rent is subject to a 2% increase on each anniversary date of the lease. b) On 9 April 2019, NMG entered into a three-year lease agreement for the property located at 6420 Sunset Corporate Drive, Las Vegas, NV, containing approximately 7,700 square feet. The Company has one option to extend the lease for an additional three-year term and an option to purchase the property at any point during the initial term. The monthly rent is $6,026 plus $1,129 in common area expenses, totaling $7,156 every month. On adoption of ASC 842, Lease Accounting, the Company recognized right-of-use assets (Note 7), and a corresponding increase in lease liabilities, in the amount of $1,187,116 which represented the present value of future lease payments using a discount rate of 12% per annum. The Company adopted the modified retrospective approach on adopting ASC 842 and accordingly the adoption was made effective August 1, 2019, with no restatement of the prior year comparatives. During the three months ended 31 October 2019, the Company recorded a lease expense of $56,704 related to the accretion of lease liabilities and the depreciation of right-of-use assets. Supplemental cash flow information related to leases was as follows: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 56,704 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 1,187,116 Weighted-average remaining lease term – operating leases 7.46 years Weighted-average discount rate – operating leases 12 % Maturities of lease liabilities were as follows: Year Ending 31 July Operating Leases 2020 $ 153,798 2021 223,398 2022 240,530 2023 248,403 2024 254,438 2025 257,827 2026 176,312 2027 179,838 2028 60,340 Total lease payments $ 1,794,884 Less imputed interest (650,857 ) Total $ 1,144,027

Income Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	20. Income Taxes A reconciliation of income taxes at statutory rates with the reported taxes for the years ended July 31, 2019 and 2018 is as follows: 2019 2018 Net loss for the period $ (3,752,751 ) $ (2,685,782 ) Federal and state income tax rates 21.00 % 26.45 % Expected income tax recovery (788,078 ) (710,389 ) Permanent differences 1,342,979 528,510 Change in estimates and others 120,554 225,902 Change in tax rates 178,289 (725,324 ) Change in benefit not recognized (853,744 ) (223,421 ) Total income tax recovery $ - $ (904,722 ) The significant components of the Company's deferred income tax assets and liabilities are as follows: As at 31 July 2019 As at 31 July 2018 Deferred income tax asset Net income tax operating loss carry forward $ 150,000 $ 985,290 Deferred tax allowance (150,000 ) (985,290 ) Deferred income tax liability Brand and License 1,716,120 1,716,120 Net deferred income tax liability $ 1,716,120 $ 1,716,120

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events On 30 November 2019, NMG CC entered into a settlement and release agreement (the “Settlement Agreement”) with SD whereby NMG CC and SD agreed to terminate the Management Agreement and to enter into a mutual release of any and all claims related to the Management Agreement, subject to the terms of the Settlement Agreement. As of 30 November 2019, SD owed NMG CC management fees (the “Monies Owed”) under the Management Agreement. In consideration of NMG CC’s discharge of the Monies Owed, SD has agreed to pay NMG CC one-hundred percent (100%) of all proceeds received from the sale of all or any part of its inventory (the “Inventory”) as of 1 November 2019. Pursuant to the Settlement Agreement, SD shall provide monthly updates of the remaining Inventory until the Inventory has been fully exhausted. NMG CC will determine the sale price for any item in Inventory subject to the Settlement Agreement. Brand Director Agreement On 30 November 2019, NMG CC entered into a brand director agreement (the “Brand Director Agreement”) with SD. Pursuant to the Brand Director Agreement, SD has engaged NMG CC to provide certain advisory and brand director services in connection with SD’s manufacture of Company-branded products, as well as certain other products (the “Managed Products”) as agreed to by NMGCC (the “Brand Director Services”). The initial term of the Brand Director Agreement is six months and the parties may renew the Brand Director Agreement for successive three-month renewal periods. The Brand Director Services include: (a) managing SD’s production of the Managed Products; (b) payment of a reimbursement fee to SD equal to the amount of direct costs and direct taxes applicable to the Managed Products; (c) managing inventory of the Managed Products; and (d) directing SD to enter into distribution agreements and sale agreements with third-party commercial cannabis licensees for the distribution and sale of the Managed Products in accordance with applicable law. Pursuant to the Brand Director Agreement, NMG CC will pay a monthly fee (the “Contribution Fee”) of $5,000 to SD. In connection with the Brand Director Agreement, as partial repayment for the principal and interest accrued under a certain loan agreement (the “Loan Agreement”) between NMG CC and SD dated 6 June 2019, SD waives payment of the Contribution Fee for the first five (5) months of the Brand Direction Agreement. In consideration for the Brand Director Services, SD (as the “Licensee”) has agreed to pay NMG CC (in its capacity as the “Brand Director”) a brand director fee for each calendar month during the term of the Brand Director Agreement, whereby Licensee shall pay to Brand Director a fee to be calculated as follows: (x) net revenue for a single calendar month, multiplied by, (y) seventy-five percent (75%); (z) plus any fees to be paid to NMG CC in connection with the equipment lease agreement (the “Equipment Lease Agreement”) dated 6 June 2019 (the "Equipment Lease Fee") added to the product of (x) and (y), the (q) total amount shall be the fee paid to NMG CC. If the net revenue, minus the product of (x) and (y) is less than the Equipment Lease Fee in any given month, the difference shall carry over to the subsequent month, to be added to that month's Equipment Lease Fee, or the difference may be paid by Licensee at its sole option. Brand License Agreement On 30 November 2019, DEP entered into a brand license agreement (the “License Agreement”) with SD. Pursuant to the License Agreement, DEP granted SD a non-exclusive, non-transferable, and non-sub-licensable right (the “License”) to use certain licensed marks in connection with or on licensed products, solely in connection with SD’s commercial cannabis activity in California. In consideration for the License, SD will pay DEP a monthly fee equal to $100, payable on a quarterly basis. During the term of the License Agreement, SD must remain in compliance with all state and local cannabis rules and regulations in California, and maintain valid commercial cannabis licenses. SD will follow the guidance of DEP and only utilize packaging and labelling materials purchased from (or at the direction of) DEP. The License Agreement will be in full force and effect for the duration of the Brand Director Agreement. Equipment Purchase Agreement On 30 November 2019, NMG CC and SD entered into an equipment purchase agreement (the “Equipment Purchase Agreement”) pursuant to which NMG CC agreed to purchase certain equipment (the “Equipment”) from SD. The aggregate purchase price for the Equipment is $235,684.93 and will be applied to the outstanding balance under the Loan Agreement. First Amendment to the Equipment Lease Agreement On 30 November 2019, NMG CC and SD entered into an amendment (the “First Amendment”) to the Equipment Lease Agreement. Pursuant to the First Amendment, NMG CC and SD amended (i) the term of the Equipment Lease Agreement to be coterminous with the Brand Director Agreement; and (ii) to update the equipment being leased pursuant to the Equipment Lease Agreement and to update the monthly rental rate for the equipment being leased. Release & Satisfaction of Loan Agreement On 30 November 2019, NMG CC and SD entered into a release and satisfaction of loan agreement (the “Release Agreement”). Pursuant to the Release Agreement, NMG CC agreed that all indebtedness of SD to NMG CC arising from the Loan Agreement (and promissory note issued in connection with the Loan Agreement) is hereby satisfied and discharged in full. The release is granted based on SD’s obligations and duties pursuant to the Equipment Purchase Agreement and its five (5) month waiver of the Contribution Fee under the Brand Director Agreement.	21. Subsequent Events i. On 12 August 2019, the Company issued a total of 4,337,111 common shares of the Company in connection with the Purchase Agreement, NMG SD Settlement Agreement and the Lease Assignment Agreement (Note 18). ii. On 12 August 2019, the Company issued 81,591 common shares upon exercise of 81,591 warrants at a price of CAD$0.66 per common share for aggregate proceeds of $40,765 (CAD$53,850). iii. On 21 August 2019, the Company granted an aggregate of 2,850,000 stock options with an exercise price of CAD$0.88 per share for a term of five years expiring on 21 August 2024. The options are subject to vesting provisions such that 25% of the options vest six months from the date of grant, 25% of the options vest twelve months from the date of grant, 25% of the options vest eighteen months from the date of grant and 25% of the options vest twenty-four months from the date of grant. iv. On 12 September 2019, the Company issued 38,912 common shares upon exercise of 38,912 warrants at a price of CAD$0.66 per common share for aggregate proceeds of $19,449 (CAD$25,682). v. On 1 October 2019, the Company granted 250,000 stock options to a director with an exercise price of CAD$0.93 per share for a term of five years expiring on 1 October 2024. The options are subject to vesting provisions such that 25% of the options vest six months from the date of grant, 25% of the options vest 12 months from the date of grant, 25% of the options vest eighteen months from the date of grant and 25% of the options vest twenty-four months from the date of grant. vi. On 4 October 2019, the Company issued 22,727 common shares upon exercise of 22,727 warrants at a price of CAD$0.90 per common share for aggregate proceeds of $15,359 (CAD$20,454). vii. On 16 October 2019, the Company cancelled 400,000 stock options previously granted to a director on 21 August 2019 with an exercise price of CAD$0.88 per share.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation These consolidated interim financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is 31 July.	Basis of presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is 31 July. Principles of consolidation These consolidated financial statements include the financial statements of the Company and its subsidiaries as follows: Name Jurisdiction Ownership Date of acquisition or formation DEP Nevada, Inc. (“Dep Nevada”) Nevada, USA 100 % 10 August 2017 Nevada Medical Group, LLC (“NMG”) Nevada, USA 100 % 14 November 2017 NMG Retail, LLC Nevada, USA 75 % 14 September 2018 NMG Long Beach, LLC California, USA 100 % 18 December 2018 NMG Cathedral City, LLC California, USA 100 % 4 January 2019 NMG Chula Vista, LLC California, USA 51 % 10 January 2019 NMG San Diego, LLC California, USA 60 % 30 January 2019 All inter-company transactions and balances are eliminated upon consolidation. These consolidated financial statements include the following investments accounted for using the equity method of accounting: Name Jurisdiction Ownership Date of acquisition or formation NMG Ohio, LLC Ohio, USA 30 % 27 April 2017
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents include highly liquid investments with original maturities of three months or less.	Cash and cash equivalents Cash and cash equivalents include highly liquid investments with original maturities of three months or less.
Amounts receivable	Amounts receivable Amounts receivable represents amounts owed from customers for sale of medical and recreational cannabis and sales tax recoverable. Amounts are presented net of the allowance for doubtful accounts, which represents the Company’s best estimate of the amount of probable credit losses in the existing accounts receivable balance. The Company determines the allowance for doubtful accounts based on historical experience and current economic conditions. The Company reviews the adequacy of its allowance for doubtful accounts on a quarterly basis. As at 31 October 2019 and 31 July 2019, the Company has no allowance for doubtful accounts.	Amounts receivable Amounts receivable represents amounts owed from customers for sale of medical and recreational cannabis and sales tax recoverable. Amounts are presented net of the allowance for doubtful accounts, which represents the Company’s best estimate of the amount of probable credit losses in the existing accounts receivable balance. The Company determines the allowance for doubtful accounts based on historical experience and current economic conditions. The Company reviews the adequacy of its allowance for doubtful accounts on a quarterly basis. As at 31 July 2019 and 2018, the Company has no allowance for doubtful accounts.
Revenue recognition	Revenue recognition The Company derives revenue primarily from the sale of medical and recreational cannabis. In accordance with ASC 606, revenue is recognized when persuasive evidence of an arrangement exists, the services have been rendered and the goods have been delivered, the amount is fixed and determinable, and collection is reasonably assured. The Company does not have standard terms that permit return of product; however, in certain markets where returns occur management estimates the amount of returns as variable consideration based on historical return experience and adjust revenue accordingly. Products that do not meet the Company’s high-quality standards are returned by the customer or recalled and destroyed and are recorded as a reduction of revenue. The reversal of revenue is recorded upon determination that the product will be recalled and destroyed. Management estimates the costs required to facilitate product returns and records them in cost of goods sold as required.	Revenue recognition In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Since its initial release, the FASB has issued several amendments to the standard, which include clarification of accounting guidance related to identification of performance obligations and principal versus agent considerations. Topic 606 became effective for the Company in the first quarter of the 2019 fiscal year. The adoption of this guidance had no impact on the Company’s financial statements. The Company derives revenue primarily from the sale of medical and recreational cannabis. In accordance with ASC 606, revenue is recognized when persuasive evidence of an arrangement exists, the services have been rendered and the goods have been delivered, the amount is fixed and determinable, and collection is reasonably assured. The Company does not have standard terms that permit return of product; however, in certain markets where returns occur management estimates the amount of returns as variable consideration based on historical return experience and adjust revenue accordingly. Products that do not meet the Company’s high-quality standards are returned by the customer or recalled and destroyed and are recorded as a reduction of revenue. The reversal of revenue is recorded upon determination that the product will be recalled and destroyed. Management estimates the costs required to facilitate product returns and records them in cost of goods sold as required.
Inventory	Inventory Inventory consists of raw material, work in progress (live plants and plants in the drying process), finished goods, and consumables. The Company values its raw material, finished goods and consumables at the lower of the actual costs or its current estimated market value less costs to sell. The Company values its work in progress at cost. The Company periodically reviews its inventory for obsolete and potentially impaired items.	Inventory Inventory consists of raw material, work in progress (live plants and plants in the drying process), finished goods, and consumables. The Company values its raw material, finished goods and consumables at the lower of the actual costs or its current estimated market value less costs to sell. The Company values its work in progress at cost. The Company periodically reviews its inventory for obsolete and potentially impaired items.
Property and equipment	Property and equipment Property and equipment are stated at cost and are amortized over their estimated useful lives on a straight-line basis as follows: Office equipment 7 years Cultivation equipment 7 years Production equipment 7 years Kitchen equipment 7 years Vehicles 7 years Vault equipment 7 years Leasehold improvements shorter of 15 years or the term of the lease Right-of-use asset Term of the lease	Property and equipment Property and equipment are stated at cost and are amortized over their estimated useful lives on a straight-line basis as follows: Office equipment 7 years Cultivation equipment 7 years Production equipment 7 years Kitchen equipment 7 years Vehicles 7 years Vault equipment 7 years Leasehold improvements shorter of 15 years or the term of the lease
Brands and licenses	Brands and licenses Intangible assets acquired from third parties are measured initially at fair value and either classified as indefinite life or finite life depending on their characteristics. Intangible assets with indefinite lives are tested for impairment at least annually and intangible assets with finite lives are reviewed for indicators of impairment at least annually. The Company’s brands and licenses have indefinite lives; therefore no amortization is recognized.	Brands and licenses Intangible assets acquired from third parties are measured initially at fair value and either classified as indefinite life or finite life depending on their characteristics. Intangible assets with indefinite lives are tested for impairment at least annually and intangible assets with finite lives are reviewed for indicators of impairment at least annually. The Company’s brands and licenses have indefinite lives; therefore no amortization is recognized.
Income taxes	Income taxes Deferred income taxes are reported for timing differences between items of income or expense reported in the consolidated financial statements and those reported for income tax purposes in accordance with ASC 740, “Income Taxes”, which requires the use of the asset/liability method of accounting for income taxes. Deferred income taxes and tax benefits are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases, and for tax losses and credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company provides for deferred taxes for the estimated future tax effects attributable to temporary differences and carry-forwards when realization is more likely than not.	Income taxes Deferred income taxes are reported for timing differences between items of income or expense reported in the consolidated financial statements and those reported for income tax purposes in accordance with ASC 740, “Income Taxes”, which requires the use of the asset/liability method of accounting for income taxes. Deferred income taxes and tax benefits are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases, and for tax losses and credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company provides for deferred taxes for the estimated future tax effects attributable to temporary differences and carry-forwards when realization is more likely than not.
Basic and diluted net loss per share	Basic and diluted net loss per share The Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excluded all dilutive potential shares if their effect is anti-dilutive.	Basic and diluted net loss per share The Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excluded all dilutive potential shares if their effect is anti-dilutive.
Segments of an enterprise and related information	Segments of an enterprise and related information ASC 280, “Segment Reporting” establishes guidance for the way that public companies report information about operating segments in annual consolidated financial statements and requires reporting of selected information about operating segments in interim consolidated financial statements issued to the public. It also establishes standards for disclosures regarding products and services, geographic areas and major customers. ASC 280 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company has evaluated this Codification and does not believe it is applicable at this time.	Segments of an enterprise and related information ASC 280, “Segment Reporting” establishes guidance for the way that public companies report information about operating segments in annual consolidated financial statements and requires reporting of selected information about operating segments in interim consolidated financial statements issued to the public. It also establishes standards for disclosures regarding products and services, geographic areas and major customers. ASC 280 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company has evaluated this Codification and does not believe it is applicable at this time.
Comprehensive loss	Comprehensive loss ASC 220, “Comprehensive Income”, establishes standards for the reporting and display of comprehensive income/loss and its components in the consolidated financial statements. As at 31 July 2019, the Company reported foreign currency translation adjustments as other comprehensive income or loss and included a schedule of comprehensive income/loss in the consolidated financial statements.	Comprehensive loss ASC 220, “Comprehensive Income”, establishes standards for the reporting and display of comprehensive income/loss and its components in the consolidated financial statements. As at 31 July 2019, the Company reported foreign currency translation adjustments as other comprehensive income or loss and included a schedule of comprehensive income/loss in the consolidated financial statements.
Foreign currency translation	Foreign currency translation The Company’s functional currency is the Canadian dollar and its reporting currency is the U.S. dollars. The Company’s subsidiaries have a functional currency of U.S. dollars. The consolidated financial statements of the Company are translated to U.S. dollars in accordance with ASC 830, “Foreign Currency Matters”. Exchange gains and losses on inter-company balances that form part of the net investment in foreign operations are included in other comprehensive income. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income.	Foreign currency translation The Company’s functional currency is the Canadian dollar and its reporting currency is the U.S. dollars. The Company’s subsidiaries have a functional currency of U.S. dollars. The consolidated financial statements of the Company are translated to U.S. dollars in accordance with ASC 830, “Foreign Currency Matters”. Exchange gains and losses on inter-company balances that form part of the net investment in foreign operations are included in other comprehensive income. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income.
Stock-based compensation	Stock-based compensation The Company accounts for stock-based compensation issued to those other than employees in accordance with ASC 505-50. Equity instruments issued to those other than employees are valued at the earlier of a commitment date or upon completion of the services, based on the fair value of the equity instruments and is recognized as expense over the service period. The Company estimates the fair value of share-based payments using the Black-Scholes Option Pricing Model for common stock options and the closing price of the Company’s common stock for common share issuances.	Stock-based compensation The Company accounts for stock-based compensation issued to those other than employees in accordance with ASC 505-50. Equity instruments issued to those other than employees are valued at the earlier of a commitment date or upon completion of the services, based on the fair value of the equity instruments and is recognized as expense over the service period. The Company estimates the fair value of share-based payments using the Black-Scholes Option Pricing Model for common stock options and the closing price of the Company’s common stock for common share issuances.
Fair value measurements	Fair value measurements The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: · Level 1 – inputs are based upon unadjusted quoted prices for identical instruments in active markets. · Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques (e.g. the Black-Scholes model) for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, credit spreads, foreign exchange rates, and forward and spot prices for currencies. · Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models. Our Level 3 assets and liabilities include investments in other private entities, and goodwill and intangible assets, when they are recorded at fair value due to an impairment charge. Unobservable inputs used in the models are significant to the fair values of the assets and liabilities. The Company measures equity investments without readily determinable fair values on a nonrecurring basis. The fair values of these investments are determined based on valuation techniques using the best information available, and may include quoted market prices, market comparables, and discounted cash flow projections. Other current financial assets and current financial liabilities have fair values that approximate their carrying values.	Fair Value Measurements The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: · Level 1 – inputs are based upon unadjusted quoted prices for identical instruments in active markets. · Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques (e.g. the Black-Scholes model) for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, credit spreads, foreign exchange rates, and forward and spot prices for currencies. · Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models. Our Level 3 assets and liabilities include investments in other private entities, and goodwill and intangible assets, when they are recorded at fair value due to an impairment charge. Unobservable inputs used in the models are significant to the fair values of the assets and liabilities. The Company measures equity investments without readily determinable fair values on a nonrecurring basis. The fair values of these investments are determined based on valuation techniques using the best information available, and may include quoted market prices, market comparables, and discounted cash flow projections. Other current financial assets and current financial liabilities have fair values that approximate their carrying values.
Use of estimates and assumptions	Use of estimates and assumptions The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenditures during the reporting period. Actual results could differ from these estimates.	Use of estimates and assumptions The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenditures during the reporting period. Actual results could differ from these estimates.
Lease accounting	Lease accounting Under ASC 842, leases are separated into two classifications: operating leases and financial leases. Lease classification under ASC 842 is relatively similar to ASC 840. For a lease to be classified as a finance lease, it must meet one of the five finance lease criteria: (1) transference of title/ownership to the lessee, (2) purchase option, (3) lease term for major part of the remaining economic life of the asset, (4) present value represents substantially all of the fair value of the asset, and (5) asset specialization. Any lease that does not meet these criteria is classified as an operating lease. ASC 842 requires all leases to be recognized on the Company’s balance sheet. Specifically, for operating leases, the Company must recognize a right-of-use asset and a corresponding lease liability upon lease commitment.
Comparative figures	Comparative figures Certain comparative figures have been adjusted to conform to the current year’s presentation.	Comparative figures Certain comparative figures have been adjusted to conform to the current year’s presentation.

Nature and Continuance of Ope_2

Nature and Continuance of Operations (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of consolidation of entities and its ownership interest	Name Jurisdiction Ownership Date of acquisition or formation DEP Nevada Inc. (“DEP Nevada”) Nevada, USA 100% 10 August 2017 Nevada Medical Group LLC (“NMG”) Nevada, USA 100% 14 November 2017 NMG Retail LLC Nevada, USA 75% 14 September 2018 NMG Long Beach LLC California, USA 100% 18 December 2018 NMG Cathedral City LLC California, USA 100% 4 January 2019 NMG Chula Vista LLC California, USA 51% 10 January 2019 NMG San Diego LLC California, USA 60% 30 January 2019	Name Jurisdiction Ownership Date of acquisition or formation DEP Nevada, Inc. (“Dep Nevada”) Nevada, USA 100 % 10 August 2017 Nevada Medical Group, LLC (“NMG”) Nevada, USA 100 % 14 November 2017 NMG Retail, LLC Nevada, USA 75 % 14 September 2018 NMG Long Beach, LLC California, USA 100 % 18 December 2018 NMG Cathedral City, LLC California, USA 100 % 4 January 2019 NMG Chula Vista, LLC California, USA 51 % 10 January 2019 NMG San Diego, LLC California, USA 60 % 30 January 2019
Schedule of ownership interest by equity method investment in consolidation	Name Jurisdiction Ownership Date of acquisition or formation NMG Ohio LLC Ohio, USA 30% 27 April 2017	Name Jurisdiction Ownership Date of acquisition or formation NMG Ohio, LLC Ohio, USA 30 % 27 April 2017

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Accounting Policies [Abstract]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]	Name Jurisdiction Ownership Date of acquisition or formation DEP Nevada Inc. (“DEP Nevada”) Nevada, USA 100% 10 August 2017 Nevada Medical Group LLC (“NMG”) Nevada, USA 100% 14 November 2017 NMG Retail LLC Nevada, USA 75% 14 September 2018 NMG Long Beach LLC California, USA 100% 18 December 2018 NMG Cathedral City LLC California, USA 100% 4 January 2019 NMG Chula Vista LLC California, USA 51% 10 January 2019 NMG San Diego LLC California, USA 60% 30 January 2019	Name Jurisdiction Ownership Date of acquisition or formation DEP Nevada, Inc. (“Dep Nevada”) Nevada, USA 100 % 10 August 2017 Nevada Medical Group, LLC (“NMG”) Nevada, USA 100 % 14 November 2017 NMG Retail, LLC Nevada, USA 75 % 14 September 2018 NMG Long Beach, LLC California, USA 100 % 18 December 2018 NMG Cathedral City, LLC California, USA 100 % 4 January 2019 NMG Chula Vista, LLC California, USA 51 % 10 January 2019 NMG San Diego, LLC California, USA 60 % 30 January 2019
Schedule Of Ownership Interest By Equity Method Investment In Consolidation [Table Text Block]	Name Jurisdiction Ownership Date of acquisition or formation NMG Ohio LLC Ohio, USA 30% 27 April 2017	Name Jurisdiction Ownership Date of acquisition or formation NMG Ohio, LLC Ohio, USA 30 % 27 April 2017
Schedule of property and equipment estimated useful lives	Office equipment 7 years Cultivation equipment 7 years Production equipment 7 years Kitchen equipment 7 years Vehicles 7 years Vault equipment 7 years Leasehold improvements shorter of 15 years or the term of the lease Right-of-use asset Term of the lease	Office equipment 7 years Cultivation equipment 7 years Production equipment 7 years Kitchen equipment 7 years Vehicles 7 years Vault equipment 7 years Leasehold improvements shorter of 15 years or the term of the lease

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Investments, All Other Investments [Abstract]
Schedule of financial assets at fair value	As at 31 October 2019 As at 31 July 2019 Financial assets at fair value Cash $ 6,898,235 $ 9,004,716 Convertible loan receivable 67,166 52,225 Total financial assets at fair value $ 6,965,401 $ 9,056,941	As at 31 July 2019 As at 31 July 2018 Financial assets at fair value Cash $ 9,004,716 $ 324,837 Convertible loan receivable 52,225 - Total financial assets at fair value $ 9,056,941 $ 324,837

Inventory (Tables)

Inventory (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Inventory Disclosure [Abstract]
Schedule of inventory Table	31 October 2019 31 July 2019 Work in progress $ 245,750 $ 208,417 Finished goods 468,162 615,108 Consumables 533,308 566,894 Total $ 1,247,220 $ 1,390,419	31 July 2019 31 July 2018 Raw materials $ - $ 9,705 Work in progress 208,417 151,039 Finished goods 615,108 567,563 Consumables 566,894 225,110 Total $ 1,390,419 $ 953,417

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Office Equipment Cultivation Equipment Production Equipment Kitchen Equipment Vehicles Vault Equipment Leasehold Improvements Right-of-use Assets Total Cost: Balance, 31 July 2018 $ 24,586 $ 435,109 $ 261,957 $ 27,694 $ 38,717 $ 1,644 $ 1,993,928 $ - $ 2,783,635 Additions 7,491 28,647 36,004 23,414 - 528 272,078 - 368,162 Balance, 31 July 2019 32,077 463,756 297,961 51,108 38,717 2,172 2,266,006 - 3,151,797 Additions 26,980 - 154,982 9,022 - - 238,796 - 429,780 ASC 842 adoption (Note 20) - - - - - - - 1,187,116 1,187,116 Balance, 31 October 2019 59,057 463,756 452,943 60,130 38,717 2,172 2,504,802 1,187,116 4,768,693 Accumulated Depreciation: Balance, 31 July 2018 3,177 41,169 25,446 2,554 5,500 228 89,663 - 167,737 Depreciation 5,119 73,597 44,547 4,546 7,751 358 153,642 - 289,560 Balance, 31 July 2019 8,296 114,766 69,993 7,100 13,251 586 243,305 - 457,297 Depreciation 1,911 19,066 12,093 2,127 1,954 100 41,346 - 78,597 Asset lease expense (Note 20) - - - - - - - 43,089 43,089 Balance, 31 October 2019 10,207 133,832 82,086 9.227 15,205 686 284,651 43,089 578,983 Net Book Value: As at 31 July 2018 21,409 393,940 236,511 25,140 33,217 1,416 1,904,265 - 2,615,898 As at 31 July 2019 23,781 348,990 227,968 44,008 25,466 1,586 2,022,701 - 2,694,500 As at 31 October 2019 $ 48,850 $ 329,924 $ 370,857 $ 50,903 $ 23,512 $ 1,486 $ 2,220,151 $ 1,144,027 $ 4,189,710	Office Equipment Cultivation Equipment Production Equipment Kitchen Equipment Vehicles Vault Equipment Leasehold Improvements Total Cost: Balance, 31 July 2017 $ - $ - $ - $ - $ - $ - $ - $ - Acquired assets (Note 14) 23,105 245,659 176,354 15,809 38,717 1,644 1,455,649 1,956,937 Additions 1,481 189,450 85,603 11,885 - - 538,279 826,698 Balance, 31 July 2018 24,586 435,109 261,957 27,694 38,717 1,644 1,993,928 2,783,635 Additions 7,491 28,647 36,004 23,414 - 528 272,078 368,162 Balance, 31 July 2019 32,077 463,756 297,961 51,108 38,717 2,172 2,266,006 3,151,797 Accumulated Depreciation: Balance, 31 July 2017 - - - - - - - - Depreciation 3,177 41,169 25,446 2,554 5,500 228 89,663 167,737 Balance, 31 July 2018 3,177 41,169 25,446 2,554 5,500 228 89,663 167,737 Depreciation 5,119 73,597 44,547 4,546 7,751 358 153,642 289,560 Balance, 31 July 2019 8,296 114,766 69,993 7,100 13,251 586 243,305 457,297 Net Book Value: As at 31 July 2018 21,409 393,940 236,511 25,140 33,217 1,416 1,904,265 2,615,898 As at 31 July 2019 $ 23,781 $ 348,990 $ 227,968 $ 44,008 $ 25,466 $ 1,586 $ 2,022,701 $ 2,694,500

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Notes Payable [Abstract]
Schedule of promissory notes tables	31 October 2019 31 July 2019 Balance, beginning $ - $ 2,175,000 Issuance of promissory notes - 4,000,000 Deferred finance costs - (822,494 ) Repayment of promissory notes - (6,695,000 ) Early repayment penalty - 200,000 Interest and accretion expense - 1,142,494 Balance, ending $ - $ -	31 July 2019 31 July 2018 Balance, beginning $ 2,175,000 $ - Issuance of promissory notes 4,000,000 1,887,863 Deferred finance costs (822,494 ) - Repayment of promissory notes (6,695,000 ) - Early repayment penalty 200,000 - Interest and accretion expense 1,142,494 277,219 Foreign exchange adjustment - 9,918 Balance, ending $ - $ 2,175,000

Convertible debenture (Tables)

Convertible debenture (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Convertible Debt [Abstract]
Schedule of convertible debenture	31 October 2019 31 July 2019 Balance, beginning $ 1,065,565 $ - Issuance of convertible debenture - 1,128,750 Interest and accretion expense - 98,392 Interest paid - (72,623 ) Interest advanced - (88,821 ) Foreign exchange adjustment - (133 ) Balance, ending $ 1,065,565 $ 1,065,565	31 July 2019 31 July 2018 Balance, beginning $ - $ - Issuance of convertible debenture 1,128,750 - Interest and accretion expense 98,392 - Interest paid (72,623 ) Interest advanced (88,821 ) Foreign exchange adjustment (133 ) - Balance, ending $ 1,065,565 $ -

Capital Stock (Tables)

Capital Stock (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Capital [Abstract]
Schedule of fair value assumptions of stock options	The fair value of the stock options was calculated to be $880,595 (CAD$1,165,117) using the Black-Scholes Option Pricing Model with the following assumptions: Expected life of the options 5 years Expected volatility 265 % Expected dividend yield 0 % Risk-free interest rate 2.03 % The total fair value of the stock options granted was calculated to be $1,373,856 (CAD$1,818,232) using the Black-Scholes Option Pricing Model with the following assumptions: Expected life of the options 5 years Expected volatility 140 % Expected dividend yield 0 % Risk-free interest rate 1.28 % The total fair value of the stock options granted was calculated to be $145,045 (CAD$191,960) using the Black-Scholes Option Pricing Model with the following assumptions: Expected life of the options 5 years Expected volatility 140 % Expected dividend yield 0 % Risk-free interest rate 1.37 %	Expected life of the options 5 years Expected volatility 198 % Expected dividend yield 0 % Risk-free interest rate 1.63 % The fair value of the stock options was calculated to be $63,101 (CAD$81,129) using the Black-Scholes Option Pricing Model with the following assumptions: Expected life of the options 5 years Expected volatility 262 % Expected dividend yield 0 % Risk-free interest rate 2.16 % The fair value of the stock options was calculated to be $880,595 (CAD$1,165,117) using the Black-Scholes Option Pricing Model with the following assumptions: Expected life of the options 5 years Expected volatility 265 % Expected dividend yield 0 % Risk-free interest rate 2.03 %
Schedule of changes in stock options activity	31 October 2019 31 July 2019 Number of options Exercise Price Number of options Exercise Price Opening balance 6,075,000 CAD$0.62 4,025,000 CAD$0.65 Granted 3,100,000 CAD$0.88 2,050,000 CAD$0.57 Forfeited (400,000 ) CAD$0.88 - - Closing balance 8,775,000 CAD$0.70 6,075,000 CAD$0.62	31 July 2019 31 July 2018 Number of options Exercise Price Number of options Exercise Price Opening balance 4,025,000 CAD$0.65 - - Options granted 2,050,000 CAD$0.57 4,025,000 CAD$0.65 Closing balance 6,075,000 CAD$0.62 4,025,000 CAD$0.65
Schedule of changes in Share purchase warrants and brokers' warrants and warrants outstanding	Share purchase warrants and brokers’ warrants 31 October 2019 31 July 2019 Number of warrants Exercise Price Number of warrants Exercise Price Opening balance 22,514,771 CAD$1.22 10,106,820 CAD$0.89 Issued - - 28,415,284 CAD$0.93 Exercised (143,230 ) CAD$0.70 (16,007,333 ) CAD$0.50 Expired (225,083 ) CAD$0.66 - - Closing balance 22,146,458 CAD$1.23 22,514,771 CAD$1.22 As at 31 October 2019, the following warrants are outstanding: Number of warrants outstanding and exercisable Exercise price Expiry dates 21,700 CAD$0.66 3 November 2019 9,072,081 CAD$0.90 14 November 2019 637,393 CAD$0.90 1 December 2019 11,780,134 CAD$1.50 17 May 2023 635,150 CAD$1.25 16 May 2023 22,146,458	Share purchase warrants and brokers’ warrants 31 July 2019 31 July 2018 Number of warrants Exercise Price Number of warrants Exercise Price Opening balance 10,106,820 CAD$0.89 - - Warrants issued 28,415,284 CAD$0.93 10,106,820 CAD$0.89 Warrants exercised (16,007,333 ) CAD$0.50 - - Closing balance 22,514,771 CAD$1.22 10,106,820 CAD$0.89 As at 31 July 2019, the following warrants are outstanding: Number of warrants outstanding and exercisable Exercise price Expiry dates 248,350 CAD$0.66 15 August 2019 58,324 CAD$0.66 16 August 2019 60,612 CAD$0.66 3 November 2019 9,094,808 CAD$0.90 14 November 2019 637,393 CAD$0.90 1 December 2019 11,780,134 CAD$1.50 17 May 2023 635,150 CAD$1.25 17 May 2023 22,514,771

Supplemental Disclosures with_2

Supplemental Disclosures with Respect to Cash Flows (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Supplemental disclosures with respect to cash flows	Three Month Period Ended 31 October 2019 2018 Cash paid during the period for interest $ - $ - Cash paid during the period for income taxes $ - $ -	Year Ended 31 July 2019 2018 Cash paid during the period for interest $ 392,623 $ - Cash paid during the period for income taxes $ - $ -

Business Acquisition (Tables)

Business Acquisition (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Business Combinations [Abstract]
Schedule of purchase consideration under business acquisition	Purchase consideration Share considerations $ 6,143,326 Cash considerations 2,309,000 Promissory notes issued 1,887,277 TOTAL $ 10,339,603 Assets acquired: Cash $ 260,842 Amounts receivable 253,697 Prepaid expenses 44,552 Inventory 498,680 Property and equipment 1,951,696 Brand 247,000 Licenses 7,925,000 Liabilities assumed: Trade payable and accrued liabilities (367,385 ) Loans payable (250,000 ) Deferred tax liability (2,860,200 ) Net assets acquired 7,703,882 Goodwill 2,635,721 TOTAL $ 10,339,603	Purchase consideration Share considerations, net of transaction costs $ 6,143,326 Cash considerations 2,309,000 Promissory notes issued 1,887,277 TOTAL $ 10,339,603 Assets acquired: Cash $ 260,842 Amounts receivable 253,697 Prepaid expenses 44,552 Inventory 498,680 Property and equipment 1,951,696 Brand 247,000 Licenses 7,925,000 Liabilities assumed: Trade payable and accrued liabilities (367,385 ) Loans payable (250,000 ) Deferred tax liability (2,860,200 ) Net identifiable assets acquired 7,703,882 Goodwill 2,635,721 TOTAL $ 10,339,603

Investment in NMG Ohio LLC (Tab

Investment in NMG Ohio LLC (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Investment in NMG Ohio LLC	31 October 2019 31 July 2019 Opening balance $ 3,465,902 $ 77,600 Acquisition costs: Common shares issued to vendors at fair value - 1,448,805 Acquisition costs: Cash payments to vendors - 1,181,250 Dispensary build-out related costs 16,469 573,633 License fees - 100,000 Equity pickup 87,651 56,466 Foreign exchange (1,377 ) 28,148 Total $ 3,568,645 $ 3,465,902 Summarized financial information for NMG Ohio is as follows: 31 October 2019 Current assets $ 768,603 Non-current assets 853,383 Total assets 1,621,986 Current liabilities 465,933 Non-current liabilities - Total liabilities 465,933 Revenues 961,444 Gross profit 420,904 Net income 292,171 Net income attributable to the Company $ 87,651	31 July 2019 Balance, 31 July 2018 $ 77,600 Acquisition costs: Common shares issued to vendors at fair value 1,448,805 Acquisition costs: Cash payments to vendors 1,181,250 Dispensary build-out related costs 573,633 License fees 100,000 Equity pickup 56,466 Foreign exchange 28,148 Total $ 3,465,902 Summarized financial information for NMG Ohio is as follows: 31 July 2019 Current assets $ 271,121 Non-current assets 923,387 Total assets 1,194,508 Current liabilities 338,427 Non-current liabilities - Total liabilities 338,427 Revenues 1,225,238 Gross profit 513,643 Net income 188,244 Net income attributable to the Company $ 56,466

Investment in and advances to_2

Investment in and advances to GLDH (Tables)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2018
Investments [Abstract]
Schedule of total investment	31 October 2019 31 July 2019 Note receivable $ 7,373,036 $ 5,200,000 Share issuances 2,752,782 - Interest income accrued on the Note 260,000 693,333 Advances for working capital 512,506 666,876 Lease Assignment Agreement payment - 783,765 Foreign exchange - 29,062 Total $ 10,898,324 $ 7,373,036	31 July 2019 Note receivable $ 5,200,000 Interest income accrued on the Note 693,333 Advances for working capital 666,876 Lease Assignment Agreement payment 783,765 Foreign exchange 29,062 Total $ 7,373,036

Lease Liabilities (Tables)

Lease Liabilities (Tables)	3 Months Ended
	Oct. 31, 2019
Leases [Abstract]
Schedule of supplemental cash flow information related to leases	Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 56,704 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 1,187,116 Weighted-average remaining lease term – operating leases 7.46 years Weighted-average discount rate – operating leases 12 %
Schedule of Maturities of lease liabilities	Year Ending 31 July Operating Leases 2020 $ 153,798 2021 223,398 2022 240,530 2023 248,403 2024 254,438 2025 257,827 2026 176,312 2027 179,838 2028 60,340 Total lease payments $ 1,794,884 Less imputed interest (650,857 ) Total $ 1,144,027

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of reconciliation of income taxes at statutory rates	2019 2018 Net loss for the period $ (3,752,751 ) $ (2,685,782 ) Federal and state income tax rates 21.00 % 26.45 % Expected income tax recovery (788,078 ) (710,389 ) Permanent differences 1,342,979 528,510 Change in estimates and others 120,554 225,902 Change in tax rates 178,289 (725,324 ) Change in benefit not recognized (853,744 ) (223,421 ) Total income tax recovery $ - $ (904,722 )
Schedule of components of deferred income tax assets and liabilities	As at 31 July 2019 As at 31 July 2018 Deferred income tax asset Net income tax operating loss carry forward $ 150,000 $ 985,290 Deferred tax allowance (150,000 ) (985,290 ) Deferred income tax liability Brand and License 1,716,120 1,716,120 Net deferred income tax liability $ 1,716,120 $ 1,716,120

Nature and Continuance of Ope_3

Nature and Continuance of Operations (Details)	Oct. 31, 2019
DEP Nevada Inc. ("DEP Nevada")
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership	100.00%
Nevada Medical Group LLC (NMG)
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership	100.00%
NMG Retail LLC
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership	75.00%
NMG Long Beach LLC
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership	100.00%
NMG Cathedral City LLC
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership	100.00%
NMG Chula Vista LLC
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership	51.00%
NMG San Diego LLC
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership	60.00%

Nature and Continuance of Ope_4

Nature and Continuance of Operations (Details 1)	Oct. 31, 2019
NMG Ohio LLC
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage	30.00%

Nature and Continuance of Ope_5

Nature and Continuance of Operations (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2019	Jul. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Jul. 31, 2017	May 31, 2004
State of incorporation	Delaware
Entity Incorporation, Date of Incorporation	Nov. 5, 1998
Cash and cash equivalents	$ 6,898,235	$ 9,004,716	$ 100,481	$ 324,837	$ 366,584
Working capital deficit	$ 8,288,767
Kaleidoscope Venture Capital, Inc
Ownership percentage						100.00%

Significant Accounting Polici_4

Significant Accounting Policies (Details)	Oct. 31, 2019
DEP Nevada Inc. ("DEP Nevada")
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage	100.00%
Nevada Medical Group LLC (NMG)
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage	100.00%
NMG Retail LLC
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage	75.00%
NMG Long Beach LLC
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage	100.00%
NMG Cathedral City LLC
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage	100.00%
NMG Chula Vista LLC
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage	51.00%
NMG San Diego LLC
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage	60.00%

Significant Accounting Polici_5

Significant Accounting Policies (Details 1)	Oct. 31, 2019
NMG Ohio LLC
Schedule of Equity Method Investments [Line Items]
Ownership percentage	30.00%

Significant Accounting Polici_6

Significant Accounting Policies (Details 2)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Office equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years	7 years
Cultivation equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years	7 years
Production equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years	7 years
Kitchen equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years	7 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years	7 years
Vault equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years	7 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives	shorter of 15 years or the term of the lease	shorter of 15 years or the term of the lease
Right-of-use asset
Property, Plant and Equipment [Line Items]
Estimated useful lives	Term of the lease

Financial Instruments (Details)

Financial Instruments (Details) - USD ($)	Oct. 31, 2019	Jul. 31, 2019	Jul. 31, 2018
Financial assets at fair value
Cash	$ 6,898,235	$ 9,004,716	$ 324,837
Convertible loan receivable	67,166	52,225	0
Total financial assets at fair value	$ 6,965,401	$ 9,056,941	$ 324,837

Financial Instruments (Details

Financial Instruments (Details Narrative) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Working capital deficit	$ 8,288,767	$ 10,262,959

Inventory (Details)

Inventory (Details) - USD ($)	Oct. 31, 2019	Jul. 31, 2019	Jul. 31, 2018
Inventory Disclosure [Abstract]
Raw materials		$ 0	$ 9,705
Work in progress	$ 245,750	208,417	151,039
Finished goods	468,162	615,108	567,563
Consumables	533,308	566,894	225,110
Total	$ 1,247,220	$ 1,390,419	$ 953,417

Convertible loan receivable (De

Convertible loan receivable (Details Narrative)	3 Months Ended	12 Months Ended
	Oct. 31, 2019USD ($)	Jul. 31, 2019USD ($)	Jul. 31, 2018USD ($)
Convertible Loan Receivable [Line Items]
Convertible Loan Receivable (Note 6)	$ 67,166	$ 52,225
Accrued interest	45,000	27,000
NMG
Convertible Loan Receivable [Line Items]
Management fee (per month)		6,000
Loan bears interest per month	$ 6,000
Percentage of monthly management fee	66.67%
CCG | Convertible loan agreement
Convertible Loan Receivable [Line Items]
Proceeds from fund construction	$ 1,250,000	1,250,000
Loan bears interest per month	$ 6,000	$ 6,000
Outstanding units percentage	0.4000	0.4000

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Movement in Property, Plant and Equipment [Roll Forward]
Balance	$ 3,151,797	$ 2,783,635	$ 2,783,635	$ 0
Acquired assets				1,956,937
Additions	429,780		368,162	826,698
ASC 842 adoption (Note 20)	1,187,116
Balance	4,768,693		3,151,797	2,783,635
Accumulated Depreciation:
Balance	457,297	167,737	167,737	0
Depreciation	78,597	69,557	289,560	167,737
Asset lease expense (Note 20)	43,089
Balance	578,983		457,297	167,737
Net Book Value
Net Book Value:	4,189,710		2,694,500	2,615,898
Office Equipment [Member]
Movement in Property, Plant and Equipment [Roll Forward]
Balance	32,077	24,586	24,586	0
Acquired assets				23,105
Additions	26,980		7,491	1,481
ASC 842 adoption (Note 20)	0
Balance	59,057		32,077	24,586
Accumulated Depreciation:
Balance	8,296	3,177	3,177	0
Depreciation	1,911		5,119	3,177
Asset lease expense (Note 20)	0
Balance	10,207		8,296	3,177
Net Book Value
Net Book Value:	48,850		23,781	21,409
Cultivation equipment
Movement in Property, Plant and Equipment [Roll Forward]
Balance	463,756	435,109	435,109	0
Acquired assets				245,659
Additions	0		28,647	189,450
ASC 842 adoption (Note 20)	0
Balance	463,756		463,756	435,109
Accumulated Depreciation:
Balance	114,766	41,169	41,169	0
Depreciation	19,066		73,597	41,169
Asset lease expense (Note 20)	0
Balance	133,832		114,766	41,169
Net Book Value
Net Book Value:	329,924		348,990	393,940
Production equipment
Movement in Property, Plant and Equipment [Roll Forward]
Balance	297,961	261,957	261,957	0
Acquired assets				176,354
Additions	154,982		36,004	85,603
ASC 842 adoption (Note 20)	0
Balance	452,943		297,961	261,957
Accumulated Depreciation:
Balance	69,993	25,446	25,446	0
Depreciation	12,093		44,547	25,446
Asset lease expense (Note 20)	0
Balance	82,086		69,993	25,446
Net Book Value
Net Book Value:	370,857		227,968	236,511
Kitchen equipment
Movement in Property, Plant and Equipment [Roll Forward]
Balance	51,108	27,694	27,694	0
Acquired assets				15,809
Additions	9,022		23,414	11,885
ASC 842 adoption (Note 20)	0
Balance	60,130		51,108	27,694
Accumulated Depreciation:
Balance	7,100	2,554	2,554	0
Depreciation	2,127		4,546	2,554
Asset lease expense (Note 20)	0
Balance	9.227		7,100	2,554
Net Book Value
Net Book Value:	50,903		44,008	25,140
Vehicles
Movement in Property, Plant and Equipment [Roll Forward]
Balance	38,717	38,717	38,717	0
Acquired assets				38,717
Additions	0		0	0
ASC 842 adoption (Note 20)	0
Balance	38,717		38,717	38,717
Accumulated Depreciation:
Balance	13,251	5,500	5,500	0
Depreciation	1,954		7,751	5,500
Asset lease expense (Note 20)	0
Balance	15,205		13,251	5,500
Net Book Value
Net Book Value:	23,512		25,466	33,217
Vault equipment
Movement in Property, Plant and Equipment [Roll Forward]
Balance	2,172	1,644	1,644	0
Acquired assets				1,644
Additions	0		528	0
ASC 842 adoption (Note 20)	0
Balance	2,172		2,172	1,644
Accumulated Depreciation:
Balance	586	228	228	0
Depreciation	100		358	228
Asset lease expense (Note 20)	0
Balance	686		586	228
Net Book Value
Net Book Value:	1,486		1,586	1,416
Leasehold improvements
Movement in Property, Plant and Equipment [Roll Forward]
Balance	2,266,006	1,993,928	1,993,928	0
Acquired assets				1,455,649
Additions	238,796		272,078	538,279
ASC 842 adoption (Note 20)	0
Balance	2,504,802		2,266,006	1,993,928
Accumulated Depreciation:
Balance	243,305	89,663	89,663	0
Depreciation	41,346		153,642	89,663
Asset lease expense (Note 20)	0
Balance	284,651		243,305	89,663
Net Book Value
Net Book Value:	2,220,151		2,022,701	1,904,265
Right-of-use asset
Movement in Property, Plant and Equipment [Roll Forward]
Balance	0	0	0
Additions	0		0
ASC 842 adoption (Note 20)	1,187,116
Balance	1,187,116		0	0
Accumulated Depreciation:
Balance	0	$ 0	0
Depreciation	0		0
Asset lease expense (Note 20)	43,089
Balance	43,089		0	0
Net Book Value
Net Book Value:	$ 1,144,027		$ 0	$ 0

Related Party Balances and Tr_2

Related Party Balances and Transactions (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Related Party Transaction [Line Items]
Consulting fees	$ 220,227	$ 2,600	$ 167,942	$ 206,913
Stock-based compensation	$ 289,578		880,595	789,679
NMG Ohio LLC
Related Party Transaction [Line Items]
Due to related party			$ 461,251
Number of shares payable to related party			929,488
Purchase of remaining ownership interest percentage	70.00%		70.00%
Consideration in cash to be paid for the acquisition of remaining interest	$ 1,575,000		$ 1,575,000
Issuance of common stock			3,173,864
President And Interim Chief Executive Officer
Related Party Transaction [Line Items]
Management Fees	34,311
Consulting fees	7,556
Chief Financial Officer and director
Related Party Transaction [Line Items]
Management Fees	22,668
Accounting fees		6,908
Due to related party			$ 5,172	1,210
Chief Operating Officer
Related Party Transaction [Line Items]
Consulting fees			90,000
Salaries and wages	45,000
Director
Related Party Transaction [Line Items]
Management Fees			225,992	144,528
Salaries and wages	50,000	33,654
Due to related party	33,333			28,810
Corporate Secretary
Related Party Transaction [Line Items]
Management Fees	5,667	11,514
Consulting fees	11,334
Interim Chief Executive Officer
Related Party Transaction [Line Items]
Management Fees		11,514	50,072
Consulting fees
Due to related party	482		7,825
Chief Financial Officer
Related Party Transaction [Line Items]
Management Fees				9,425
Accounting fees			37,791	29,531
Due to related party	7,888			4,033
Directors and offices
Related Party Transaction [Line Items]
Stock-based compensation	$ 187,705		579,904	377,443
Former Chief Executive Officer and former director
Related Party Transaction [Line Items]
Management Fees			90,696	66,759
Due to related party				17,028
Former Chief Financial Officer
Related Party Transaction [Line Items]
Management Fees			62,353	47,124
Former Chief Executive Officer
Related Party Transaction [Line Items]
Management Fees				$ 2,712

Notes Payable (Details)

Notes Payable (Details) - USD ($)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019	Jul. 31, 2018
Notes Payable [Abstract]
Balance, beginning	$ 0	$ 2,175,000	$ 0
Issuance of promissory notes	0	4,000,000	1,887,863
Deferred finance costs	0	(822,494)	0
Repayment of promissory notes	0	(6,695,000)	0
Early repayment penalty	0	200,000	0
Interest and accretion expense	0	1,142,494	277,219
Foreign exchange adjustment	0	0	9,918
Balance, ending	$ 0	$ 0	$ 2,175,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Nov. 14, 2017	Nov. 29, 2018	Oct. 31, 2019	Jul. 31, 2019	Jul. 31, 2018
Notes Payable [Line Items]
Promissory note			$ 1,000,000	$ 1,000,000
Interest rate			10.00%	10.00%
Repayment of promissory note			$ 1,175,000	$ 1,175,000
Promissory notes description			On 12 November 2018 the notes were amended such that $1,175,000 was repaid and the balance of $1,000,000 would be due on 14 February 2019. As the balance was not repaid on 14 February 2019, interest commenced accruing at 8% per annum and the principal plus interest is to be repaid on the earlier of i) 12 months from due date or ii) within 10 business days of closing a financing greater than $5,000,000. During the year ended 31 July 2019, because the Company completed a financing of more than $500,000,	On 12 November 2018 the notes were amended such that $1,175,000 was repaid and the balance of $1,000,000 would be due on 14 February 2019. As the balance was not repaid on 14 February 2019, interest commenced accruing at 8% per annum and the principal plus interest is to be repaid on the earlier of i) 12 months from due date or ii) within 10 business days of closing a financing greater than $5,000,000. During the year ended 31 July 2019, because the Company completed a financing of more than $500,000,
Common stock shares issued			101,760,232	97,279,891	47,774,817
Deferred finance costs			$ 0	$ (822,494)	$ 0
Prepayment Penalty			$ 0
Accrued interest and accretion				1,242,808	277,219
Notes Payable [Member]
Notes Payable [Line Items]
Accrued interest and accretion				24,443	277,219
Financing cost				500,000
Australis Capital Inc [Member]
Notes Payable [Line Items]
Promissory note		$ 4,000,000
Interest rate		15.00%
Common stock shares issued		1,105,083
Deferred finance costs		$ 822,494
Prepayment Penalty				200,000
Accrued interest and accretion				$ 1,118,051	$ 0
Maturity terms		2 years
NMG
Notes Payable [Line Items]
Promissory note	$ 2,175,000
Present value factor	12.00%
Present value of promissory note	$ 1,887,863
Debt in default, interest rate description	Any unpaid amounts at maturity will bear interest at a rate of 10% per annum
TI Nevada
Notes Payable [Line Items]
Promissory note	$ 500,000

Convertible debenture (Details)

Convertible debenture (Details) - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Convertible Debt [Abstract]
Balance, beginning	$ 1,065,565	$ 0	$ 0	$ 0
Issuance of convertible debenture	0		1,128,750	0
Interest and accretion expense	0		98,392	0
Interest paid	0	$ 0	392,623	0
Interest advanced	0		(88,821)	0
Foreign exchange adjustment	0		0	9,918
Balance, ending	$ 1,065,565		$ 1,065,565	$ 0

Convertible debenture (Details

Convertible debenture (Details Narrative)	3 Months Ended		12 Months Ended
	Oct. 31, 2019USD ($)shares	Oct. 31, 2019CAD ($)shares	Jul. 31, 2019USD ($)shares	Jul. 31, 2019CAD ($)shares	Jul. 31, 2018USD ($)	Oct. 31, 2019CAD ($)	Jul. 31, 2019CAD ($)	Oct. 30, 2018USD ($)	Oct. 30, 2018$ / shares
Short-term Debt [Line Items]
Interest rate	11.30%		11.30%			11.30%	11.30%
Beneficial conversion feature	$ 88,797	$ 116,714	$ 88,797	$ 116,714
Accrued interest expense			98,392
Convertible debentures	1,128,750		1,128,750			$ 1,483,636	$ 1,483,636
Interest and accretion expense	0		98,392		0
Interest advanced	0		(88,821)		0
Interest paid			$ 72,623
Conversion shares issued | shares	2,909,091	2,909,091	2,909,091	2,909,091
Australis Capital Inc | Investment Agreement
Short-term Debt [Line Items]
Unsecured convertible debenture								$ 1,600,000
Interest rate								8.00%
Acquired warrant unit price | $ / shares									$ 0.55
Conversion shares issued | shares	2,909,091	2,909,091

Capital Stock (Details)

Capital Stock (Details)	Oct. 01, 2019	Dec. 11, 2018	Jun. 06, 2018	Aug. 21, 2019	Nov. 24, 2017
Capital [Abstract]
Expected life of the options	5 years	5 years	5 years	5 years	5 years
Expected volatility	140.00%	265.00%	262.00%	140.00%	198.00%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%
Risk-free interest rate	1.37%	2.03%	2.16%	1.28%	1.63%

Capital Stock (Details 1)

Capital Stock (Details 1) - Stock options - $ / shares	Oct. 01, 2019	Dec. 11, 2018	Jun. 06, 2018	Nov. 24, 2017	Oct. 31, 2019	Jul. 31, 2019	Jul. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Opening balance					6,075,000	4,025,000	0
Granted	250,000	2,050,000	175,000	3,850,000	3,100,000	2,050,000	4,025,000
Forfeited					(400,000)	0
Closing balance					8,775,000	6,075,000	4,025,000
Weighted average exercise price, opening balance					$ 0.62	$ 0.65	$ 0
Weighted average exercise price, options granted	$ 0.93	$ 0.57	$ 0.47	$ 0.66	0.88	0.57	0.65
Weighted average exercise price, options cancelled					0.88	0
Weighted average exercise price, closing balance					$ 0.7	$ 0.62	$ 0.65

Capital Stock (Details 2)

Capital Stock (Details 2) - $ / shares	1 Months Ended		3 Months Ended	12 Months Ended
	Jul. 16, 2019	Nov. 30, 2018	Oct. 31, 2019	Jul. 31, 2019	Jul. 31, 2018
Class of Warrant or Right [Line Items]
Weighted average exercise price, Issued	$ 0.90	$ 0.50
Share purchase warrants and brokers' warrants
Class of Warrant or Right [Line Items]
Opening balance			22,514,771	10,106,820	0
Issued			0	28,415,284	10,106,820
Exercised			(143,230)	(16,007,333)	0
Expired			(225,083)	0
Closing balance			22,146,458	22,514,771	10,106,820
Weighted average exercise price, opening balance			$ 1.22	$ 0.89	$ 0
Weighted average exercise price, Issued			0	0.93	0.89
Weighted average exercise price, Exercised			0.70	0.50	0
Weighted average exercise price, Expired			0.66	0
Weighted average exercise price, closing balance			$ 1.23	$ 1.22	$ 0.89

Capital Stock (Details 3)

Capital Stock (Details 3) - $ / shares	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019	Oct. 04, 2019	Sep. 12, 2019	Aug. 12, 2019	Jul. 31, 2018	Jul. 31, 2017
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.90	$ 0.66	$ 0.66
Share purchase warrants and brokers' warrants
Class of Warrant or Right [Line Items]
Number of warrants outstanding and exercisable	22,146,458	22,514,771				10,106,820	0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.23	$ 1.22				$ 0.89	$ 0
Share purchase warrants and brokers' warrants | Exercise price CAD$0.66
Class of Warrant or Right [Line Items]
Number of warrants outstanding and exercisable	21,700	248,350
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.66	$ 0.66
Expiry dates	3 November 2019	15 August 2019
Share purchase warrants and brokers' warrants | Exercise price CAD$0.90
Class of Warrant or Right [Line Items]
Number of warrants outstanding and exercisable	9,072,081	9,094,808
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.9	$ 0.9
Expiry dates	14 November 2019	14 November 2019
Share purchase warrants and brokers' warrants | Exercise price CAD$0.90
Class of Warrant or Right [Line Items]
Number of warrants outstanding and exercisable	637,393	637,393
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.90	$ 0.90
Expiry dates	1 December 2019	1 December 2019
Share purchase warrants and brokers' warrants | Exercise price CAD$1.50
Class of Warrant or Right [Line Items]
Number of warrants outstanding and exercisable	11,780,134	11,780,134
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50	$ 1.50
Expiry dates	17 May 2023	17 May 2023
Share purchase warrants and brokers' warrants | Exercise price CAD$1.25
Class of Warrant or Right [Line Items]
Number of warrants outstanding and exercisable	635,150	635,150
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.25	$ 1.25
Expiry dates	16 May 2023	17 May 2023
Share purchase warrants and brokers' warrants | Exercise price CAD$0.66
Class of Warrant or Right [Line Items]
Number of warrants outstanding and exercisable		58,324
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.66
Expiry dates		16 August 2019
Share purchase warrants and brokers' warrants | Exercise price CAD$0.66
Class of Warrant or Right [Line Items]
Number of warrants outstanding and exercisable		60,612
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.66
Expiry dates		3 November 2019

Capital Stock (Details Narrativ

Capital Stock (Details Narrative)	Oct. 04, 2019USD ($)shares	Oct. 01, 2019USD ($)shares	Oct. 01, 2019CAD ($)$ / sharesshares	Sep. 12, 2019USD ($)shares	Sep. 12, 2019CAD ($)$ / sharesshares	Aug. 12, 2019USD ($)shares	Aug. 12, 2019CAD ($)$ / sharesshares	Dec. 11, 2018USD ($)shares	Dec. 11, 2018CAD ($)$ / sharesshares	Nov. 02, 2018USD ($)$ / sharesshares	Nov. 02, 2018CAD ($)$ / sharesshares	Jun. 06, 2018USD ($)shares	Jun. 06, 2018CAD ($)$ / sharesshares	Dec. 01, 2017USD ($)$ / sharesshares	Dec. 01, 2017CAD ($)$ / sharesshares	Nov. 14, 2017USD ($)shares	Nov. 14, 2017CAD ($)$ / sharesshares	Aug. 15, 2017USD ($)$ / sharesshares	Aug. 15, 2017CAD ($)$ / sharesshares	Aug. 21, 2019USD ($)shares	Aug. 21, 2019CAD ($)$ / sharesshares	Jul. 16, 2019USD ($)shares	Jul. 16, 2019CAD ($)$ / sharesshares	May 28, 2019USD ($)shares	May 28, 2019CAD ($)$ / sharesshares	May 17, 2019USD ($)$ / sharesshares	May 17, 2019CAD ($)$ / sharesshares	Jan. 31, 2019USD ($)shares	Nov. 30, 2018USD ($)shares	Nov. 30, 2018CAD ($)$ / sharesshares	Nov. 29, 2018USD ($)shares	Nov. 24, 2017USD ($)shares	Nov. 24, 2017CAD ($)$ / sharesshares	Oct. 31, 2017USD ($)$ / sharesshares	Oct. 31, 2017CAD ($)$ / sharesshares	Aug. 16, 2017USD ($)$ / sharesshares	Aug. 16, 2017CAD ($)$ / sharesshares	Oct. 31, 2019USD ($)$ / sharesshares	Oct. 31, 2019CAD ($)$ / sharesshares	Jul. 31, 2019USD ($)$ / sharesshares	Jul. 31, 2019CAD ($)$ / sharesshares	Jul. 31, 2018USD ($)$ / sharesshares	Jul. 31, 2018$ / shares$ / sharesshares	Oct. 04, 2019CAD ($)$ / shares	May 14, 2019USD ($)shares	May 16, 2018USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Capital stock, par value | $ / shares																																						$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001
Capital stock, shares authorized																																						900,000,000		900,000,000		900,000,000	900,000,000
Preferred stock converted into common shares																																						2,909,091	2,909,091	2,909,091	2,909,091
Common stock shares issued																						7,333	7,333						3,206,160	3,206,160
Amount payable in common shares | $																																								$ 15,088,414		$ 5,026,494
Warrants shares issued																						7,333	7,333						3,206,160	3,206,160
Warrant exercisable price per share | $ / shares																							$ 0.90							$ 0.50
Number of warrants exercised	22,727			38,912	38,912	81,591	81,591
Proceeds from issuance of common stock				$ 19,450	$ 25,682																	$ 5,057	$ 6,600						$ 1,205,196	$ 1,603,080								$ 75,549		$ 21,561,568		$ 4,806,025
Exercised						$ 40,765	$ 53,850
Common stock share subscriptions receivable	$ 15,360																																											$ 20,454
Common stock shares issued upon exercise of warrants	22,727			38,912	38,912	81,591	81,591
Warrants price per share | $ / shares					$ 0.66		$ 0.66																																					$ 0.90
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted		250,000	250,000					2,050,000	2,050,000			175,000	175,000																			3,850,000	3,850,000					3,100,000	3,100,000	2,050,000	2,050,000	4,025,000
Exercise price | $ / shares			$ 0.93						$ 0.57				$ 0.47																				$ 0.66						$ 0.88		$ 0.57		$ 0.65
Term of options								5 years	5 years			5 years	5 years																			5 years	5 years
Expiry period								Dec. 10, 2023	Dec. 10, 2023			Jun. 6, 2023	Jun. 6, 2023																			Nov. 24, 2022	Nov. 24, 2022
Fair value of stock options		$ 145,045	$ 191,960					$ 880,595	$ 1,165,117			$ 63,101	$ 81,129							$ 1,373,856	$ 1,818,232											$ 726,578	$ 922,403
Stock-based compensation																																						$ 12,591	$ 16,663
Percentage of issued and outstanding common shares																																						10.00%		10.00%
Purchase Agreement N M G S D Settlement Agreement And Lease Assignment Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued						4,337,111	4,337,111
Australis
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued																															1,105,083
Number of warrants exercised																								12,793,840	12,793,840
Finance fee fair valued | $																															$ 822,494
Exercised																								$ 4,746,515	$ 6,396,920
Common stock shares issued upon exercise of warrants																								12,793,840	12,793,840
Warrants price per share | $ / shares																									$ 0.50
Australis | Senior secured note
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repayment of senior debt | $																								$ 4,495,890
Australis | Investment Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued																												1,768,545
Amount payable in common shares | $																												$ 787,123
Consultant | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted								2,050,000	2,050,000
Exercise price | $ / shares									$ 0.57
Fair value of stock options								$ 880,595	$ 1,165,117
Toro Pacific Management Inc. (the "Transferor")
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Escrowed shares issued																																													70,500	70,500
Escrowed shares fair value | $																																													$ 22,689	$ 27,328
NMG Ohio LLC
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued																												2,380,398
Amount payable in common shares | $																												$ 1,448,805
Acquiring revenue remaining performance obligation																												70.00%
Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted																				2,850,000	2,850,000
Exercise price | $ / shares																					$ 0.88
Expired																				400,000	400,000
Stock-based compensation																																						$ 276,987	$ 366,779
NMG
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued																18,827,000	18,827,000
Amount payable in common shares | $																$ 6,337,365
Number of warrants purchase exercisable shares																9,102,141
Warrant exercisable price per share | $ / shares																	$ 0.66
Exercise price | $ / shares																	$ 0.90
Term of options																24 months	24 months
Business acquisition shares issued or issuable																423,000	423,000
Business acquisition, fair value of shares issued or issuable | $																$ 135,202
NMG | Broker warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrant																$ 62,357	$ 78,122
Warrants shares issued																367,286
Warrant exercisable price per share | $ / shares																	$ 0.90
Share issuance costs																$ 219,459	$ 279,352
Term of options																24 months	24 months
Options vest six months from the date of grant | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period percentage		25.00%	25.00%
Options vest six months from the date of grant | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period percentage																				25.00%	25.00%
Options vest twelve months from the date of grant | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period percentage		25.00%	25.00%
Options vest twelve months from the date of grant | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period percentage																				25.00%	25.00%
Options vest eighteen months from the date of grant | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period percentage		25.00%	25.00%
Options vest eighteen months from the date of grant | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period percentage																				25.00%	25.00%
Options vest twenty-four months from the date of grant | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period percentage		25.00%	25.00%
Options vest twenty-four months from the date of grant | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period percentage																				25.00%	25.00%
Private placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maturity period																										48 months	48 months
Private placements shares issued										16,000,000	16,000,000			637,393	637,393
Subscription receipts per price | (per share)										$ 0.30	$ 0.40			$ 0.52	$ 0.66											$ 0.93	$ 1.25
Proceeds from issuance of private placement										$ 4,883,840	$ 6,400,000			$ 330,486	$ 420,680											$ 10,956,241	$ 14,726,130
Cash paid for finder fees | $										$ 152,720
Common stock shares issued										322,581	322,581
Amount payable in common shares | $										$ 221,691
Warrant exercisable price per share | $ / shares											$ 0.50				$ 0.90												$ 1.50
Warrant exercisable period														24 months	24 months
Number of units issued under private placement																										11,780,904	11,780,904
Description for the units issued under private placement																										Each unit is comprised of one common share and one common share purchase warrant.	Each unit is comprised of one common share and one common share purchase warrant.
Description for the exercise of warrants																										Each warrant entitles the holder to acquire one common share of the Company at an exercise price of CAD$1.50 for a period of 48 months following the closing date, subject to adjustment in certain events.	Each warrant entitles the holder to acquire one common share of the Company at an exercise price of CAD$1.50 for a period of 48 months following the closing date, subject to adjustment in certain events.
Commission received by the agent under offering																										$ 589,499	$ 793,938
Private placement | Broker warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maturity period																										48 months	48 months
Description for the exercise of warrants																										Each broker warrant entitles the holder to acquire one unit at an exercise price of CAD$1.25 per unit for a period of 48 months following the closing date.	Each broker warrant entitles the holder to acquire one unit at an exercise price of CAD$1.25 per unit for a period of 48 months following the closing date.
Warrants issued as additional consideration																											635,150
Warrants price per share | $ / shares																											$ 1.25
Corporate Finance Fee																										$ 63,774	$ 84,750
Private placement | Options vest six months from the date of grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Private placements shares issued																		8,276,294	8,276,294
Subscription receipts per price | (per share)																		$ 0.52	$ 0.66
Proceeds from issuance of private placement																		$ 4,270,017	$ 5,462,354
Private placement | Options vest twelve months from the date of grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Private placements shares issued																																				8,276,294	8,276,294
Subscription receipts per price | (per share)																																				$ 0.52	$ 0.66
Proceeds from issuance of private placement																																				$ 4,270,017	$ 5,462,354
Private placement | Options vest eighteen months from the date of grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Private placements shares issued																																		757,666	757,666
Subscription receipts per price | (per share)																																		$ 0.52	$ 0.66
Proceeds from issuance of private placement																																		$ 390,822	$ 500,060
Private placement | Options vest twenty-four months from the date of grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Private placements shares issued																																								68,181	68,181
Subscription receipts per price | (per share)																																								$ 0.52	$ 0.66
Proceeds from issuance of private placement																																								$ 35,169	$ 45,000
Private placement one
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Private placements shares issued														637,393	637,393
Subscription receipts per price | (per share)														$ 0.52	$ 0.66
Proceeds from issuance of private placement														$ 330,486	$ 420,680
Warrant exercisable price per share | $ / shares															$ 0.90
Warrant exercisable period														24 months	24 months

Segmented Information and Maj_2

Segmented Information and Major Customers (Details Narrative) - Customers	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019	Jul. 31, 2018
Segment Reporting [Abstract]
Number of costumer		1
Revenues from major customer	10.00%	12.00%	37.00%

Supplemental Disclosures with_3

Supplemental Disclosures with Respect to Cash Flows (Details) - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Supplemental Cash Flow Elements [Abstract]
Cash paid during the period for interest	$ 0	$ 0	$ 392,623	$ 0
Cash paid during the period for income taxes	$ 0	$ 0	$ 0	$ 0

Business Acquisition (Details)

Business Acquisition (Details) - USD ($)	Nov. 14, 2017	Oct. 31, 2019	Jul. 31, 2019	Jul. 31, 2018
Liabilities assumed:
Goodwill		$ 2,635,721	$ 2,635,721	$ 2,635,721
Nevada Medical Group LLC (NMG)
Purchase consideration
Share considerations	$ 6,143,326
Cash considerations	2,309,000
Promissory notes issued	1,887,277
TOTAL	10,339,603
Assets acquired:
Cash	260,842
Amounts receivable	253,697
Prepaid expenses	44,552
Inventory	498,680
Property and equipment	1,951,696
Brand	247,000
Licenses	7,925,000
Liabilities assumed:
Trade payable and accrued liabilities	(367,385)
Loans payable	(250,000)
Deferred tax liability	(2,860,200)
Net assets acquired	7,703,882
Goodwill	2,635,721
TOTAL	$ 10,339,603

Business Acquisition (Details N

Business Acquisition (Details Narrative)	Nov. 14, 2017USD ($)shares	Nov. 13, 2017USD ($)shares	Jul. 31, 2019	Jul. 16, 2019shares	Nov. 30, 2018shares	Nov. 14, 2017$ / shares
Business Acquisition [Line Items]
Number of common shares issued upon exercise of warrants				7,333	3,206,160
Description of subscription receipts under concurrent financing			The Company completed a concurrent financing consisting of 9,102,141 subscription receipts of the Company (the "Subscription Receipts"), at an issue price of CAD$0.66 per Subscription Receipt, with each Subscription Receipt being automatically converted, at no additional cost to the subscriber, upon the completion of the Acquisition for one common share and one share purchase warrant exercisable at a price of CAD$0.90 for a period of 24 months from the date of issuance. Each warrant is subject to acceleration provisions following the six-month anniversary of the date of closing, if the closing trading price of the common shares is equal to or greater than CAD$1.20 for seven consecutive trading days, at which time the Company may accelerate the expiry date of the warrants by issuing a press release announcing the reduced warrant term whereupon the warrant will expire 21 calendar days after the date of such press release.
Toro Pacific Management Inc. (the "Transferor")
Business Acquisition [Line Items]
Number of shares issued under acquisition	423,000
Fair value of number of shares issued under acquisition | $	$ 135,202
Toro Pacific Management Inc. (the "Transferor") | Assignment Agreement
Business Acquisition [Line Items]
Description of subscription receipts under concurrent financing		The Assignment Agreement was amended, whereby the Company would issue the 1,000,000 common shares as follows: a. 470,000 common shares to Benjamin Rutledge upon closing of the Acquisition (issued); b. 60,000 common shares to Chris Hunt upon closing of the Acquisition (issued); c. 470,000 common shares to the Transferor according to the following schedule: · 1/10 of the Transferor's shares upon closing of the Acquisition (issued); · 1/6 of the remaining Transferor's shares 6 months after closing the Acquisition (issued); · 1/5 of the remaining Transferor's shares 12 months after closing the Acquisition; · 1/4 of the remaining Transferor's shares 18 months after closing the Acquisition; · 1/3 of the remaining Transferor's shares 24 months after closing the Acquisition; · 1/2 of the remaining Transferor's shares 30 months after closing the Acquisition; and · the remaining Transferor's shares 36 months after closing the Acquisition.
Nevada Medical Group LLC (NMG)
Business Acquisition [Line Items]
Number of shares issued under acquisition	16,000,000
Fair value of number of shares issued under acquisition | $	$ 5,386,155
Promissory note issued, gross | $	2,175,000
Cash considerations | $	2,309,000
Transaction costs | $	330,324
Promissory notes issued | $	1,887,277
Present value of promissory note | $	$ 1,887,863
Nevada Medical Group LLC (NMG) | Assignment Agreement
Business Acquisition [Line Items]
Number of shares issued under acquisition		1,000,000
Remaining number of shares issued under acquisition		423,000
Remaining fair value of number of shares issued under acquisition | $		$ 135,202
Nevada Medical Group LLC (NMG) | Share Exchange Agreement
Business Acquisition [Line Items]
Number of shares issued under acquisition	9,102,141
Shares issue price | $ / shares						$ 0.66
Warrant exercisable price for 24 months from date issuance | $ / shares						0.90
Closing trading price | $ / shares						$ 1.20
Nevada Medical Group LLC (NMG) | Benjamin Rutledge
Business Acquisition [Line Items]
Number of shares issued under acquisition	470,000
Fair value of number of shares issued under acquisition | $	$ 159,114
Nevada Medical Group LLC (NMG) | Benjamin Rutledge | Assignment Agreement
Business Acquisition [Line Items]
Number of shares issued under acquisition		470,000
Nevada Medical Group LLC (NMG) | Chris Hunt
Business Acquisition [Line Items]
Number of shares issued under acquisition	60,000
Fair value of number of shares issued under acquisition | $	$ 20,192
Nevada Medical Group LLC (NMG) | Chris Hunt | Assignment Agreement
Business Acquisition [Line Items]
Number of shares issued under acquisition		60,000
Nevada Medical Group LLC (NMG) | Toro Pacific Management Inc. (the "Transferor")
Business Acquisition [Line Items]
Number of shares issued under acquisition	47,000
Fair value of number of shares issued under acquisition | $	$ 15,816
Nevada Medical Group LLC (NMG) | Toro Pacific Management Inc. (the "Transferor") | Assignment Agreement
Business Acquisition [Line Items]
Number of shares issued under acquisition		470,000
Nevada Medical Group LLC (NMG) | TI Nevada
Business Acquisition [Line Items]
Number of shares issued under acquisition	2,037,879
Fair value of number of shares issued under acquisition | $	$ 685,788
Nevada Medical Group LLC (NMG) | Charles Fox
Business Acquisition [Line Items]
Number of shares issued under acquisition	212,121
Fair value of number of shares issued under acquisition | $	$ 71,383

Commitments Narrative (Details)

Commitments Narrative (Details)	Jun. 13, 2019USD ($)	Apr. 09, 2019USD ($)	Mar. 08, 2019USD ($)	Nov. 14, 2017USD ($)	Nov. 11, 2014USD ($)	Oct. 31, 2019USD ($)	Oct. 30, 2018USD ($)	Jul. 31, 2019USD ($)	Aug. 21, 2019USD ($)	Aug. 21, 2019CAD ($)	Oct. 25, 2017USD ($)
Loss Contingencies [Line Items]
Frequency of periodic payment							Monthly
Periodic consulting fees payable	$ 15,000						$ 10,000
Term of contract							5 years
President And Interim Chief Executive Officer
Loss Contingencies [Line Items]
Periodic rent payable, amount									$ 12,500
Chief Financial Officer [Member]
Loss Contingencies [Line Items]
Periodic rent payable, amount										$ 10,000
Chief Operating Officer [Member]
Loss Contingencies [Line Items]
Periodic rent payable, amount									15,000
Corporate Secretary [Member]
Loss Contingencies [Line Items]
Periodic rent payable, amount										$ 7,500
President Of Nmg And Director [Member]
Loss Contingencies [Line Items]
Periodic rent payable, amount									16,666
Former Chief Executive Officer And Advisor [Member]
Loss Contingencies [Line Items]
Periodic rent payable, amount									$ 12,500
Investment Agreement [Member]
Loss Contingencies [Line Items]
Frequency of periodic payment						monthly	monthly
Periodic consulting fees payable						$ 12,000	$ 10,000
Increased in periodic payments of consulting fees						$ 16,500
Term of contract						5 years
Ownership percentage for increased in monthly services fee						10.00%
Carroll Road [Member]
Loss Contingencies [Line Items]
Description for lease option to extend	The company has three options to extend the lease and each option is for five years.
Periodic rent payable, amount	$ 15,000
Term of lease	5 years
Carroll Road [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Percentage of increased minimum monthly rent	6.00%
Carroll Road [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Percentage of increased minimum monthly rent	1.00%
E Anaheim St [Member]
Loss Contingencies [Line Items]
Description for lease option to extend					The Company has five options to extend the lease and each option is for five years.
Periodic rent payable, amount			$ 6,636.40
Term of lease			5 years
Frequency of periodic payment					Monthly
Percentage of increased minimum monthly rent			5.00%
Monthly rent and common area expenses			$ 8,000
Nmg Ohio Llc [Member]
Loss Contingencies [Line Items]
Periodic rent payable, amount					$ 12,500						$ 4,200
Term of lease					5 years						5 years
Nmg Ohio Llc [Member] | On January One Two Thousand Eighteen [Member]
Loss Contingencies [Line Items]
Description for lease option to extend								The guaranteed minimum monthly rent is subject to a 3% increase on each anniversary date of the lease.
Frequency of periodic payment								Monthly
Sunset Corporate Drive [Member]
Loss Contingencies [Line Items]
Periodic rent payable, amount		$ 7,156
Promissory note								$ 12,000
Monthly rent		6,026
Common area expenses		$ 1,129
Ti Nevada [Member] | Consulting Agreement [Member] | Officer [Member]
Loss Contingencies [Line Items]
Frequency of periodic payment				Monthly
Periodic consulting fees payable				$ 16,667
Term of contract				3 years
Toro Pacific Management Inc [Member] | Consulting Agreement [Member]
Loss Contingencies [Line Items]
Periodic consulting fees payable				$ 10,000			$ 12,000

Investment Agreement (Details N

Investment Agreement (Details Narrative)

Sep. 12, 2019USD ($)

Sep. 12, 2019CAD ($)

Jul. 16, 2019USD ($)shares

Jul. 16, 2019CAD ($)shares

Jan. 31, 2019USD ($)shares

Nov. 30, 2018USD ($)shares

Nov. 30, 2018CAD ($)shares

Nov. 29, 2018shares

Oct. 30, 2018USD ($)shares

Oct. 31, 2019USD ($)

Jul. 31, 2019USD ($)

Jul. 31, 2018USD ($)

Nov. 28, 2018

Oct. 30, 2018CAD ($)

Schedule of Investments [Line Items]

Term of contract

5 years

Common stock shares issued

7,333

7,333

3,206,160

3,206,160

Proceeds from issuance of common stock

$ 19,450

$ 25,682

$ 5,057

$ 6,600

$ 1,205,196

$ 1,603,080

$ 75,549

$ 21,561,568

$ 4,806,025

Australis

Schedule of Investments [Line Items]

Common stock shares issued

1,105,083

Investment Agreement | Australis

Schedule of Investments [Line Items]

Number of units issued for unsecured convertible debentures

16,000,000

Unsecured convertible debentures | $

$ 1,600,000

Interest rate per annum

8.00%

8.00%

Ownership percentage

35.783%

Percentage of issued and outstanding common shares

10.00%

20.00%

10.00%

Common stock shares issued

1,768,545

Proceeds from issuance of common stock | $

$ 787,123

Commercial advisory agreement | Australis Capital (Nevada) Inc.

Schedule of Investments [Line Items]

Frequency of periodic payment

Monthly

Periodic consulting fees payable per month | $

$ 10,000

Term of contract

5 years

Investment in NMG Ohio LLC (Det

Investment in NMG Ohio LLC (Details) - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Schedule of Equity Method Investments [Line Items]
Opening balance	$ 3,465,902	$ 77,600	$ 77,600
Foreign exchange	(82,920)	(71,554)	(241,862)	$ (193,959)
Total	3,568,645		3,465,902	77,600
Nmg Ohio Llc [Member]
Schedule of Equity Method Investments [Line Items]
Opening balance	3,465,902	$ 77,600	77,600
Acquisition costs: Common shares issued to vendors at fair value	0		1,448,805
Acquisition costs: Cash payments to vendors	0		1,181,250
Dispensary build-out related costs	16,469		573,633
License fees	0		100,000
Equity pickup	87,651		56,466
Foreign exchange	(1,377)		28,148
Total	$ 3,568,645		$ 3,465,902	$ 77,600

Investment in NMG Ohio LLC (D_2

Investment in NMG Ohio LLC (Details 1) - USD ($)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Schedule of Equity Method Investments [Line Items]
Current assets	$ 768,603	$ 271,121
Non-current assets	853,383	923,387
Total assets	1,621,986	1,194,508
Current liabilities	465,933	338,427
Non-current liabilities	0	0
Total liabilities	465,933	338,427
Revenues	961,444	1,225,238
Gross profit	420,904	513,643
Net income	292,171	188,244
Net income attributable to the Company	87,651	56,466
NMG Ohio LLC
Schedule of Equity Method Investments [Line Items]
Revenues	961,444	1,148,465
Net income	292,171	$ 188,244
Net income attributable to the Company	$ 87,651

Investment in NMG Ohio LLC (D_3

Investment in NMG Ohio LLC (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Schedule of Equity Method Investments [Line Items]
Remaining cash payments totaling		$ 393,750
Remaining issuance of common stock shares		793,466
Investment in NMG Ohio LLC		$ 3,465,902
Revenues	$ 961,444	1,225,238
Net income	292,171	188,244
Equity pickup	87,651	$ 56,466
Net income related to 30% pro rata shares	$ 125,000
NMG Ohio LLC
Schedule of Equity Method Investments [Line Items]
Percentage of voting interest acquired	100.00%	100.00%
Purchase of remaining ownership interest percentage	70.00%	70.00%
Consideration in cash to be paid for the acquisition of remaining interest	$ 1,575,000	$ 1,575,000
Common stock shares issued		2,380,398
Issuance of common stock		3,173,864
Common stock shares fair value		$ 1,448,805
Cash payments		1,181,250
Remaining cash payments totaling	$ 393,750
Remaining issuance of common stock shares	793,466
Ownership percentage	30.00%
Revenues	$ 961,444	1,148,465
Expenses	669,273	960,244
Net income	292,171	188,244
Equity pickup	$ 87,651
Net income related to 30% pro rata shares		$ 56,466

Investment in and advances to_3

Investment in and advances to GLDH (Details) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Investments [Abstract]
Note receivable	$ 7,373,036	$ 5,200,000
Share issuances	2,752,782	0
Interest income accrued on the Note	260,000	693,333
Advances for working capital	512,506	666,876
Lease Assignment Agreement payment	0	783,765
Foreign exchange	0	29,062
Total	$ 10,898,324	$ 7,373,036

Investment in and advances to_4

Investment in and advances to GLDH (Details Narrative)	1 Months Ended					12 Months Ended
	Jul. 16, 2019shares	Nov. 30, 2018shares	Nov. 29, 2018shares	Nov. 28, 2018USD ($)shares	Nov. 28, 2018CAD ($)shares	Jul. 31, 2019USD ($)	Jul. 31, 2018USD ($)	Oct. 04, 2019$ / shares	Sep. 12, 2019$ / shares	Aug. 12, 2019$ / shares	May 28, 2019$ / shares	Nov. 28, 2018$ / shares
Schedule of Investments [Line Items]
Maximum number of common shares	7,333	3,206,160
Maximum consideration | $						$ 15,088,414	$ 5,026,494
Warrants price per share | $ / shares								$ 0.90	$ 0.66	$ 0.66
David Barakett | Binding interim agreement
Schedule of Investments [Line Items]
Percentage of issued and outstanding common shares				100.00%
Common shares of VWAP | $ / shares												$ 0.7439
USD/CAD exchange rate				1.3296
Maximum number of common shares				11,255,899	11,255,899
Maximum consideration				$ 6,297,580	$ 8,373,263
Senior secured convertible note | $				$ 5,200,000
Interest rate per annum				20.00%
David Barakett | Binding interim agreement | Eligibility condition one
Schedule of Investments [Line Items]
Issuance of Earn Out shares				5,627,950	5,627,950
Issuance of Earn Out shares, percentage				50.00%	50.00%
David Barakett | Binding interim agreement | Eligibility condition two
Schedule of Investments [Line Items]
Revenue | $				$ 3,300,000
Issuance of Earn Out shares				4,502,360	4,502,360
Issuance of Earn Out shares, percentage				40.00%	40.00%
David Barakett | Binding interim agreement | Eligibility condition three
Schedule of Investments [Line Items]
Issuance of Earn Out shares				1,125,589	1,125,589
Issuance of Earn Out shares, percentage				10.00%	10.00%
Australis
Schedule of Investments [Line Items]
Maximum number of common shares			1,105,083
Warrants price per share | $ / shares											$ 0.50
Australis | Loan agreement
Schedule of Investments [Line Items]
Loan, face amount | $				$ 4,000,000
Common stock, shares exercised				3,206,160	3,206,160
Warrant exercised				3,206,160	3,206,160
Warrants price per share | $ / shares												$ 0.50
Aggregate proceeds of common shares and warrants | $				$ 1,200,000

Investment in and advances to_5

Investment in and advances to GLDH (Details Narrative 1)	Jul. 03, 2019USD ($)shares	Jul. 31, 2019USD ($)	Jul. 31, 2018USD ($)	Jul. 03, 2019$ / shares
Schedule of Investments [Line Items]
Amount payable in common shares		$ 15,088,414	$ 5,026,494
Consulting Agreement | David Barakett
Schedule of Investments [Line Items]
Payment of consulting and advisory services	$ 200,000	50,000
Payment of consulting and advisory services in subsequent to year end		$ 90,000
GLDH
Schedule of Investments [Line Items]
Loan, face amount	$ 200,000
Interest rate per annum	12.00%
Forgive operating loan amount	$ 800,000
GLDH | Settlement Agreement
Schedule of Investments [Line Items]
Ownership percentage	60.00%
GLDH | Settlement Agreement | Eligibility condition one
Schedule of Investments [Line Items]
Amount to be paid in common shares	$ 500,000
GLDH | Settlement Agreement | Eligibility condition two | David Barakett
Schedule of Investments [Line Items]
Amount to be paid in common shares	$ 750,000
Share price per share | $ / shares				$ 0.7439
Maximum number of common shares | shares	1,340,502
Start-up costs percentage	40.00%
GLDH | Settlement Agreement | Eligibility condition three | David Barakett
Schedule of Investments [Line Items]
Amount to be paid in common shares	$ 750,000
Share price per share | $ / shares				0.7439
Maximum number of common shares | shares	1,340,502
Start-up costs percentage	40.00%
GLDH | Lease Assignment Agreement
Schedule of Investments [Line Items]
Cash and share payments	$ 2,283,765
Interest rate per annum	5.00%
GLDH | Lease Assignment Agreement | San Diego operation
Schedule of Investments [Line Items]
Ownership percentage	60.00%
GLDH | Lease Assignment Agreement | Eligibility condition one
Schedule of Investments [Line Items]
Amount payable in cash	$ 750,000
GLDH | Lease Assignment Agreement | Eligibility condition two
Schedule of Investments [Line Items]
Amount payable in cash	783,765
GLDH | Lease Assignment Agreement | Eligibility condition three
Schedule of Investments [Line Items]
Amount payable in cash	750,000
GLDH | Purchase Agreement
Schedule of Investments [Line Items]
Investment purchase price	6,700,000
Note to be applied towards the Purchase Price	$ 5,200,000
GLDH | Purchase Agreement | GLDH's Long Beach, California dispensary
Schedule of Investments [Line Items]
Ownership percentage	100.00%
GLDH | Purchase Agreement | Eligibility condition one
Schedule of Investments [Line Items]
Amount to be paid in common shares	$ 1,500,000
Share price per share | $ / shares				$ 0.7439
Maximum number of common shares | shares	2,681,006
Licensor
Schedule of Investments [Line Items]
Licensor grants	2 years
Payment to Licensor of gross receipts from sales	3.00%

Other Investments (Details Narr

Other Investments (Details Narrative) - Satellites Dip, LLC - Management Agreement	Jun. 06, 2019USD ($)
Schedule of Investments [Line Items]
Management fee description	NMG CC will be paid a management fee of 30% of Net Profits or $10,000 per month, whichever is greater
Loan, face amount	$ 250,000
Debt due date	Jun. 6, 2020
Interest rate per annum	12.00%

Lease Liabilities (Details)

Lease Liabilities (Details)	3 Months Ended
	Oct. 31, 2019USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 56,704
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 1,187,116
Weighted-average remaining lease term - operating leases	7 years 5 months 16 days
Weighted-average discount rate - operating leases	12.00%

Lease Liabilities (Details 1)

Lease Liabilities (Details 1)	3 Months Ended
	Oct. 31, 2019USD ($)
Leases [Abstract]
2020	$ 153,798
2021	223,398
2022	240,530
2023	248,403
2024	254,438
2025	257,827
2026	176,312
2027	179,838
2028	60,340
Total lease payments	1,794,884
Less imputed interest	(650,857)
Total	$ 1,144,027

Lease Liabilities (Details 2)

Lease Liabilities (Details 2) - USD ($)	Apr. 09, 2019	Nov. 10, 2017	Oct. 30, 2018	Oct. 31, 2019
Lessee, Lease, Description [Line Items]
Frequency of periodic payment			Monthly
Operating lease, right-of-use asset and increase in lease liabilities				$ 1,187,116
Discount rate for present value of future lease payments				12.00%
Lease expense				$ 56,704
NMG
Lessee, Lease, Description [Line Items]
Description for lease option to extend	The Company has one option to extend the lease for an additional three-year term	The Company has four options to extend the lease and each option is for five years.
Periodic rent payable, amount	$ 6,026	$ 12,500
Frequency of periodic payment		monthly		monthly
Common area expenses	1,129
Monthly rent and common area expenses	$ 7,156	$ 12,875
Percentage of increased minimum monthly rent				2.00%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Income Tax Disclosure [Abstract]
Net loss for the period	$ (896,797)	$ (88,239)	$ (3,752,751)	$ (2,685,782)
Federal and state income tax rates			21.00%	26.45%
Expected income tax recovery			$ (788,078)	$ (710,389)
Permanent differences			1,342,979	528,510
Change in estimates and others			120,554	225,902
Change in tax rates			178,289	(725,324)
Change in benefit not recognized			(853,744)	(223,421)
Total income tax recovery			$ 0	$ (904,722)

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Jul. 31, 2019	Jul. 31, 2018
Deferred income tax asset
Net income tax operating loss carry forward	$ 150,000	$ 985,290
Deferred tax allowance	(150,000)	(985,290)
Deferred income tax liability
Brand and License	1,716,120	1,716,120
Net deferred income tax liability	$ 1,716,120	$ 1,716,120

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Oct. 16, 2019$ / sharesshares	Oct. 04, 2019USD ($)shares	Oct. 04, 2019CAD ($)$ / sharesshares	Oct. 01, 2019$ / sharesshares	Sep. 12, 2019USD ($)shares	Sep. 12, 2019CAD ($)$ / sharesshares	Dec. 11, 2018shares	Jun. 06, 2018shares	Nov. 30, 2019USD ($)	Aug. 21, 2019$ / sharesshares	Jul. 16, 2019USD ($)	Jul. 16, 2019CAD ($)	Nov. 30, 2018USD ($)	Nov. 30, 2018CAD ($)	Nov. 24, 2017shares	Oct. 31, 2019USD ($)shares	Aug. 12, 2019USD ($)shares	Aug. 12, 2019CAD ($)$ / sharesshares	Jul. 31, 2019USD ($)shares	Jul. 31, 2018USD ($)shares
Subsequent Event [Line Items]
Proceeds from issuance of common stock					$ 19,450	$ 25,682					$ 5,057	$ 6,600	$ 1,205,196	$ 1,603,080		$ 75,549			$ 21,561,568	$ 4,806,025
Common stock shares issued																101,760,232			97,279,891	47,774,817
Exercise price of warrants | $ / shares			$ 0.90			$ 0.66												$ 0.66
Employee Stock Option
Subsequent Event [Line Items]
Stock option granted				250,000			2,050,000	175,000							3,850,000	3,100,000			2,050,000	4,025,000
Subsequent Event | Employee Stock Option
Subsequent Event [Line Items]
Exercise price of warrants | $ / shares	$ 0.88			$ 0.93						$ 0.88
Option vesting desceiption				The options are subject to vesting provisions such that 25% of the options vest six months from the date of grant, 25% of the options vest 12 months from the date of grant, 25% of the options vest eighteen months from the date of grant and 25% of the options vest twenty-four months from the date of grant.						The options are subject to vesting provisions such that 25% of the options vest six months from the date of grant, 25% of the options vest twelve months from the date of grant, 25% of the options vest eighteen months from the date of grant and 25% of the options vest twenty-four months from the date of grant.
Expiry date				1 October 2024						21 August 2024
Stock option granted				250,000						2,850,000
Maturity period				5 years						5 years
Stock option cancelled	400,000
Subsequent Event | Warrant
Subsequent Event [Line Items]
Proceeds from issuance of common stock		$ 15,359	$ 20,454		$ 19,449	$ 25,682											$ 40,765	$ 53,850
Common stock shares issued			22,727			38,912												81,591
Exercise price of warrants | $ / shares			$ 0.90			$ 0.66												$ 0.66
Warrant exercised		22,727	22,727		38,912	38,912											81,591	81,591
Subsequent Event | Settlement Agreement
Subsequent Event [Line Items]
Percentage of proceeds received from the sale of inventory									100.00%
Subsequent Event | Brand Director Agreement
Subsequent Event [Line Items]
Contribution fee | $									$ 5,000
Subsequent Event | License Agreement
Subsequent Event [Line Items]
Monthly fee payable on a quarterly basis | $									100
Subsequent Event | Equipment Purchase Agreement
Subsequent Event [Line Items]
Equipment purchase price | $									$ 235,684.93
Subsequent Event | NMG SD Settlement Agreement
Subsequent Event [Line Items]
Common stock shares issued																		4,337,111